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ABSTRACT 
The standard Medicare prescription drug benefit includes a coverage gap ($3,850 
in true out-of-pocket expenses in 2007) during which beneficiaries pay 100% of their 
drug costs.  The objective of this study was to assess the impact of the Medicare Part D 
coverage gap on prescription drug utilization and medication adherence by using data 
from Medicare beneficiaries enrolled in a large health plan in New Mexico. 
A quasi-experimental, cross-sectional, retrospective, pre-post with control group 
study design was used to assess the study objectives. Pre- and post-coverage gap 
prescription drug utilization and medication adherence, of beneficiaries enrolled in a 
health plan with no prescription drug coverage during the coverage gap (no coverage 
plan) was compared with that of beneficiaries enrolled in a plan with generic drug 
coverage (generic coverage plan) and beneficiaries enrolled in a plan with full 
prescription drug coverage during the coverage gap (full coverage plan). Pre- and post-
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coverage gap prescription drug utilization was assessed using per member total number 
of prescriptions. Medication Possession Ratio (MPRm) and the Proportion of Days 
Covered (PDC) were used as measures of medication adherence. Difference-in difference 
analysis was used to compare pre- and post-coverage gap prescription drug utilization 
and medication adherence between the three plans. 
Of the 14,846 beneficiaries who met the study inclusion and exclusion criteria, 
2,661 beneficiaries (17.92%) hit the prescription coverage gap in the year 2007. 
Difference-in-difference analyses indicated that post-coverage gap, beneficiaries enrolled 
in the no coverage gap plan, filled significantly less number of prescriptions (14.67 
prescriptions less; p=0.001) than beneficiaries in the full coverage plan, and generic 
coverage plan (12.52 prescriptions less; p=0.001). A significant decrease in post-
coverage gap medication adherence was observed between beneficiaries in the no 
coverage versus full coverage plans for beneficiaries on statins (5.8%), ARB’s (16%) and 
PPI’s (18.1%) when measured using the PDC as a measure of adherence. Similarly, a 
decrease in post-coverage gap medication adherence was observed between beneficiaries 
in the no coverage versus generic coverage plans for beneficiaries on statins (1.1%) and 
ARB’s (12%) when measured using the PDC as a measure of adherence.  No significant 
post-coverage gap differences were observed between beneficiaries enrolled in the full 
coverage plan and generic coverage plan for any of the drug classes. 
In conclusion, the results of this study indicate that lack of prescription drug 
coverage during the Medicare Part D coverage gap leads to decreased utilization and 
adherence to certain essential prescription drugs. 
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CHAPTER 1 
INTRODUCTION 
 
Medicare 
 
Medicare, a federal insurance program established in 1965, provides health 
insurance to Americans aged 65 and older and to individuals under age 65 with certain 
disabilities or end-stage renal disease. (Centers for Medicare and Medicaid Services, 
2008a) In 2008, 44 million elderly and disabled Americans, accounting for 15% of the 
total US population, were eligible for Medicare benefits. (Kaiser Family Foundation, 
2008) Prior to 2006, Medicare included three parts - Part A, B and C. In 2006, a 
prescription drug benefit, referred to as ‘Medicare Part D’, was introduced.  
Medicare Part A, also referred to as hospital insurance, covers inpatient care in 
hospitals, skilled nursing facilities, hospice care services and home health care services. 
(Centers for Medicare and Medicaid Services, 2008a) Medicare Part B, also referred to as 
medical insurance, includes coverage for medically necessary services (such as outpatient 
care, emergency room services) and some preventive services not covered under Part A. 
Medicare Part C, also referred to as Medicare Advantage, includes coverage provided by 
private health insurance companies which contract with the federal government to 
provide Medicare Part A and B services and typically cover additional benefits such as 
prescription drug coverage, vision, dental, extra days in hospitals, etc. (Centers for 
Medicare and Medicaid Services, 2008a) Medicare Part D, also referred to as Medicare 
prescription drug coverage, includes prescription drug coverage for all Medicare 
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beneficiaries.  
 
Medicare Part D: The need for prescription drug coverage 
In 2002, about 90% of Medicare beneficiaries’ were prescribed at least one 
prescription drug and 30% had three or more chronic conditions requiring prescription 
drugs. (J Cubanski, Voris, Kitchman, Neuman, & Potetz, 2005) Nearly 45% of Medicare 
beneficiaries lacked a full year of prescription drug coverage in 2002 and reported about 
$1,000/year in average out-of-pocket (OOP) expenses on prescription drugs. Further, 
nearly half of all Medicare beneficiaries had incomes below 200 percent of the federal 
poverty level (FPL). (J Cubanski, et al., 2005) The statistics presented above define four 
principal characteristics of Medicare beneficiaries in 2002: 1) they had a disproportionate 
need for prescription drugs 2) the majority lacked a full year of prescription drug 
coverage 3) incurred high OOP expenses (relative to their income) and 4) had limited 
financial resources. 
To increase Medicare beneficiaries’ access to medications and help lower their 
prescription drug costs, the Medicare Prescription Drug, Improvement, and 
Modernization Act (MMA) of 2003 introduced a prescription drug benefit for all 
Medicare beneficiaries. (Centers for Medicare and Medicaid Services, 2004) Beginning 
January 1, 2006, this voluntary outpatient prescription drug benefit, commonly  referred 
to as ‘Medicare Part D’, was made available to all individuals entitled to Medicare Part A 
or enrolled in Medicare Part B. (Centers for Medicare and Medicaid Services, 2004)  
 
Medicare prescription drug plans  
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Medicare beneficiaries can obtain Part D benefits either by enrolling in a 
prescription drug plan or a Medicare Advantage prescription drug plan. Beneficiaries 
enrolled in the traditional fee-for-service Medicare (Part A and B enrollees) can receive 
Medicare Part D benefits from prescription drug plans (PDP).(Centers for Medicare and 
Medicaid Services, 2004; Department of Health and Human Services, 2008) Prescription 
drug plans are stand-alone plans, that is, these plans only provide prescription drug 
coverage. Medicare Advantage prescription drug (MA-PD) plans are prescription drug 
plans offered for beneficiaries enrolled in Medicare Advantage (Medicare Part C) plans. 
All PDP and MA-PD plans are required to offer a prescription drug benefit that is either 
based on a standard benefit structure established by the MMA or is actuarially equivalent 
to the standard benefit structure. Details about PDP and MA-PD plans will be discussed 
in the next chapter.  
 
Standard Medicare Part D benefit structure 
In 2007, the standard Medicare prescription drug benefit included a $265 
deductible and 25% coinsurance up to an initial coverage limit of $2,400 in total drug 
costs. (Kaiser Family Foundation, 2007c) After the initial coverage limit of $2,400 in 
total drug costs, Medicare offers no coverage until beneficiaries reach $5,451 in total 
drug costs ($3,850 in true out-of-pocket expenses). During this gap referred to as the 
‘coverage gap’ or the ‘doughnut hole’, beneficiaries pay 100% of their drug costs. For 
drug spending above $5,451, referred to as the catastrophic coverage limit, beneficiaries 
are responsible for a greater of $2/$5 (for generics/brand) co-payments or 5% 
coinsurance on the amount they spend on prescription drugs.  
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Medicare Part D Coverage Gap 
Initiation of Medicare Part D increased prescription drug coverage and provided 
financial assistance for a large number of Medicare beneficiaries. One study indicated 
that Medicare Part D decreased out-of-pocket prescription drug expenditures by 13% and 
increased prescription utilization by about 6%. (Yin et al., 2008)  However, certain 
aspects of the Part D benefit structure such as cost-sharing requirements and the coverage 
gap have been controversial issues. Medicare Part D has been structured to include 
substantial cost-sharing from beneficiaries in the form of deductibles, co-payments and 
tiered payments. A literature review indicates that elderly patients are price responsive to 
cost-sharing for prescription drugs, with an estimated price elasticity of -0.2 to -0.6, 
indicating that a 10% increase in cost-sharing would lead to a 2-6% reduction in 
utilization of prescription drugs. (Chandra, Gruber, & McKnight, 2007; Gilman & 
Kautter, 2008; Johnson, Goodman, Hornbrook, & Eldredge, 1997; Pauly, 2004; Tamblyn 
et al., 2001a) In addition to deductibles and co-insurance, the Medicare Part D coverage 
gap, during which beneficiaries are required to pay 100% of drug costs, constitutes the 
highest cost-sharing component.  
The coverage gap creates a situation where a beneficiary has no prescription drug 
coverage. Lack of prescription drug coverage has been associated with decreased 
medication adherence and higher out-of-pocket expenses, with more pronounced effects 
for low income and ethnic minorities. (Safran et al., 2005; S. Soumerai et al., 2006; 
Steinman, Sands, & Covinsky, 2001; Stuart & Grana, 1998) High costs of medications 
have also been reported to be predictors of poor medication adherence. (National Council 
on Patient Information and Education, 2007; Osterberg & Blaschke, 2005; P. Rogers & 
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Bullman, 1995) Poor medication adherence due to the high costs of prescription drugs 
has been associated with adverse health outcomes, increased hospitalizations and patients 
perceiving their health as poor. (Cramer JA et al., 2008; DiMatteo MR, Giordani PJ, 
Lepper HS, & Croghan TW, 2002; Osterberg & Blaschke, 2005; Rector & Venus, 2004)  
The Medicare Part D coverage gap also mirrors the prescription drug benefit caps 
commonly instituted in supplementary Medicare prescription drug plans. Prescription 
benefit caps have been reported to decrease Medicare beneficiaries’ prescription 
utilization by about 8-30%, decrease medication adherence and increase hospitalizations 
and emergency room visits. (R Balkrishnan, Byerly, Camacho, Shrestha, & Anderson, 
2001; Cox & Henderson, 2002; Hsu et al., 2006; Joyce, Goldman, Karaca-Mandic, & 
Zheng, 2007; Tseng, Brook, Keeler, Steers, & Mangione, 2004)  
In summary, cost-sharing associated with prescription drugs has been associated 
with decreased prescription drug utilization and adverse clinical and economic outcomes. 
Based on pharmacy claims data from 1.9 million Medicare beneficiaries, a Kaiser Family 
Foundation study reported that 14% of Part D enrollees (3.4 million Medicare 
beneficiaries) reached the coverage gap in 2007. (Hoadley J et al., 2007) Further, the 
study also reported that 72% PDP and 68% MA-PD plans did not offer any gap coverage 
in 2007.  
The need for this study 
 
Given the large number of Medicare Part D beneficiaries who hit the coverage 
gap, do not have any prescription drug coverage during the coverage gap and the 
potentially adverse clinical and economic outcomes associated with decreased 
prescription utilization and medication adherence, it is important to empirically analyze 
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the impact of the Medicare Part D coverage gap on prescription utilization and 
medication adherence. It is important to assess if Medicare beneficiaries exhibit different 
prescription drug utilization and medication adherence prior to the Medicare Part D 
coverage gap and during the coverage gap. 
The current literature provides limited evidence on the impact of the coverage gap 
on prescription drug utilization and medication adherence. Using pharmacy claims data, 
Sun and Lee reported that after reaching the coverage gap, prescription drug utilization 
decreased by 15.85% and out-of-pocket expenses increased by 88.94%. (F. R. 
Lichtenberg & Sun, 2007) However, caution should be exercised when interpreting these 
results as the authors assumed a fixed month, June, as the month beneficiaries hit the 
coverage gap versus using actual coverage gap dates and referred to the period January-
June as the pre-coverage period and the period July to December as the post-coverage 
gap period. One study based on 2006 data from a large health plan in Pennsylvania 
reported that prescription drug utilization of beneficiaries with no coverage during the 
coverage gap was 14% lower  compared to beneficiaries with full coverage during the 
gap. (Zhang, Donohue, Newhouse, & Lave, 2009)  
A 2007 Kaiser Family Foundation study, based on pharmacy claims data for 1.9 
million Medicare beneficiaries, reported that 20% of the beneficiaries who reached the 
coverage gap either stopped taking their medications, switched to another medication in 
the same class, or reduced the number of medications they were taking within the same 
therapeutic class. (Hoadley J, et al., 2007) Similar results of decreased medication 
adherence were reported in a survey of Medicare beneficiaries enrolled in a Kaiser 
Permanente Colorado Medicare Advantage plan. (Cronk, Humphries, Delate, Clark, & 
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Morris, 2008) Beneficiaries with no gap coverage were nearly five times more likely than 
beneficiaries with gap coverage to report using a medication cost-lowering strategy such 
as using less medication than was prescribed or stop taking medication during the 
coverage gap.  
Raebel et al., (2008) used data from two Kaiser Permanente Colorado health plans 
and reported that beneficiaries who reached the coverage gap had an 85% greater 
likelihood of inpatient hospitalizations; 60% greater likelihood of ED visit and 12% 
greater likelihood of office visits compared to beneficiaries who did not reach the 
coverage gap. (Raebel, Delate, Ellis, & Bayliss, 2008) Further, during the coverage gap, 
significant reduction in adherence to anti-hyperlipidemics, anti-hypertensives, and anti-
depressants was reported.  
In summary, a number of studies assessing the impact of Medicare Part D 
coverage gap on prescription drug utilization and medication adherence are descriptive in 
nature (Cronk, et al., 2008; Hoadley, Hargrave, Cubanski, & Neuman, 2008). Studies 
which are based on retrospective claims data either include health plan data and lack 
direct comparison with a control group (Raebel, et al., 2008); or include a control group 
and lack health plan data or do not control for selection bias. (Zhang, et al., 2009) Studies 
are also limited by assumptions of a pseudo coverage gap month. (F. R. Lichtenberg & 
Sun, 2007)  
Therefore, despite evidence of potentially adverse clinical and economic 
outcomes associated with the lack of prescription drug coverage; an elderly population 
with disproportionately high need of prescription drugs, high OOP expenses (relative to 
their income) and limited financial resources, the current literature does not include 
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methodologically robust studies assessing the impact of the coverage gap on Medicare 
beneficiaries’ utilization of prescription drugs and medication adherence. This study uses 
a methodologically robust research design which enables control of not only 
demographic and health plan characteristics but more importantly controls for the effect 
of time and within person variations while comparing with a control group by using 
robust econometric analyses. In using a methodologically robust study design with 
appropriate control of confounding factors, this study will bring forth, the much needed 
assessment of the impact of lack of prescription drug coverage during the Medicare Part 
D coverage gap on Medicare beneficiaries’ prescription drug utilization and medication 
adherence.  
 
Medicare in New Mexico 
With Medicare part D data not released by CMS, impact of the Medicare Part D 
coverage gap cannot be assessed in a national sample of Medicare beneficiaries. In the 
absence of availability of Medicare data at a national level, use of Medicare data from 
local health plans might provide a reasonable estimate of the impact of Medicare Part D 
coverage gap on prescription drug utilization and medication adherence. For the purposes 
of this study, data from Medicare beneficiaries enrolled in a large health plan in New 
Mexico was used. To ensure that  data from New Mexico Medicare beneficiaries would 
provide a reasonable estimate of the impact of  Part D coverage gap on all Medicare 
beneficiaries’, demographics and eligibility statistics of New Mexico Medicare 
beneficiaries were compared with that of Medicare beneficiaries in the Unites States.  
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As of February, 2009, 15% (292,603) of the total population in the state of New 
Mexico received Medicare benefits. Similarly, 15% of total US population received 
Medicare benefits in 2009. In 2007, three-quarters of New Mexico Medicare 
beneficiaries were 65 years or older (compared to 83% in US); 55% were female 
(compared to 57% in US); 39% were Hispanic (compared to 7% in US); and nearly half 
(48%) were living below 200% of the Federal Poverty Level (compared to 47% in US). 
(Kaiser Family Foundation, 2007e, 2007f, 2007g, 2007h) In 2008, of the 292,636 New 
Mexico Medicare beneficiaries eligible to receive Part D benefits, nearly 40% were 
enrolled in stand alone PDP plans (compare to 39% in US); 22% were enrolled in MA-
PD plans (compared to 20% in US); 6% were enrolled in employee plans taking retiree 
drug subsidies (compared to 13% in US); and nearly 16% received some other form of  
prescription drug coverage (compared to 13% in US).(Kaiser Family Foundation, 2009) 
About 85% (251,768) of the Medicare beneficiaries eligible to receive Part D benefits 
had known creditable drug coverage, that is, had coverage that meets or exceeds the 
actuarial value of standard Part D coverage in 2009 (compare to 86% in US). (Kaiser 
Family Foundation, 2009)  
Given that Medicare Part D data has not been released by CMS and demographics 
and eligibility statistics of New Mexico Medicare beneficiaries are very similar to 
Medicare beneficiaries in the Unites States except for the distribution based on ethnicity, 
the results from this study will provide a reasonable estimate of the impact of Medicare 
Part D coverage gap on Medicare beneficiaries’ prescription drug utilization and 
medication adherence.  
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  The purpose of this study is thus to assess the impact of the Medicare Part D 
coverage gap on prescription drug utilization and medication adherence by using data 
from beneficiaries enrolled in a large health plan in New Mexico. The specific objectives 
of this study are as follows.  
Study Objectives and Hypotheses  
 
Prescription Drug Utilization 
1. To compare prescription drug utilization of a sample of New Mexico Medicare 
beneficiaries enrolled in a Medicare Part D plan with full prescription drug coverage 
during the coverage gap with prescription drug utilization of Medicare beneficiaries 
enrolled in a plan providing no prescription drug coverage during the coverage gap. 
Ho: There is no difference in prescription drug utilization of a sample of New Mexico 
Medicare beneficiaries enrolled in a Medicare Part D plan with full prescription drug 
coverage during the coverage gap and prescription drug utilization of Medicare 
beneficiaries enrolled in a plan providing no prescription drug coverage during the 
coverage gap. 
 
2. To compare prescription drug utilization of a sample of New Mexico Medicare 
beneficiaries enrolled in a Medicare Part D plan covering generic drugs during the 
coverage gap with prescription drug utilization of Medicare beneficiaries enrolled in a 
plan providing no prescription drug coverage during the coverage gap. 
Ho: There is no difference in prescription drug utilization of a sample of New Mexico 
Medicare beneficiaries enrolled in a Medicare Part D plan covering generic drugs 
during the coverage gap and prescription drug utilization of Medicare beneficiaries 
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enrolled in a plan providing no prescription drug coverage during the coverage gap. 
 
3. To compare prescription drug utilization of a sample of New Mexico Medicare 
beneficiaries enrolled in a Medicare Part D plan with full prescription drug coverage 
during the coverage gap with prescription drug utilization of Medicare beneficiaries 
enrolled in a plan covering generic drugs during the coverage gap. 
Ho: There is no difference in prescription drug utilization of a sample of New Mexico 
Medicare beneficiaries enrolled in a Medicare Part D plan with full prescription drug 
coverage during the coverage gap and prescription drug utilization of Medicare 
beneficiaries enrolled in a plan covering generic drugs during the coverage gap. 
 
4. To compare medication adherence (to select drug classes) of a sample of New 
Mexico Medicare beneficiaries enrolled in a Medicare Part D plan with full 
prescription drug coverage during the coverage gap with medication adherence of 
Medicare beneficiaries enrolled in a plan providing no prescription drug coverage 
during the coverage gap. 
Ho: There is no difference in medication adherence (to select drug classes) of a 
sample of New Mexico Medicare beneficiaries enrolled in a plan with full 
prescription drug coverage during the coverage gap and medication adherence of 
Medicare beneficiaries enrolled in a plan providing no prescription drug coverage 
during the coverage gap. 
 
5. To compare medication adherence (to select drug classes) of a sample of New 
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Mexico Medicare beneficiaries enrolled in a Medicare Part D plan covering generic 
drugs during the coverage gap with medication adherence of Medicare beneficiaries 
enrolled in a plan providing no prescription drug coverage during the coverage gap. 
Ho: There is no difference in medication adherence (to select drug classes) of a 
sample of New Mexico Medicare beneficiaries enrolled in a Medicare Part D plan 
covering generic drugs during the coverage gap and medication adherence of 
Medicare beneficiaries enrolled in a plan providing no prescription drug coverage 
during the coverage gap. 
 
6. To compare medication adherence (to select drug classes) of a sample of New 
Mexico Medicare beneficiaries enrolled in a Medicare Part D plan with full 
prescription drug coverage during the coverage gap with medication adherence of 
Medicare beneficiaries enrolled in a plan covering generic drugs during the coverage 
gap. 
Ho: There is no difference in medication adherence (to select drug classes) of a 
sample of New Mexico Medicare beneficiaries, enrolled in a Medicare Part D plan 
with full prescription drug coverage during the coverage gap and medication 
adherence of Medicare beneficiaries enrolled in a plan covering generic drugs during 
the coverage gap. 
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CHAPTER 2 
LITERATURE REVIEW 
 
This chapter provides a review of the literature as related to topics of significant 
importance to this study. The literature review is divided into four major sections: 1) an 
overview of Medicare, 2) Medicare and cost-sharing, 3) medication adherence and 4) 
theoretical framework used to conduct the study.  
Section I begins with an overview of Medicare Parts A, B, and C with description 
of eligibility requirements, enrollment rates, cost and financing of each of the three 
Medicare parts. Next, the need to introduce Medicare Part D is described, followed by a 
description of Medicare Part D eligibility requirements, enrollment rates, types of 
Medicare Part D plans and the standard Medicare prescription drug benefit structure.  
Section II of this chapter includes an overview of the literature surrounding 
Medicare and cost-sharing, beginning with a description of the concept of cost-sharing. 
Next, the impact of cost-sharing in Medicare on health care utilization is described with 
reference to six key topics: i) impact of Medicare eligibility on utilization of health care 
services ii) impact of prescription drug coverage on Medicare beneficiaries’ prescription 
drug utilization, medication adherence and health care utilization iii) impact of changes in 
co-payments on Medicare beneficiaries’ prescription drug utilization, medication 
adherence and health care utilization iv) impact of prescription benefit caps on Medicare 
beneficiaries’ prescription drug utilization, medication adherence and health care 
utilization v) impact of Medicare Part D on Medicare beneficiaries’ prescription drug 
utilization, medication adherence and health care utilization and vi) impact of Medicare 
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Part D coverage gap on Medicare beneficiaries’ prescription drug utilization, medication 
adherence and health care utilization.  
Section III is dedicated to medication adherence and includes descriptions related 
to definition of adherence, factors affecting medication adherence, measurement of 
medication adherence and adherence measures used in this study. Section IV describes 
the theoretical framework used in this study. Finally, a summary of literature review is 
provided.  
 
PART I: AN OVERVIEW OF MEDICARE  
Medicare, a federal insurance program, established in 1965 under Title XVIII of 
the Social Security Act, provides health insurance to Americans aged 65 and older and to 
individuals under age 65 with certain disabilities or end-stage renal disease. (Centers for 
Medicare and Medicaid Services, 2008a) In 2008, about 44.2 million elderly and disabled 
Americans, accounting for 15% of the total US population, were eligible for Medicare 
benefits. (Kaiser Family Foundation, 2008)  
Medicare was initially established (in 1965) to only include individuals aged 65 or 
older. (Kaiser Family Foundation, 2007d) In 1972, Medicare eligibility was expanded to 
include individuals under age 65 with permanent disabilities and End-Stage Renal 
Disease (ESRD). In 2001, the program was expanded to cover individuals with Lou 
Gehrig’s disease.(Kaiser Family Foundation, 2007d) In 2007, Medicare eligibility 
required an individual to be a citizen or permanent resident of the United States; over age 
65; or under age 65 and a Social Security Disability Insurance beneficiary (individuals 
with a medical determination of disability by Social Security); or under age 65, with 
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ESRD or Lou Gehrig’s disease. (Centers for Medicare and Medicaid Services, 2008b; 
Social Security Administration, 2008) In 2007, of the nearly 44 million Medicare 
beneficiaries, 37 million qualified to receive Medicare benefits based on their age (65 and 
older) and 7 million qualified to receive Medicare benefits due to disabilities or covered 
disease states (under 65). (Kaiser Family Foundation, 2007d) 
Medicare consists of four parts: Part A, B, C and D. Medicare Part A covers 
inpatient care in hospitals, skilled nursing facilities, hospice care services and home 
health care services. (Centers for Medicare and Medicaid Services, 2007) Medicare Part 
B covers physicians’ services and outpatient care. Medicare Part C includes coverage for 
all Medicare Part A and B services and typically includes additional benefits such as 
vision, hearing, dental, prescription drug coverage, extra days in hospitals, etc. Medicare 
Part D is an outpatient prescription drug benefit made available to all individuals entitled 
to Medicare Part A or enrolled in Medicare Part B. Detailed coverage, eligibility 
requirements and costs associated with Medicare Part A, B, C and D are provided below.  
 
Medicare Part A 
Medicare Part A also referred to as hospital insurance, covers inpatient care in 
hospitals, including care in critical access hospitals (small facilities that give limited 
outpatient and inpatient services to people in rural areas), and skilled nursing facilities 
(not custodial or long-term care). Medicare Part A also covers hospice care and some 
home health care. In 2007, about 43.7 million individuals were entitled to receive 
Medicare Part A benefits. (Kaiser Family Foundation, 2007d)  
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Eligibility: Individuals 65 years of age or older are entitled to receive premium 
free Part A if they are a citizen or permanent resident of the United States and  they are 
either receiving or are eligible to receive benefits from either Social Security or the 
Railroad Retirement Board or had Medicare-covered government employment; or they 
(or their spouse) worked for at least 10 years in Medicare-covered employment. 
Individuals under the age of 65 who have received disability benefits from Social 
Security or Rail Road Retirement Board for 24 months; or under age 65 with ESRD or 
Lou Gehrig’s disease are eligible to receive premium free Medicare Part D benefits. 
Individuals not eligible to receive premium free Medicare Part A can purchase it.   
Enrollment: Individuals with Social Security or Rail Road retirement benefits or 
disabled individuals are auto enrolled in Medicare Part A. Individuals with Social 
Security or Rail Road retirement benefits receive their Medicare card about 3 months 
before their 65th birthday, disabled individuals receive Medicare benefits on the 25th 
month of disability; and individuals with ESRD or Lou Gehrig’s disease receive Part A 
the month their disability benefits begin. (Centers for Medicare and Medicaid Services, 
2008a)  
 Individuals not eligible for premium-free Part A, can purchase Medicare Part A 
either during a 7-month initial enrollment period (which begins 3 months before the 
individuals 65th  birthday and ends 3 months after the individuals 65th birthday); or during 
the general enrollment period from January 1st–March 31st each year. Individuals 
receiving health coverage through their (or their spouse’s) employer or union can 
purchase Part A anytime while they are covered under the employer’s health plan or 
during a special enrollment period. The special enrollment period lasts for a 8-month 
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period that begins the month the employment ends, or the health plan coverage ends, 
whichever happens first. (Centers for Medicare and Medicaid Services, 2008a) 
Cost: In 2007, individuals who were not eligible to receive premium free Part A 
could purchase it by paying a monthly premium of $410.  
Financing: Part A is funded by Medicare taxes with employers and employees 
each contributing 1.45% of earnings. (Kaiser Family Foundation, 2007b) In 2006, 
Medicare Part A contributed to about 40% of the total Medicare spending. (Kaiser Family 
Foundation, 2007d) 
 
Medicare Part B 
Medicare Part B, also referred to as medical insurance, includes coverage for 
medically necessary and some preventive services not covered under Part A. These 
include physicians’ services, outpatient care (including outpatient mental health care), 
emergency room services, urgently needed services (ambulance services, blood, etc) 
kidney dialysis and services, some preventive services (bone mass measurement, 
cardiovascular screening, colorectal cancer screening, diabetes screening, mammograms, 
pap test, prostate cancer screenings, smoking cessation services, vaccinations, etc) and 
other medically necessary services (laboratory and diagnostic tests, diabetes supplies, 
durable medical equipment, occupational therapy, physical therapy, etc). (Centers for 
Medicare and Medicaid Services, 2008a) In 2007, approximately 40.6 million 
beneficiaries enrolled in Medicare Part B. (Kaiser Family Foundation, 2007d) 
Eligibility: Beneficiaries enrolled in Medicare Part A are automatically enrolled 
in Medicare Part B unless they specifically decline enrollment in Part B. (Kaiser Family 
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Foundation, 2007d) About 95% of beneficiaries who enroll in Medicare Part A also 
enroll in Medicare Part B. Individuals over the age of 65, not enrolled in Medicare Part 
A, can enroll in Medicare Part B if they are a US citizen or have lived lawfully in the US 
for at least 5 years. (Social Security Administration, 2008)  
Enrollment: Beneficiaries can enroll in Medicare Part B during three periods: 
initial enrollment period, special enrollment period and general enrollment period. Initial 
enrollment period includes a 7-month period which begins 3 months before the 
beneficiary’s 65th birthday and ends 3 months after the beneficiary’s 65th birthday. 
(Centers for Medicare and Medicaid Services, 2007; Social Security Administration, 
2008) Beneficiaries, who choose not to enroll in Medicare Part B during the initial 
enrollment period, may be subject to a late enrollment penalty unless they are eligible to 
enroll during the special enrollment period. The special enrollment period refers to a 
period of eight months following the end of qualified employer coverage. Beneficiaries 
who do not enroll in the initial or special enrollment can still enroll during the general 
enrollment period, which includes the first three months of each year (January 1st to 
March 31st). However, they are subject to a late enrollment penalty. The penalty is a 10% 
premium increase for each 12-month period that a beneficiary did not have Medicare Part 
B. Beneficiaries are required to pay this penalty as long as they have Part B.  
Cost: To receive Part B services, beneficiaries are required to pay a deductible 
and a monthly premium. Medicare Part B premium amounts differ based on a 
beneficiary’s income. A standard Part B premium is applicable to beneficiaries with 
annual income less than $80,000 filing an individual tax return (or income less than 
$160,000 for beneficiaries filing joint tax returns). In 2007, the deductible was set at $131 
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and the standard Part B premium was set at $93.50 per month. After the deductible, 
Medicare pays 80% of the costs and beneficiaries are responsible for 20% of the costs 
incurred. Beneficiaries with higher annual incomes are required to pay a higher monthly 
premium. For example, in 2007, beneficiaries with income between $80,001-100,000 
filing individual tax returns (or income between $160,001-$200,000 for beneficiaries 
filing joint tax returns) paid a monthly Part B premium of $105.80.  
Funding: General revenues of the federal government and beneficiary premiums 
fund Part B. (Kaiser Family Foundation, 2007b) In 2006, Part B accounted for 35% of 
Medicare spending. (Kaiser Family Foundation, 2007d) 
 
Medicare Part C 
Medicare Part C, also referred to as Medicare Advantage (and previously as 
Medicare +Choice), includes coverage provided by private health insurance companies 
which contract with the federal government to provide all Medicare Part A and B services 
and typically cover additional benefits such as vision, hearing, dental, prescription drug 
coverage, extra days in hospitals, health and wellness programs, etc. Medicare 
beneficiaries enrolled in a Medicare Advantage plan pay an additional health plan 
premium (in addition to their Part B premium) depending on the services covered by their 
plan. (Centers for Medicare and Medicaid Services, 2008a) In 2007, about 20% (8.7 
million) of the Medicare beneficiaries nationwide and 59,177 Medicare beneficiaries in 
New Mexico were enrolled in Medicare Advantage plans. (Kaiser Family Foundation, 
2007d) 
There are five different types of Medicare Advantage (MA) plans from which 
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beneficiaries can choose from to receive Medicare Part C benefits. These include Health 
Maintenance Organizations (HMO), Preferred Provider Organizations (PPO), Private 
Fee-for-Service Plans (PFFS), Special Needs Plans (SNP), and Medical Savings Account 
Plans (MSA). These plans differ based on their coverage for services obtained from 
providers associated within the plans network (in-network) or from providers’ outside of 
the plans network (out-of-network).  
MA-HMO plans only cover services obtained from in-network providers. 
Beneficiaries enrolled with MA-PPO plans are covered for services from out-of-network 
providers, but receive a financial incentive for obtaining services from in-network 
providers. Beneficiaries enrolled with MA-PFFS plans may receive services from any 
Medicare-approved provider or hospital that accepts the plan’s payment. MA-SNP plans 
provide coverage for beneficiaries who require more focused and specialized health care 
such as those who have both Medicare and Medicaid, who reside in a nursing home, or 
have certain chronic medical conditions. MA-MSA plan combines a high deductible 
health plan with a medical savings account. Beneficiaries enrolled in an MSA plan 
receive an annual deposit into an interest-bearing account, from the Center for Medicare 
and Medicaid Services (CMS), which they can use to pay for their health care costs. 
Beneficiaries must meet a high deductible (maximum of $9,500 in 2007), before the plan 
covers Medicare services. After a beneficiary reaches his/her deductible, the plan is 
responsible for all Medicare-covered costs. In 2007, MSA plans only covered Part A and 
B and did not offer any supplemental benefits. However, beneficiaries pay the same cost 
for receiving care from in-network or out-of-network providers. (Centers for Medicare 
and Medicaid Services, 2008a) 
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In 2007, about 71 % MA beneficiaries enrolled in local HMO and PPO plans. Of 
these, a majority (92%) of the beneficiaries opted to enroll in HMO plans. In order to 
provide beneficiaries in rural areas greater access to MA plans, the Medicare 
Modernization Act of 2003 established regional PPO plans in addition to local PPO 
plans. PFFS plans accounted for 18% of total MA enrollment in 2007. In 2007, over 
930,000 beneficiaries (majority of who were dual eligible’s) enrolled in SNP plans and 
about 2,249 beneficiaries enrolled in MSA plans.  
Eligibility: Individuals entitled to Medicare Part A and enrolled in Medicare Part 
B are eligible to enroll in MA plan. (Centers for Medicare and Medicaid Services, 2007) 
However, individuals with ESRD are not eligible to enroll in MA HMO, PPO, PFFS or 
MSA plans. Beneficiaries with ESRD could join a MA-SNP plan if one is available in 
their area of service. If an individual develops ESRD while enrolled in a Medicare 
Advantage plan, then they can continue to be enrolled in that plan. Further, beneficiaries 
with successful kidney transplants are eligible to join a MA plan.  
Enrollment: Beneficiaries can enroll in MA plans during the initial enrollment 
period which includes a 7-month period that begins 3 months before the beneficiary’s 
65th birthday and ends 3 months after the beneficiary’s 65th birthday. Beneficiaries, who 
do not join during the initial enrollment period, can join a MA plan between November 
15th and December 31st of each year. Beneficiaries can also join or switch MA plans 
during the general enrollment period, which includes the first three months of each year. 
(Centers for Medicare and Medicaid Services, 2007) 
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Managed care versus traditional Medicare 
Proponents of managed care indicate that HMO plans provide greater benefits to 
individuals through the use of services such as preventive care and provision of 
additional benefits such as reduced deductibles, etc. Opponents of managed care 
however, contend that managed care creates barriers to access, for example through use 
of referrals, etc. Based on an analysis of responses to a CMS survey of approximately 
500,000 Medicare beneficiaries, Landon et al (2004) reported that Medicare HMO’s are 
better at providing preventive services while traditional Medicare provides better access 
to care and more patient satisfaction. (Landon, Zaslavsky, Bernard, Cioffi, & Cleary, 
2004) 
 
Characteristics of MA enrollees 
The Kaiser Family Foundation released a report comparing MA plan beneficiaries 
with original Medicare fee for service plan beneficiaries, based on their income, 
ethnicity, rural versus urban enrollment and health status. (Kaiser Family Foundation, 
2007a) This report was based on an analysis of the Medicare Current Beneficiary Survey 
(MCBS) data for the year 2005. 
Income: The Kaiser Family Foundation report indicates that income levels of MA 
plan beneficiaries are similar to income levels of the original Medicare plan beneficiaries. 
The report indicates that nearly half (48%) of original Medicare and an equal number of 
MA plan beneficiaries (50%) live on annual incomes less than $20,000; 19% of original 
Medicare plan and 22% MA plan beneficiaries have income between $20,000-30,000; 
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and 34% of original Medicare and 28% of MA plan beneficiaries have income above 
$30,000.  
Ethnicity: Based on the Kaiser Family Foundation report, in 2005, more White 
(87%) and African American (85%) beneficiaries enrolled in original Medicare plans. 
While only 13% White and 15% African American beneficiaries enrolled in MA plans, 
nearly 25% of Hispanic beneficiaries enrolled in MA plans.  
Rural versus Urban enrollment: The Kaiser Family Foundation report indicated 
that MA plan enrollment was higher in urban metro areas compared to rural areas. In 
2005, only 2 % of rural Medicare beneficiaries enrolled in MA plans while 18% of 
beneficiaries in urban metro areas enrolled in MA plans. However, in 2007, the number 
of rural Medicare beneficiaries enrolling in MA plans increased to about 7%.   
Health status measures: The Kaiser Family Foundation report indicates that MA 
plan beneficiaries are healthier than original Medicare plan beneficiaries when compared 
on a number of health measures. About 29% original Medicare plan beneficiaries report 
that they are in fair or poor health status compared to 24% MA plan beneficiaries; 17% 
original Medicare plan enrollees are under age 65 and have permanent disabilities 
compared to 7% MA plan enrollees; and 5% of original Medicare plan beneficiaries live 
in nursing homes and other institutions compared to 3% MA plan beneficiaries. 
  
Medicare Part D 
Need for Medicare Part D  
Based on data from the Congressional Budget Office, it has been reported that in 
2000, approximately 28% of Medicare beneficiaries did not have prescription drug 
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coverage. (Pauly, 2004) Prior to 2003, despite Medicare coverage, seniors (age 65 or 
older) who did not qualify for federal assistance programs, may have spent up to 50% of 
their income on medical expenses. (Dalen & Hartz, 2005) In 2003, Medicare 
beneficiaries spent, on average, $2,322/year for prescription drugs and about 16% of 
Medicare beneficiaries incurred drug costs greater than $4,000. (Dalen & Hartz, 2005)  
To increase Medicare beneficiaries’ access to medications and help lower their 
prescription drug costs, the Medicare Prescription Drug, Improvement, and 
Modernization Act (MMA) of 2003 introduced a prescription drug benefit for all 
Medicare beneficiaries. (Centers for Medicare and Medicaid Services, 2004) Beginning 
January 1, 2006, this voluntary outpatient prescription drug benefit, referred to as 
‘Medicare Part D’, was made available to all eligible Medicare beneficiaries. According 
to the U.S. Department of Health & Human Services, in 2007, 23.9 million beneficiaries 
were enrolled in Medicare Part D plans, 15.2 million had creditable drug coverage (from 
retiree plans, TRICARE, FEHB, Veterans Administration, etc). (Kaiser Family 
Foundation, 2007c) However, about 4 million beneficiaries, representing about 10% of 
the Medicare population, despite meeting eligibility requirements, did not enroll in a plan 
with creditable drug coverage in 2007. (Kaiser Family Foundation, 2007c) 
Eligibility: All individuals entitled to Medicare Part A or enrolled in Medicare 
Part B are eligible to receive Medicare Part D benefits.  
Enrollment: Beneficiaries can enroll in Medicare Part D during an initial 
enrollment period, the special enrollment period or the annual enrollment period. 
(Centers for Medicare and Medicaid Services, 2007) It is important to note that, although 
enrollment in Medicare Part D program is voluntary, beneficiaries are subject to a penalty 
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for late enrollment. Beneficiaries can join the Medicare Part D program, without paying a 
penalty, if they enroll during the initial enrollment period (which includes a 7-month 
period that begins 3 months before the beneficiary’s 65th birthday and ends 3 months 
after the beneficiary’s 65th birthday). Beneficiaries are eligible to enroll in Medicare Part 
D, without paying a penalty, during special enrollment periods, if they move out of the 
service area of the plan they are in; if they have both Medicare and Medicaid; if they live 
in, or move into or out of an institution (like a nursing home); or if they have creditable 
prescription drug coverage and that coverage ends. The CMS defines creditable coverage 
as coverage provided through a group health plan and other specified coverage that meets 
or exceeds the actuarial value of standard Part D coverage. Unless covered by the initial 
or special enrollment periods, beneficiaries can pay the late enrollment penalty and enroll 
in Medicare Part D during an annual six week enrollment period, from November 15th 
through December 31st. The penalty for late enrollment is calculated by multiplying 1% 
of the national base beneficiary premium for the year ($27.35 x 1% = $.27 in 2007) by 
the number of full months that a beneficiary was eligible to join a Medicare drug plan but 
did not enroll in one. This penalty amount is added each month to the beneficiary’s 
Medicare drug plan premium for as long as they are enrolled in Medicare Part D.  
 
Medicare Part D plan types 
Medicare beneficiaries can obtain the prescription drug benefit either by enrolling 
in a prescription drug plan (PDP) or from a Medicare Advantage prescription drug plan 
(MA-PD). Prescription drug plans (PDP) are stand-alone plans, that is, these plans only 
provide prescription drug coverage. Beneficiaries enrolled in the traditional fee-for-
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service Medicare (Part A and B enrollees) can receive Medicare Part D benefits from a 
PDP. (Centers for Medicare and Medicaid Services, 2004; Department of Health and 
Human Services, 2008) Medicare Advantage prescription drug (MA-PD) plans are 
prescription drug plans offered for Medicare beneficiaries enrolled in Medicare 
Advantage (Medicare Part C). Beneficiaries enrolled in Medicare Advantage HMO, PPO 
and SNP plans can receive Part D benefits only from a MA-PD plan. However, 
beneficiaries enrolled in a MA-MSA or MA-PFFS plans, which do not offer qualified 
Part D drug coverage, can receive Part D benefits from a stand-alone PDP.  
 
Enrollment in PDP and MA-PD plans 
In 2006, PDP plans had higher enrollment rates compared to MA-PD plans (72 % 
PDP versus 28 % MA-PD). (Juliette Cubanski & Neuman, 2007)  High enrollment in 
PDP plans may be explained in part by the large number of beneficiaries enrolled in the 
traditional FFS Medicare. Prior to 2006, 90% of Medicare beneficiaries were enrolled in 
the traditional FFS program. Beneficiaries in traditional FFS Medicare receive their 
prescription drug benefit by enrolling in a PDP plan. Further, in 2006, about 7 million 
low-income beneficiaries were auto-enrolled into PDP plans. Low income beneficiaries 
accounted for more than 40 percent of all PDP enrollees in 2006. (Juliette Cubanski & 
Neuman, 2007) The trend of higher enrollment in PDP plans continued through 2007. 
According to the U.S. Department of Health & Human Services, in 2007, of the 23.9 
million Medicare Part D enrollees, 17.3 million were enrolled in stand-alone PDP plans 
and about 6.6 million were enrolled in MA-PD plans. (Kaiser Family Foundation, 2007c)   
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Cost of Medicare Part D plans 
The cost of Part D plans varies from one region to another, depending on the 
benefit design, covered drugs, utilization management tools, etc. The monthly national 
base beneficiary premium for Medicare prescription drug  plan, set by CMS, in 2007 was 
$27.35.(Centers for Medicare and Medicaid Services, 2007) The cost of PDP plans in 
2007 ranged from $9.50 for a basic benefit PDP to $135.70 for a PDP with enhanced 
benefits. (Kaiser Family Foundation, 2007c) In 2006, nearly half of MA-PD HMO plans 
had no monthly premium and the average premium for MA-PD HMO plans was nearly 
half that of PDP plans ($16 for MA-PD versus $37 for PDP plans). (Juliette Cubanski & 
Neuman, 2007) 
 
Standard Medicare prescription drug benefit  
The CMS requires that all Medicare Part D plans offer beneficiaries a prescription 
drug benefit that is either based on a standard benefit structure or is actuarially equivalent 
to the standard benefit structure. In 2007, the standard Medicare prescription drug benefit 
included a $265 deductible and 25% coinsurance up to an initial coverage limit of $2,400 
in total drug costs. (Kaiser Family Foundation, 2007c) After the initial coverage limit of 
$2,400, Medicare offers no coverage until beneficiaries reach $5,451 in drug costs 
($3,850 in true out-of-pocket expenses). During this gap commonly referred to as the 
‘coverage gap’ or the ‘doughnut hole’, beneficiaries pay 100% of their drug costs. For 
drug spending above $5,451, also referred to as the catastrophic coverage limit, 
beneficiaries are responsible for a greater of $2/$5 (generics/brand name) co-payment or 
5% coinsurance on the amount they spend on prescription drugs.  
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In 2006, however, only seventeen percent of Part D beneficiaries were enrolled in 
plans offering the standard benefit structure. (Juliette Cubanski & Neuman, 2007) About 
half (52%) of Medicare beneficiaries were enrolled in plans which were actuarially 
equivalent to the standard benefit. The actuarially equivalent plans, typically, have no 
deductible and offer tiered co-payments for covered drugs in lieu of the 25% coinsurance 
in the standard Part D benefit structure. About 30% of beneficiaries were enrolled in 
plans which provided enhanced drug benefits, such as prescription drug coverage during 
the coverage gap, etc. It has also been reported that, compared to PDP plans, a higher 
number of MA-PD plan enrollees had enhanced coverage in 2006 (17% PDP versus 73% 
MA-PD).  
 
PART II: MEDICARE AND COST-SHARING 
The Medicare program (including Parts A, B and D) has been structured to 
include substantial cost-sharing from beneficiaries in the form of deductibles, co-
payments, and tiered payments. It has been estimated that Medicare pays for less than 
half (45%) of the costs that beneficiaries incur annually. (Kaiser Family Foundation, 
2007b) 
Standard and enhanced Medicare Part D benefit structures typically incorporate 
some level of cost-sharing. While some plans may include a deductible ($250), most 
include a coinsurance (25% co-insurance in the initial coverage limit), or a co-payment 
($5 for generics, $15 for brand name, etc). A majority of Part D plans include an annual 
prescription drug coverage cap where beneficiaries pay 100 % of drug costs.  
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With Medicare Part D data not released by CMS, very few studies assessing the 
impact of Medicare Part D cost-sharing requirements have been conducted. However, a 
significant body of literature has been dedicated to understanding the impact of cost-
sharing on Medicare beneficiaries’ prescription drug utilization, medication adherence 
and health outcomes before Medicare Part D was initiated. Findings from these studies 
may provide reasonable estimates of the impact of the cost-sharing in Medicare Part D. 
The following section describes the impact of cost-sharing in Medicare on health care 
utilization. However, in order to better understand the impact of cost-sharing on Medicare 
beneficiaries’ health care utilization, it is important to first review the theoretical 
concepts underlying cost-sharing.   
 
Concept of cost-sharing  
Economic theory suggests that, in the absence of insurance, an individual’s 
willingness to pay for goods and services is based upon their weighing the costs and 
benefits of the goods and the services. (Cutler, Zeckhauser, & Anthony, 2000; Remler & 
Greene, 2009) However, in the presence of insurance, an individual’s contribution to the 
cost of the product might be very little to none, resulting in decreased cost-consciousness 
on the consumer’s part and encouraging higher expenditure. This introduces the moral 
hazard associated with insurance. As defined by Cuter et al, “moral hazard refers to the 
likely malfeasance of an individual making purchases that are partly or fully paid for by 
others”. (Cutler, et al., 2000) The concept of moral hazard suggests that individuals will 
use more services in the presence of insurance, than they would if they had to pay for it 
themselves. With respect to health insurance, moral hazard is described as individuals 
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using greater medical care when they have insurance compared to when they do not have 
health insurance.  
Over-utilization of medical care, attributed to moral-hazard, has been contained 
by employing restrictions on both the demand and the supply side of the provision of 
medical care. The demand-side control includes consumers sharing in the cost of medical 
care. Cost-sharing reflects out-of-pocket expenses borne by individuals while seeking 
medical care. The most commonly used cost-sharing techniques include instituting 
deductibles, co-insurances, co-payments and prescription drug benefit limits. (Rasell, 
1995; Remler & Greene, 2009) Co-insurance refers to a predetermined fixed percentage 
of total medical costs that an enrollee is responsible to pay (for example, 20% of hospital 
costs). Co-payment refers to a flat dollar amount, paid by an enrollee each time a medical 
service is accessed (for example, $10 for each physician visit). Deductibles refer to the 
amount an enrollee is required to pay each year before the insurance provider starts 
paying (for example, $250 deductible before prescription drug coverage begins). 
Prescription drug benefit limits, commonly referred to as ‘benefit caps’ or ‘caps’, refer to 
coverage provided by the insurer up to a certain fixed amount, beyond which the enrollee 
pays all the costs (for example, a $750 cap on prescription drug coverage). The supply-
side control includes monitoring health care providers to ensure that they only provide 
essential medical care. This dissertation will focus on demand-side control, that is, cost-
sharing techniques used to contain medical care costs.  
Cost-sharing techniques have been implemented for decades to prevent over-
utilization of health care services. However, one of the biggest concerns associated with 
cost-sharing is that while utilization of non-essential health care services might be 
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reduced, it might also lead to decreased utilization of essential health care services. 
(Fairman, 2008; Gianfrancesco, Baines, & Richards, 1994; Goldman, Joyce, & Zheng, 
2007; Remler & Greene, 2009) These concerns are based on the complexities involved 
with making health care decisions. Health care decisions involve considerable uncertainty 
and trade-offs over time, and consumers might not always make the most rational 
decisions. To offset short-term cost of medical care, individuals might forgo essential 
health care, which in the long run might eventually lead to increased health care 
spending. For example, cost-sharing requirements might prompt individuals to forgo 
utilization of prescription drugs or preventive care, which might result in long term 
adverse health outcomes and increased hospitalizations. The literature provides ample 
evidence of cost-sharing resulting in individuals using fewer health care services 
compared to when they receive free care or are not subject to any cost-sharing. 
(Goldman, et al., 2007; Johnson, et al., 1997; Rice & Matsuoka, 2004) Studies conducted 
with different populations, in different countries, and with different levels of cost-sharing, 
indicate that cost-sharing reduces health care utilization and thus aids cost-containment. 
(Goldman, et al., 2007; S. Soumerai, Avorn, Ross-Degnan, & Gortmaker, 1987; Tamblyn 
et al., 2001b) 
A number of studies conducted in the 1970’s indicated that medical care demand 
was responsive to cost-sharing. However, elasticities ranging from -0.14 to -1.5 were 
reported, indicating that a 10 percent increase in cost-sharing would be associated with a 
1.4 to 15 percent decrease in utilization of medical services. (Cutler, et al., 2000) 
Methodological challenges (lack of control of health insurance generosity and use of 
average price instead of marginal price) and the high range of elasticities prompted the 
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United States government to fund a social insurance experiment commonly referred to as 
the RAND Health Insurance Experiment (HIE). 
 One of the most important and the largest health insurance study ever conducted, 
the RAND Health Insurance Experiment (HIE), assessed the impact of cost sharing on 
utilization of health care services, quality of care, and health status. This landmark,  
multi-million dollar, randomized field trial, conducted from November 1974-January 
1982 addressed two key questions in health care financing: how much more medical care 
will people use if it is provided free of charge and what are its consequences for their 
health. The HIE enrolled 3,958 individuals (belonging to 2005 families), between the 
ages of 14 and 61, from six sites across the United States to provide a regional and 
urban/rural balance.(Newhouse, 1996) The study excluded any individual who qualified 
or would qualify during the study period to receive Medicare benefits. 
Participating families were randomized to one of fifteen types of health insurance 
plans: fourteen fee-for-service plans and one HMO-style group plan. Of the fourteen fee-
for-service plans, one type offered free care (zero coinsurance) and the other thirteen 
types involved varying levels of patient cost sharing -25%, 50% or 95% cost-sharing. 
Three fee-for-service plans offered 25% coinsurance; three offered 50% coinsurance; 
three offered 95% coinsurance and three offered 25% coinsurance for all services except 
outpatient dental and mental health which were subject to 50% coinsurance. Out-of-
pocket spending for these twelve fee-for-service plans was capped at 5, 10, or 15 % of 
family income or at $1,000 annually, whichever was lower. One fee-for-service plan 
referred to as the individual deductible plan included a 95% co-insurance for outpatient 
services and 0% coinsurance for inpatient services. Out-of-pocket spending for the plan 
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was capped at $150 per person, with a maximum of spending of $450 per family. 
Families assigned to the only HMO plan in the study received their care free of charge, 
similar to the zero percent coinsurance fee-for-service plans. Families participated in the 
experiment for 3–5 years. (Newhouse, 1996)  
Overall, the results of the study indicated that cost sharing resulted in decreased 
utilization of all types of services – physician services, hospital admissions, prescriptions, 
dental visits, and mental health treatment. However, the reduced use of health care 
services were found to have little or no net adverse effect on the health of an average 
person. However, adverse effects of cost-sharing were reported for the economically 
disadvantaged (6% of the population). Economically disadvantaged poor, enrolled in free 
care plans, had lower blood pressure measurements, better vision, better dental health and 
less prevalence of serious symptoms compared to beneficiaries in co-insurance plans. 
(Newhouse, 1996) Specific results of the effects of cost-sharing in the RAND study are 
described below. 
Impact of co-insurance rate on medical service utilization: As the co-insurance 
rates increased, the likelihood of use of any medical service decreased. It was reported 
that 86.8% of individuals enrolled in a free care plan used medical services compared to 
an utilization of 78.8% amongst those with 25 percent co-insurance plan and 67.7% 
amongst those with a 95 percent co-insurance plan. It was reported that cost-sharing led 
to an equal decrease in utilization of services deemed by experts as medically effective 
and medically ineffective.  
        Impact of co-insurance rate on spending indicated that per-person expenditure 
decreased with increasing co-insurance. The reduced spending with higher cost-sharing 
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plans was attributed to individuals using fewer services by deciding not to initiate care 
and not to participants finding lower prices. Beneficiaries enrolled in the 25 percent 
coinsurance plans spent 20% less than participants with free care, and those with 95 
percent coinsurance spent about 30% less than participants with free care. However, it 
was observed that once a patient entered the health care system, cost sharing only 
modestly affected the intensity or cost of an episode of care. No differential response to 
health care expenditure was found across different cost sharing plans based on family 
income, health status, number of years of enrollment and site of the study. 
 Impact of co-insurance rate on prescription drug utilization indicated that like 
other health care services, utilization of prescription drugs decreased with increasing 
cost-sharing. However, significant differences in utilization between free care and co-
insurance plans were reported only for anti-infectives and analgesics.  
Impact of co-insurance rate on use of preventive services indicated that cost-
sharing resulted in a decrease in the number of preventive services used. For example, 
among women 45 to 65 years of age, cost sharing reduced the use of pap smears from 65 
percent to 52 percent over a three-year period. However, although a significant difference 
in utilization of preventive services was reported between the free care and co-insurance 
plans, the percentage of people using any preventive service in the free care plan was 
only marginally higher than the co-insurance plan.  
Participants assigned to the HMO-style group plan were reported to have 39% 
fewer hospital admissions compared to participants with free care in the fee-for-service 
system, but they had similar use of outpatient services. Reduced hospitalization rates in 
the HMO group were attributed to possibly a more intensive out-patient treatment by 
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HMO’s compared to fee-for-service plans. However, no significant differences in health 
outcomes were found between the HMO and the fee-for-service groups. (Newhouse, 
1996)  
Given the scope, methodological robustness and length of time over which the 
RAND HIE was carried out, it has often been referred to as a ‘gold standard’ for studies 
assessing the impact of insurance. Results of the RAND study indicated that while cost-
sharing reduced utilization of all medical services and decreased spending it did not have 
adverse effects on the health of an average individual. While the HIE had immense health 
policy implications, the study did not focus on elderly (over age 65). The following 
sections describe the impact of cost-sharing as related to the Medicare population with 
reference to six key topics:  a) impact of Medicare eligibility on utilization of health care 
services b) impact of prescription drug coverage on Medicare beneficiaries’ prescription 
drug utilization, medication adherence and health care utilization c) impact of changes in 
co-payments on Medicare beneficiaries’ prescription drug utilization, medication 
adherence and health care utilization d) impact of prescription benefit caps on Medicare 
beneficiaries’ prescription drug utilization, medication adherence and health care 
utilization e) impact of Medicare Part D on prescription drug utilization, medication 
adherence and health care utilization and f) impact of Medicare Part D coverage gap on 
prescription drug utilization, medication adherence and health care utilization.  
 
Impact of cost-sharing in Medicare on health care utilization  
a) Impact of Medicare eligibility on utilization of health care services  
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Medicare provides a valuable source of health insurance to retirees, previously uninsured 
individuals and individuals with less comprehensive insurance coverage before Medicare 
eligibility. Studies have been conducted to assess the impact of Medicare eligibility on 
utilization of health care services. (Card, Dobkin, & Maestas, 2004; Lichtenberg 2002; 
McWilliams, Meara, Zaslavsky, & Ayanian, 2007)  
Using data from the Health and Retirement Study, Baker et al., assessed the 
impact of gaining Medicare coverage on overall health and physical functioning for 
previously uninsured (no insurance before age 65) and previously insured (had private 
insurance before age 65) individuals. (Baker et al., 2006) Data was collected for 
previously uninsured and previously insured individuals at three time points: two years 
before age 65 (t−2), at age 65 (t0) and 2 years after age 65 (t2). Changes in overall health 
were reported for 2 periods: t−2 to t0 and t0 to t2. In the time between t−2 to t0, previously 
uninsured adults reported poor overall health (adjusted relative risk 1.46; 95% CI: 1.03 to 
2.04), developing physical difficulty affecting mobility (ARR 1.24; 95% CI: 0.96 to 1.56) 
and poor agility (ARR 1.33; 95% CI: 1.12 to 1.54), when compared to previously insured 
individuals. However, after 2 years of receiving Medicare benefits (t0 to t2), no difference 
in overall health and physical functioning was observed between previously uninsured 
and previously insured individuals.  
 McWilliams et al (2007), also used data from the Health and Retirement Study 
and reported that previously uninsured individuals with cardiovascular disease or diabetes 
reported significant improvements in self-reported health status measures upon receiving 
Medicare eligibility. (McWilliams, et al., 2007) Compared to individuals with insurance 
(n=3103), previously uninsured individuals with cardiovascular disease or diabetes (n= 
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1340), reported significantly improved trends in general health status (differential change 
in annual trend, +0.26; p = .006), change in general health (+0.02; p= .03), mobility 
(+0.04; p= .05), agility (+0.08; p = .003);  and adverse cardiovascular outcomes such as 
MI, CHF, etc (–0.015; p = .02) upon Medicare eligibility.(McWilliams, et al., 2007) 
However, no significant differences were found between the two groups in depressive 
symptoms (+0.04; p = 0.32). (McWilliams, et al., 2007) 
Litchenberg (2002) compared Medicare beneficiaries’ hospital discharges, 
physician visits, and days spent in bed before and after the onset of Medicare benefits. (F. 
Lichtenberg, 2002)  Using data from the National Hospital Discharge Survey for the 
period 1979-92, Litchenberg (2002) reported trends in hospital discharges as individual’s 
progressed from age 62 to 74. Frequency of hospital discharges were reported to have 
remained constant over the age 62-64, increased by 9.5% between the ages 64 and 65 and 
increased by about 0.5% per year between ages 65-74. Using data from the National 
Ambulatory Medical Care Surveys for the period 1973-1998, Litchenberg reported that 
the number of physician visits increased by about 2.7% per year from age 65 to 75 and 
the number of physician visits where at least one drug was prescribed increased by 11.3% 
from age 64 to age 65. Analysis of data from the National Health Interview Survey for 
the period 1987-91, indicated that the mean number of days spent in bed (a morbidity 
measure) over a 12 month period were lower for ages 65-69 compared to ages 60-64 
(9.21 versus 9.29 respectively). While the study conducted by Litchenberg provides 
useful descriptive data, it is important to note that the analysis does not control for any 
confounding factors such as health status and type of health insurance coverage prior to 
age 65.  
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Using data from multiple sources to control for demographic and health status 
factors, Card et al (2004) reported similar increases in health care utilization with the 
onset of Medicare benefits.(Card, et al., 2004) Using data from the National Health 
Interview Surveys (NHIS) for the years 1992-2001 and the Behavioral Risk Factor 
Surveillance System (BRFSS) for the years 1998-2002, the authors report that hospital 
admissions increased by 5 to 10 percent at the onset of Medicare benefits. It is interesting 
to note that higher numbers of hospital admissions were observed for elective procedures 
(e.g. joint replacement surgeries) compared to emergency admissions. While significant 
increases in the number of physician visits were reported at age 65 for less educated 
minorities (blacks and Hispanics), no significant differences were observed for the 
educated whites. Less educated minorities also reported an improvement in their health 
status at age 65.  
In summary, eligibility to receive Medicare services has been related to an 
increase in the utilization of health care services. The studies described above indicate 
that gaining Medicare eligibility leads to about a 5-10% increase in hospital admissions, 
increase in the number of physician visits for less educated minorities and improvements 
in general health status for the previously uninsured elderly.  
 
B) Impact of prescription drug coverage on Medicare beneficiaries’ prescription 
drug utilization, medication adherence and health care utilization 
Medicare Part D coverage gap presents a situation where beneficiaries are 
required to pay 100% of the costs for prescription drugs. The coverage gap thus simulates 
a situation where Medicare beneficiaries do not have any form of prescription drug 
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coverage. This section describes studies that have assessed the impact of prescription 
drug coverage on Medicare beneficiaries’ prescription drug utilization, medication 
adherence, health care utilization and spending.  
A number of studies have used the Medicare Current Beneficiary Survey (MCBS) 
to assess the impact of prescription drug coverage on medical services utilization and 
spending. MCBS is a continuous, panel survey of nearly 12,000 nationally representative 
aged, disabled, and institutionalized Medicare beneficiaries and since 1991 it has been 
conducted annually by the CMS.  
Using MCBS data for 1995, Davis et al., (1999) indicated that prescription drug 
utilization for Medicare beneficiaries with no drug coverage was 31% lower than 
Medicare beneficiaries who had some form of drug coverage. (Davis, Poisal, Chulis, 
Zarabozo, & Cooper, 1999) In 1995, beneficiaries with no drug coverage, paid an 
average of $432 in out-of-pocket (OOP) payments for drug expenses compared to $232 
in OOP expenses paid by beneficiaries who had some form of drug coverage.  
Blustein (2000) used a sample of 4,334 Medicare beneficiaries from the 1995 
MCBS to assess the association between prescription drug coverage and likelihood of 
purchasing anti-hypertensive medications.(Blustein, 2000) The results of the study 
indicated that, after controlling for demographics, beneficiaries who did not have any 
drug coverage were 40% more likely to fail to purchase anti-hypertensive drugs 
compared to beneficiaries with some form of drug insurance (OR=1.42, p=0.002). One of 
the limitations of this study was that the generosity of different types of drug coverage 
was not accounted for. Beneficiaries were divided into two broad groups of either having 
drug coverage or having no drug coverage.  
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Using data from the MCBS for the year 1997, Federman et al (2001) assessed the 
impact of prescription drug coverage on utilization of cardiovascular drugs among 
Medicare beneficiaries with coronary heart disease. (Federman, Adams, Ross-Degnan, 
Soumerai, & Ayanian, 2001) The study results indicated that Medicare beneficiaries with 
a history of coronary heart disease and without any form of supplemental prescription 
drug coverage (i.e., traditional Medicare or self purchased supplemental insurance 
without prescription drug coverage) were significantly less likely to use statins (OR= 
0.16, 95% CI 0.05-0.49;) and nitrates (0.63; 95% CI= 0.40-0.99;) compared to 
beneficiaries with some form of supplemental insurance (Medicaid, other public program, 
Medigap, HMO or employer sponsored coverage). However, no significant differences 
were found in the utilization of β-blockers between Medicare beneficiaries without any 
drug coverage and beneficiaries with drug coverage. Medicare beneficiaries with no 
supplemental insurance were also reported to have disproportionately high out-of-pocket 
expenses compared to beneficiaries with supplemental insurance. 
 Stuart et al., (2004) assessed the impact of prescription drug coverage on 
prescription drug utilization and expenditure on hospitalization and physician services, 
for Medicare beneficiaries diagnosed with COPD. (Stuart, Doshi, Briesacher, Wrobel, & 
Baysac, 2004) Using the 2000 MCBS data and controlling for patient characteristics, co-
morbidities and selection bias (by using propensity score matching), the authors report 
that prescription drug coverage results in a large, statistically significant 61% difference 
in prescription drug utilization in beneficiaries with drug coverage compared to those 
without drug coverage. While the study reported no significant difference in spending on 
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hospitalizations between the two groups, a statistically significant difference of 29% was 
observed in spending on physician services between the two groups.  
 A survey of 4,066 Pennsylvania Medicare beneficiaries indicated that 
beneficiaries with prescription drug coverage were on average 1.6 times more likely to 
take prescription medications compared to beneficiaries who did not have any 
prescription drug coverage.(Stuart & Grana, 1998) Further, beneficiaries with annual 
income levels greater than $18,000 were 18% more likely to take prescription drugs to 
treat their medical problems compared to low income beneficiaries (income less $6,000).  
Using data from a sample of elderly patients who completed the Survey of Asset 
and Health Dynamics Among the Oldest Old (1995-96), Steinman et al., (2001) reported 
that for 4,896 elderly American’s age 70 years and older, medication restriction (taking 
less medication than prescribed) owing to the high cost of prescription medications, was 
higher amongst beneficiaries with no prescription drug coverage compared to 
beneficiaries with partial prescription drug coverage, and with full prescription drug 
coverage.(Steinman, et al., 2001) Amongst beneficiaries with no prescription drug 
coverage, medication restriction was higher among ethnic minorities compared to whites 
(OR=2.9, 95% CI: 2-4.2), individuals with income levels less than $10,000 compared to 
individuals with income levels greater than $20,000 (OR=3.8, 95% CI = 2.4-6.1), and 
individuals with monthly OOP costs greater than $100 compared to individuals with 
monthly OOP costs less than $20 (OR=3.3, 95% CI:1.5-7.2). Low income, ethnic 
minority and beneficiaries with high out-of-pocket expenses who did not have any 
prescription drug coverage were 3 to15 times more likely to report medication restriction 
than beneficiaries with partial or full prescription drug coverage.  
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Results of a study of 3,751 Medicare beneficiaries covered by Medicare and 
private supplemental insurance, indicated that beneficiaries with least generous 
prescription drug coverage had a significantly increased risk for mortality compared to 
beneficiaries with the most generous supplemental insurance drug coverage (adjusted HR 
= 1.4; 95% CI: 1.0-1.9).(Doescher, Franks, Banthin, & Clancy, 2000) 
Soumerai et al., (2006) estimated cost-related medication nonadherence (CRN) 
among Medicare beneficiaries, by using self-reports of CRN from the 2004 MCBS data. 
Results of the study indicated that 13% of the elderly beneficiaries reported CRN in 
2004. (S. Soumerai, et al., 2006) Medicare beneficiaries, who were younger, female, 
African-American, had lower income, reported poor health, greater morbidities, and had 
less generous drug coverage had a significantly greater likelihood of reporting CRN. 
Beneficiaries with no drug coverage were nearly three times (OR = 2.8; 95% CI: 2.0-3.8) 
more likely to report CRN; beneficiaries with partial drug coverage were two times (OR 
= 2.0; 95% CI: 1.5-2.7) more likely and beneficiaries with employer coverage were 
nearly one and half times more likely (OR = 1.6 ; 95% CI: 1.2-2.2) to report CRN 
compared to beneficiaries with Medicaid drug coverage. ((S. Soumerai, et al., 2006) 
Safran et al., (2002) assessed the impact of prescription drug coverage on out-of-
pocket (OOP) costs and medication adherence, using responses from a mail survey of 
Medicare beneficiaries (n=10,416) residing in eight geographically diverse states, with 
different types of prescription drug coverage (no coverage, Medicaid, Medigap, 
employer-sponsored, HMO, state-drug assistance and VA) and in different income 
groups (low income - up to 200% FPL and non-poor - income greater than 200% FPL). 
(Safran et al., 2002)  
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About 18-31 % of seniors did not have prescription drug coverage in the 8 states 
assessed in this study. Aggregate analyses, including beneficiaries from all 8 states, 
indicated that 43% of the beneficiaries without any drug coverage spent greater than $100 
in monthly OOP costs. For both low-income and non-poor beneficiaries, compared across 
beneficiaries taking similar number of medications, Medigap was reported to have the 
least protective drug coverage (35% had ≥$100 monthly OOP costs). Beneficiaries in 
employer-sponsored, VA, HMO and state drug programs reported much lower monthly 
OOP costs (12% employer and VA, 19% HMO, and 25% in state drug programs had 
≥$100 monthly OOP costs). Seniors with Medicaid had the lowest OOP costs (8% had 
≥$100 monthly OOP costs). With respect to medication adherence, about a quarter of 
beneficiaries without drug coverage reported not filling their prescriptions or skipping 
doses due to the cost of prescription medications. Further, both low income and non-poor 
beneficiaries with no drug coverage were nearly three times more likely to forgo taking 
their medications and not fill their medications compared to beneficiaries with drug 
coverage (OR = 2.5, p< 0.001).  
The studies described above indicate that absence of prescription drug coverage 
decreases utilization of prescription drugs, reduces medication adherence and increases 
monthly OOP costs. However, these studies provide a very wide estimate – an 18-31% 
increase in utilization of prescription drugs with provision of prescription drug coverage. 
Still higher percentages are reported for specific drug classes (40% increase in anti-
hypertensives utilization, 63% for COPD drugs, etc). It is important to note that although 
the results of the studies described above are based on a relatively large sample size, they 
are cross-sectional in nature, thus precluding causal inferences. Further, none of the 
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studies except for the one conducted by Stuart et al (1998), account for self-selection bias 
associated with health insurance.  
Self-Selection bias: Self-selection bias stems from the possibility that sicker 
individuals are more likely to seek health insurance than the healthy.(Cutler, et al., 2000) 
Individuals who expect to use more services are also more likely to choose more 
generous insurance plans compared to individuals who expect to use fewer services. 
Thus, individuals who purchase health insurance or self-select into a more generous 
health plan may be different from individuals who do not have insurance coverage. It is 
thus important to control for this bias, commonly referred to as the selection bias, when 
assessing the effect of prescription drug coverage on utilization. Over the last few years, 
methodologically robust studies using quasi-experimental study designs that control for 
selection bias (Khan, Kaestner, & Lin, 2007; Lillard, Rogowski, & Kington, 1999; Shea, 
Terza, Stuart, & Briesacher, 2007) have been conducted to assess the impact of 
prescription drug coverage on prescription drug utilization.  
Using data from the RAND Elderly Health Supplement to the 1990 Panel Study 
of Income Dynamics, and after controlling for demographics, health status, and selection 
bias associated with sicker enrollees choosing prescription drug coverage, Lillard, et al 
(1999), indicated that prescription drug coverage significantly increased the probability 
of use of any drug. They predicted that addition of prescription drug coverage in the 
Medicare program would increase utilization of prescription drugs by about 12% in 
beneficiaries who have Medicare only (no supplemental prescription drug insurance). 
(Lillard, et al., 1999) 
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Shea et al., (2007) assessed the effect of insurance coverage on prescription 
utilization on Medicare beneficiaries by using 1999 MCBS data. After adjusting for 
selection bias, the authors report a price elasticity of demand of -0.54, indicating that with 
a 10% reduction in the price of medications (by purchasing prescription drug coverage), 
utilization of prescription drugs increases by 5.4%. (Shea, et al., 2007) 
 Using the MCBS data for the period 1992-2000, Khan et al., (2007) assessed the 
causal effect of prescription drug coverage on Medicare beneficiaries’ prescription drug 
utilization and health, by using a fixed effects analysis, after conforming sufficient 
within-person variation in prescription drug coverage and random movement of an 
individual moving into or out of prescription drug coverage over time. (Khan, et al., 
2007) After controlling for demographics and health status, the authors report that 
prescription drug utilization increased by 14% with public insurance coverage, utilization 
increased by 6% with employer-sponsored and Medicare HMO coverage; while there 
was no significant increase in prescription drug utilization with Medigap coverage. The 
results of the study indicate no effect of prescription drug coverage on hospitalization 
rates or improvements in health or functional ability; with an exception of improvement 
in functional ability with Medicare HMO coverage. (Khan, Kaestner, & Lin, 2008; Khan, 
et al., 2007) The authors do report that prescription drug coverage was associated with a 
4% improvement in functional disability for older elderly (age >70 years) and 
beneficiaries with more than 3 conditions.(Khan, et al., 2008)  
Yang et al., (2004) estimated the impact of prescription drug coverage on 
prescription drug utilization and future health care utilization and spending, using the 
MCBS data over the period 1992-98. (Yang, Gilleskie, & Norton, 2004) In addition to 
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controlling for health status, patient characteristics and adverse selection, Yang et al 
accounted for the dynamics of insurance choice. The authors postulated that i) a patient’s 
health status influences their preference for health insurance, ii) current consumption of 
different type of medical care (hospitalizations, physician visits, etc) is correlated, iii) 
past medical care consumption influences current medical care consumption, and iv) 
current medical consumption influences future medical consumption. Using computer 
simulations, the authors report that prescription drug coverage increases the demand for 
prescription drugs by 12-17% over a period of 5 years. However, prescription drug 
coverage was reported to only slightly increase Medicare Part A and B expenditures over 
a period of 5 years (average per person expenditure on Part A would increase by 0.9% 
and Part B by 2.5%). Further the authors report that while prescription drug would 
decrease mortality rate (5 year survival rate increases by 1.57 percentage points), it would 
increase disability rate, as the sicker population would live longer. The estimates 
provided by Yang et al are lower than those predicted by other studies. However, it is 
important to note that Yang et al present a methodologically robust estimation that 
accounts for the dynamic nature of insurance choice.  
 Gowrisankaran and Town (2004) estimate the impact of prescription drug coverage 
on mortality of Medicare beneficiaries. (Gowrisankaran & Town, 2004) Using county 
level data for 420 counties, for the period 1993-2000 and controlling for self-selection 
bias, the authors report that compared to a Medicare FFS plan, enrollment in Medicare + 
Choice plans without prescription drug coverage significantly increases mortality while 
enrollment in Medicare + Choice plans providing prescription drug coverage has no 
effect on mortality rates. The study results indicate that providing prescription drug 
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coverage to 10% beneficiaries enrolled in Medicare + Choice plans without drug 
coverage would decrease elderly mortality rate by 2.8 percentage points. In absolute 
numbers, a 10% increase in enrollment in Medicare + Choice plans which provide drug 
coverage is expected to save about 49,000 lives.  
In summary, the studies described above indicate that prescription drug coverage 
increases utilization of prescription drugs by 12-17%, with higher values for specific drug 
classes. Further, lack of prescription drug coverage results in decreased medication 
adherence and higher out-of-pocket expenses, with more pronounced effects for low 
income and ethnic minorities. Beneficiaries with high OOP expenses reported 3-15 times 
higher medication restriction. However, while no associations between prescription drug 
coverage and use of health care services was reported in studies where methodologically 
robust research designs were used; a study with a strong design reported decreased 
mortality with increased prescription drug coverage. 
 
C) Impact of changes in co-payments on Medicare beneficiaries’ prescription drug 
utilization, medication adherence and health care utilization 
As indicated earlier, Medicare Part D benefit structure institutes considerable 
amount of beneficiary cost-sharing. The following section reviews the literature 
examining the impact of co-payments on prescription drug utilization, medication 
adherence and health care utilization. 
A landmark study assessing the impact of cost-sharing on utilization of health 
care services was conducted by Soumerai et al., (1997) who reported that restrictive drug 
policies in the New Jersey Medicaid program resulted in decreased utilization of 
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prescription drugs. (S. Soumerai, et al., 1987) Soumerai et al compared the state of New 
Hampshire’s Medicaid policy limit of three paid prescriptions per month, replaced nearly 
a year later by a policy of $1 copayment with the Medicaid policy of the state of New 
Jersey, which imposed no co-payment requirements. Using 48 months of claims data 
among 10,734 continuously enrolled Medicaid recipients, the authors indicated that three 
paid prescriptions per month limit resulted in a 30 percent decrease in the number of 
prescriptions filled per patient per month with no change observed in the state of New 
Jersey which implemented no cost-sharing. For patients, on multiple drugs, the three drug 
limit had the largest impact – with a 46 percent decrease in the number of prescriptions 
obtained. Decrease in prescription medications was observed for both nonessential (58 
percent), and essential medications, such as insulin (28 percent), thiazides (28 percent), 
and furosemide (30 percent). Reductions in Medicaid prescriptions were minimally offset 
by increases in the size of the prescription or in out-of-pocket payments.(S. Soumerai, et 
al., 1987) Instituting a $1 co-pay resulted in near pre-cap level fills and had less effect on 
patients on multiple drugs. It is also important to note that drug cost savings with the $1 
co-payment policy ($0.8 million annually) were comparable to drug cost savings with the 
three prescription capping policy ($0.4 million annually).  
Soumerai et al., (1994) also assessed the impact of the cap on use of psychotropic 
drugs and acute mental health care by non-institutionalized patients with schizophrenia. 
(S. Soumerai, McLaughlin, Ross-Degnan, Casteris, & Bollini, 1994) The authors report 
that the cap resulted in decreased utilization of antipsychotic drugs, antidepressants and 
lithium, and anxiolytic and hypnotic drugs (range:15 to 49 %, P<0.01); increased visits to 
community mental health centers (range:43 to 57%; P<0.001) and increased utilization of 
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emergency mental health services and partial hospitalization (1.2 to 1.4 episodes per 
patient per month). Discontinuation of the caps resulted in prescription drug utilization 
and mental health services utilization return to base line levels (14 months before cap).  
In yet another study, Soumerai et al., (1991) reported that for Medicaid 
beneficiaries aged 60 years or older taking more than 3 prescriptions per month, the 3 
drug limit was associated with an increase in the rates of admission to nursing homes (RR 
= 2.2, 95% CI: 1.2-4.1) and risk of hospitalization (RR = 1.2, 95% CI: 0.8-1.6) when 
compared to the state of New Jersey which instituted no limits. (S. Soumerai, Ross-
Degnan, Avorn, McLaughlin, & Choodnovskiy, 1991) Discontinuation of the caps 
resulted in return to base line levels of nursing home admissions.  
Stuart et al predicted a 15.5% reduction in annual drug use in states with co-
payment policies for dual eligible’s, by analyzing a sample of 1,302 dual eligibles from 
the 1992 Medicare Current Beneficiary Survey. (Stuart & Zacker, 1999) 
The studies conducted by Soumerai et al while being landmark studies, are based 
on the Medicaid population. Numerous studies have assessed the impact of changes in 
co-payments on Medicare beneficiaries’ health care utilization. Johnson et al., (1997) 
compared changes in prescription drug utilization corresponding to changes in co-
payments, over four time periods (each lasting two years 1987-88, 88-89, 89-90 and 90-
91), for Medicare beneficiaries enrolled in two plans (Social HMO and Medicare Plus) 
offered by Northwest division of Kaiser Permanente.(Johnson, et al., 1997) Beneficiaries 
enrolled in the Social HMO plan had a more generous prescription drug benefit design 
and their co-payment per prescription rose from $1 to $3 to $5 per dispensing from 1987-
88-89 and no change thereafter till 1991. Medicare Plus enrollees’ had a more restrictive 
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benefit design and their co-payments increased from 50% with $25 maximum payment 
per dispensing from 1987-89 to 70% with $30 maximum payment per dispensing in 
1989-90, and no change thereafter till 1991.  
The results of the study indicated that overall, utilization of prescription drugs 
decreased with an increase in co-payments over time for both the groups. However, 
changes in prescription drug utilization were significantly lower in the generous 
prescription drug benefit design (Social HMO) compared to the restrictive benefit plan 
(Medicare Plus). After using ANCOVA and controlling for health status, age and 
baseline costs., the study results indicated that, over the period from 1987 to 1988 (base 
year), change in annual number of prescription per capita in the HMO group was 1.25 
compared to a change of 1.77 in the Medicare Plus group; over the period 1988-89, a 
change of  -1.80 in the HMO group versus a change of -0.10 in Medicare Plus was 
observed; over the period 1989-90, a change of 1.96 in HMO versus -0.36 in Medicare 
Plus and over the period 1990-91, a change of 1.73 for HMO versus 1.01 for Medicare 
Plus group was observed. However, no consistent annual changes in office visits, 
emergency room visits, home health care visits, hospitalizations or total medical care 
expenses over the four year period, with changes in the prescription drug benefit structure 
were reported. The results of this study should be interpreted with caution as the analysis 
did not control for demographic factors other than age, which might affect utilization, and 
more importantly did not control for selection bias.  
Using data from the California Public Employees Retirement System (CalPERS) 
Board,  Chandra et al., (2007) assessed the impact of changes in co-payment policies on 
prescription drug utilization for Medicare supplemental plan members, continuously 
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enrolled in four health plans over the period of January 2000-2003. (Chandra, et al., 
2007) In 2001, co-payments for prescription drugs for all PPO plans were increased from 
$5/$10/$30 to $5/ $15/$30 for generics/formulary brand names/non-formulary brand 
names respectively, with a $1000 stop-loss per year. In 2002, co-payments for HMO’s 
were increased from $1/$1/$30 to $5/ $15/$30 for generics/formulary brand names/non-
formulary brand name respectively. The authors indicate that elderly patients are price 
responsive to cost-sharing for prescription drugs and reported a price elasticity ranging 
from -0.46 for PPO’s to -1.4 for HMO’s, indicating that a 10 percent increase in cost-
sharing would lead to a 4.6 percent reduction in drug spending for PPO’s and 14% 
reduction for HMO’s.(Chandra, et al., 2007) Additionally, the study results also indicated 
that higher cost-sharing for HMO’s was associated with increased hospitalizations, 
especially for those with chronic illness or those with high previous medical costs.  
Using Marketscan's 2002 Medicare Supplemental and Coordination of Benefits 
database, Gilman and colleagues (2008) reported a much lower price elasticity of demand 
for prescription drug expenditure of -0.23, indicating that a 10 percent increase in the out-
of-pocket costs would lead to a 2.3 percent reduction in consumer drug spending.(Gilman 
& Kautter, 2008) It should however, be noted that Gilman et al used data for one year 
period as against a three year period used by Chandra et al.  
Decreased utilization associated with increases in co-payment has also been 
reported in Canada. Tamblyn et al., (2001) used data from the Régie de l’assurance 
maladie du Québec (RAMQ), the government health insurance system in Quebec, to 
assess the impact of a change in prescription drug cost-sharing policy on the utilization of 
essential and less-essential medications by elderly (age ≥ 65) patients. (Tamblyn, et al., 
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2001b) Prior to the cost-sharing policy reform, low income elderly had no cost-sharing 
requirements and all other elderly paid Canadian (CDN) $2 per prescription. In 1996, a 
new policy was initiated requiring all elderly patients, including low income elderly, to 
pay 25% coinsurance on all their prescription drugs, with a maximum income based 
annual ceiling of CDN$200, $500 or $750. In January, 1997, a CDN$100 annual 
deductible was introduced and the deductible and the coinsurance were prorated 
quarterly. In July 1997, the policy was changed again and the quarterly prorated 
deductible and coinsurance, were now prorated monthly to reduce per month payments; 
with a per month maximum payment ranging from CDN$16.67- $62.50 (based on 
income).  
To assess the impact of the change in the cost-sharing policy on utilization of 
essential and less-essential medications by elderly (n= 149,283), the researchers analyzed 
the RAMQ data for 32 months before the August 1996 policy change and 17 months after 
the August 1996 policy change. The researchers also assessed the adverse events (acute 
care hospitalization, long term care admission, or death) and ED visits associated with 
reduction in prescription drug utilization, by analyzing data for a period of 10 months 
before the August 1996 policy change (pre-policy period) and for 10 months after the 
August 1996 policy change (post-policy period). Using random-effects, pooled-time 
series regression with an individual as a unit of analysis, an autoregressive first-order 
correlation structure (to represent the dependence among subsequent observations) and 
after adjusting for linear trend across time, seasonal variations, demographics and health 
status, the authors reported that cost-sharing resulted in a 9.12% decrease in use of 
essential drugs (95% CI: 8.7%-9.6%) and 15.14% (95% CI, 14.4%-15.9%) decrease in 
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use of less essential drugs in elderly persons. The rate (per 10,000 person-months) of 
adverse events associated with reductions in use of essential drugs increased from 5.8 in 
the pre-policy period to 12.6 in the post-policy period (a net increase of 6.8, 95% CI, 5.6-
8.0) and ED visit rates increased by 14.2 (95% CI, 8.5-19.9) per 10,000 person-months. 
(Tamblyn, et al., 2001b) 
However, using the same RAMQ data base for the period 1992-97, Blais et al., 
(2001) reported no significant reductions in prescription drug utilization. Blais et al 
assessed the impact of the change in the Quebec prescription drug cost-sharing policy on 
the utilization of anti-hypertensives (n= 133,146), anticoagulants (n= 45,534), nitrates 
(n=54,771), and benzodiazepines (n= 26,165). (Blais, Boucher, Couture, Rahme, & 
LeLorier, 2001) Monthly consumptions of the study medications for the period between 
August 1992 and June 1996 were compared with monthly consumptions for 13 months 
(August 1996 to August 1997) following the policy change. Using time series analysis, 
with the number of prescriptions dispensed per month as the unit of analysis and 
controlling for data fluctuations from one month to another and seasonal variations, the 
authors reported no significant changes in utilization for any of the four drug classes 
during the 13 months following the implementation of cost-sharing. A statistically non-
significant decrease (in the number of prescriptions) of 5.1% for nitrates, 1.1% for 
antihypertensives, 0.8% for benzodiazepines, and a statistically non-significant increase 
of 1.6% for anticoagulants was observed. However, it is important to note that compared 
to the study conducted by Blais and colleagues, the study conducted by Tamblyn was 
methodologically robust in controlling for potential confounders. Further, the unit of 
analysis (total number of prescriptions dispensed per month) used by Blais et al may have 
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been too short a period to detect an effect.  
Pilote et al., (2002) also used the RAMQ database for the periods 1994-98 and 
reported that for patients discharged with a diagnosis of acute Myocardial infarction, the 
proportion of patients who received prescriptions for essential cardiac medications did not 
decline after the policy change and increased over time. (Pilote, Beck, Richard, & 
Eisenberg, 2002) Compared to patients admitted in pre-policy periods, patients admitted 
after the policy reform were more likely to receive prescriptions for β-blockers (OR=1.23, 
95% CI 1.16–1.30), ACE inhibitors (OR=1.26, 95% CI 1.19–1.33) and lipid-lowering 
agents (OR=2.57, 95% CI 2.38–2.78). However, patients admitted in the post-reform 
period were less likely to receive a prescription for Acetyl Salicylic Acid (OR 0.82, 95% 
CI 0.78–0.87). The analyses also indicated no change in within-class shift from more to 
less expensive drugs, after the policy change. No change was reported in rates of 
readmission for complications, visits to individual physicians, to emergency departments, 
and mortality rates. The findings did not vary with sex or socioeconomic status. (Pilote, et 
al., 2002)  It is important to note that this study was restricted to individuals with a 
diagnosis of acute Myocardial infarction while the Tamblyn study assesses the impact of 
the policy change across a number of other conditions. It is also possible that the 
diagnosis of a disease state like MI might make individuals less price sensitive, 
encouraging them to fill prescriptions despite a co-pay increase.   
 In addition to decreased prescription drug utilization, studies have also reported 
decreased adherence and poor health outcomes with increases in co-payments. Poor 
medication adherence associated with increase in drug co-payments was reported by Cole 
et al. (Cole, Norman, Weatherby, & Walker, 2006) Using a two-stage regression model, 
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the authors reported that a $10 increase in co-payment of angiotensin-converting enzyme 
inhibitors was associated with a 2.6% decrease (95% CI: 2.0 to 3.1) in adherence; 0.8% 
decrease in medical costs (95% CI: -4.2 to 2.5) and 6.1% increase in the risk of 
hospitalization for CHF (95% CI: 0.5 to12.0). Among patients taking β-blockers, a $10 
increase in co-payment was associated with a 1.8% (95% CI: 1.4 to 2.2) decrease in 
adherence; 2.8% decrease in medical costs (95% CI: -5.9 to 0.1) and 8.7% increase in the 
risk of hospitalization for CHF (95% CI: 3.8–13.8).(Cole, et al., 2006) 
 Chernew et al., (2008) assessed the impact of decreasing co-payments on 
medication adherence of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin-
receptor blockers (ARB), beta-blockers, statins, diabetes medications and inhaled 
corticosteroids. (Chernew et al., 2008) The researchers compared two large employers 
utilizing the same disease management program but with differing co-payment options. 
In 2005, the intervention employer reduced its co-payments (generic drugs reduced from 
$5 to 0 and brand name co-payments reduced by 50%) while the control group employer 
had no reductions in co-payments. Using difference-in-difference analysis for data 
spanning a year before and a year after the intervention employer reduced co-payments, 
the results indicated a statistically significant increase in medication adherence in the 
intervention group, with an increase of  2.59 percentage points for ACEI/ARB’s; 3.02 
percentage points for beta-blockers; 4.02 percentage points for diabetes medications; and 
3.39 percentage points for statins. However, no significant increase in adherence was 
observed for inhaled corticosteroids. The elasticity of demand values ranged from -0.11 
to -0.2 (ACEI/ARB = -0.118, beta-blockers = -0.112, statins = -0.182, diabetes 
medications = -0.136 and inhaled corticosteroids = -0.202).  
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Magid et al., (1997) reported that co-payment requirements did not have an 
impact on seeking emergency care (assessed by calculating time needed to arrive at a 
hospital to seek care) after onset of symptoms of Myocardial Infarction for 830 Medicare 
HMO beneficiaries, after adjusting for confounding factors. (Magid et al., 1997)  
  In summary, based on the results of methodologically robust studies 
described above, it is evident that cost-sharing associated with increased co-insurance 
rates decreases prescription drug utilization by 2-6%, with larger decreases for specific 
drug classes. Based on published literature reviews, Pauly estimated a price elasticity of 
demand for the prescription drug coverage to be in the range of -0.3 to -0.4, indicating 
that with a 10% increase in the price of medications, utilization of prescription drugs 
increases by 3-4%. (Pauly, 2004) Cost-sharing has also been associated with decreased 
adherence, increased costs, and increased out-of-pocket expenses. 
 
D) Impact of prescription benefit caps on Medicare beneficiaries’ prescription drug 
utilization, medication adherence and health care utilization 
 Prior to Medicare Part D, a majority of Medicare+Choice plans were structured to 
include an annual dollar cap in their prescription drug benefit. Ninety-four percent of 
Medicare+Choice plans had an annual cap in the range of $750-$2,000 in 2002. (Tseng, 
Brook, Keeler, & Mangione, 2003) Beneficiaries were responsible for 100% of the 
prescription drug costs once they reached their annual caps. Given that very few studies 
have been conducted using the Medicare Part D data, studies assessing the impact of 
prescription drug caps might provide a good estimate of the potential impact of the 
coverage gap in Medicare Part D benefit structure. 
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Cox et al., (2001) analyzed the impact of capped prescription benefits on 
medication taking behavior of 378 elderly patients enrolled in a Medicare HMO plan in 
Arizona. Beneficiaries who reached their prescription cap were more likely to obtain 
samples from their physicians (OR=2.02, 95% CI: 1.22-3.34), take less than prescribed 
medications (OR=2.83, 95% CI: 1.55-5.20), and discontinue taking their medications 
(OR=3.36, 95% CI: 1.63-6.94) compared with beneficiaries who did not reach their 
prescription cap limit. (Cox, Jernigan, Coons, & Draugalis, 2001) 
Tseng et al., (2004) surveyed 1,308 Medicare+Choice beneficiaries with annual 
prescription drug benefits capped at $750, $1,200 or $2,000. Beneficiaries’ exceeding 
their annual cap of $750 or $ 1,200 were compared with a control group of beneficiaries 
matched on age and monthly drug spending, who did not exceed their annual cap of 
$2,000. After controlling for demographic and health characteristics, the results of the 
study indicated that beneficiaries who exceeded their annual caps reported using less 
prescribed medication than controls (18% vs. 10%, respectively; P<.001). (Tseng, et al., 
2004) Beneficiaries who exceeded their caps indicated that they decreased utilization of 
statins, proton pump inhibitors, cyclooxygenase 2 inhibitors, diuretics, nonsedating 
antihistamines, bronchodilators, narcotics, selective serotonin reuptake inhibitors, 
hormones (conjugated estrogens, thyroid), angiotensin-converting enzyme inhibitors, 
calcium channel blockers, beta-blockers, antiplatelet blood thinners, benzodiazepines, 
nonsteroidal anti-inflammatory drugs, H2 blockers, and steroid inhalers.  
 Hsu et al., (2006) assessed the impact of prescription drug benefit caps on clinical 
and economic outcomes by comparing 157,275 Medicare+Choice beneficiaries with an 
annual $1,000 cap and 41,904 beneficiaries with no annual cap. (Hsu, et al., 2006) 
58 
 
Beneficiaries’ with annual caps had a 15 percent lower (95 % CI, 11.4 to 18.1) 
prescription drug utilization of anti-hypertensives; 27 percent lower (95 % CI, 23.1 to 
30.4) utilization of lipid-lowering agents and 21 percent lower (95 % CI, 14.3 to 26.6 
percent) utilization of anti-diabetic drugs compared to beneficiaries with no annual cap. 
Adherence to long therapy was lower for beneficiaries’ with annual caps compared to 
beneficiaries with no annual caps as indicated by odds ratios of 1.30 (95 % CI:1.23 to 
1.38) for beneficiaries using anti-hypertensives; 1.27 (95 % CI:1.19 to 1.34) for 
beneficiaries using lipid-lowering agents, and 1.33 (95 % CI:1.18 to 1.48) for 
beneficiaries using anti-diabetic drugs.(Hsu, et al., 2006) Beneficiaries’ with annual caps 
were also reported to have higher relative rates of visits to the emergency department 
(relative rate: 1.09, 95 % CI: 1.04 to 1.14), nonelective hospitalizations (relative rate: 
1.13, 95 % CI: 1.05 to 1.21), and death (relative rate: 1.22, 95 % CI: 1.07 to 1.38). It is 
interesting to note that beneficiaries with caps had 28 percent lower pharmacy costs (95 
% CI, 25.6 to 30.4) and 4 percent lower office-visit costs (95 % CI, 0.6 to 7.0) than for 
beneficiaries with no caps.(Hsu, et al., 2006) However, hospital costs for beneficiaries 
with caps were 13 percent higher (95 % CI, 1.3 to 26.5) and emergency department costs 
were 9 percent higher (95 % CI, 1.0 to 17.7) compared to beneficiaries with no caps. 
Further, no significant difference in annual total medical costs were reported between 
beneficiaries with annual caps and beneficiaries with no annual caps on their prescription 
drug benefits.  
 Joyce et al., (2007) compared the impact of prescription drug benefit caps on 
retirees (age > 65) enrolled in employer sponsored health plans with annual caps of either 
$1,000 or $2,500 with retirees enrolled in non-capped plans over the period of 2003-
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2005. (Joyce, et al., 2007) Using generalized estimating equations to control for 
demographics, health status, differential monthly trends and enrollment in a capped plan, 
the authors report that difference in utilization of six classes (anti-hypertensives, anti-
diabetics, lipid-lowering, anti-depressant, anti-ulcerants and NSAIDS) of medications 
was the largest in the last quarter of each year. December of each year of the study 
marked 15-28% decreased utilization of anti-hypertensives, anti-diabetics, and lipid-
lowering agents ; 5-10% decreased utilization of anti-depressants and 20-30% decreased 
utilization of anti-ulcerants and NSAIDS for beneficiaries enrolled in the $2,500 capped 
plans compared to those in non-capped plans. However, beneficiaries in capped plans 
reported higher rates of resumption of drug therapy (after renewed coverage in the 
following year) for all six drug classes, compared to beneficiaries in non-capped plans. 
Utilization of generic drugs for beneficiaries in capped and non-capped plans was similar 
in the first quarter, with the difference increasing towards the end of the year.  
Balkrishnan et al., (2001) conducted a study to assess changes in healthcare 
service utilization after a large HMO changed its prescription drug coverage twice over a 
period of two years. (R Balkrishnan, et al., 2001) The benefit cap was increased from 
$500 per year to $200 quarterly, co-payments changed from $6 /$12 in 1997 to $7 /$15 in 
1998 for generic/brand names respectively. In 1999, the prescription drug benefit was 
changed to include unlimited coverage of generic drugs, with a $5 co-payment, and a 
restriction of brand name drugs to $25-per-month coverage, with a $15 co-payment. The 
1998 policy change resulted in 29% increase in prescription costs, 25% increase in annual 
inpatient admissions, 38% increase in total costs for the HMO while the 1999 policy 
change resulted in 27% decrease in prescription costs, a 4% decrease in physician visits, 
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and a 6% decrease in total costs for the HMO. Thus, the results of the study indicate that 
a prescription drug benefit with no caps on utilization of generic drugs was associated 
with a reduction in prescription costs and no increases in nonprescription-related 
healthcare service utilization.  
 A survey of 221 Medicare+Choice beneficiaries with annual prescription drug 
caps of either $500 or $1,000 indicated that nearly  a quarter of the beneficiaries (24%) 
took less than the prescribed amount, about 45% obtained samples from physicians, 37% 
reduced spending on food and/or clothing and about 29% shopped around at other 
pharmacies to obtain medications at 
a lower cost and about 17% received financial assistance from family or friends. (Cox & 
Henderson, 2002)  
 In summary, similar to cost-sharing associated with increased co-insurance rates, 
prescription benefit caps are reported to decrease prescription utilization by about 8-30%. 
Prescription benefit caps are also reported to increase hospitalizations and emergency 
room visits, thereby increasing total costs by 13-30%, on average.  
The review thus far summarizes studies assessing the impact of prescription drug 
coverage and cost-sharing on utilization of health care services, using data from 
prescription drug plans offering coverage before the initiation of Medicare Part D. As 
indicated earlier these studies provide a good estimate of the impact of Medicare Part D. 
The following sections of the review relate to studies directly assessing the impact of 
Medicare Part D by using data from Medicare beneficiaries enrolled in health plans 
offering Medicare Part D.  
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E) Impact of Medicare Part D on Medicare beneficiaries’ prescription drug 
utilization, medication adherence and health care utilization 
Given that Medicare Part D is a relatively new program and that CMS has not 
released Medicare Part D data, very few studies directly related to Medicare Part D have 
been conducted. 
Using data from 1998-2000 MCBS and controlling for selection bias, Stuart et 
al.,(2005) assessed the impact of prescription gaps (months with no prescription drug 
coverage) on spending for all Medicare beneficiaries and for beneficiaries suffering from 
diabetes, chronic lung disease and mental illness. (Stuart, Simoni-Wastila, & Chauncey, 
2005) More than half (51.3%) of the study population had gaps in their prescription drug 
coverage, with about a quarter of them with no prescription drug coverage and a quarter 
with one or more gaps in coverage during the study period. The results of the study 
indicated that each month with no prescription drug coverage increased spending on 
average by $25.13 (p<0.001); by $74.81 (p<0.001) for those with chronic lung disease, 
$86.91 (p<0.001) for mental illness and by $48.55 (p<0.06) for diabetics.  
The authors then simulated the impact of Medicare Part D prescription drug 
coverage on total and out-of-pocket spending. The authors report that Medicare 
beneficiaries with previous prescription drug coverage would on average spend $2,683 on 
prescription drugs in 2006, those suffering from diabetes would spend $4,005; with 
chronic lung disease would spend $4,000 and with mental disease would spend $4,729 in 
total drug costs in 2006.(Stuart, et al., 2005) If beneficiaries with no prescription drug 
coverage enrolled in Medicare Part D spending would increase by 56% for all Medicare 
beneficiaries (from $1,584 to $2,472); by 43% (from $2,320 to $3,331) for diabetics, by 
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79% (from $1,779 to $3,185) for beneficiaries with chronic lung disease and by 61% 
(from $2,207 to $3,594) for those with mental disease.(Stuart, et al., 2005)  
On average, Medicare beneficiaries were projected to be in the coverage gap for 
2.3 months, those with diabetes for 4.8 months, those with chronic lung disease for 4.4 
months and those with mental illness for 5.3 months.(Stuart, et al., 2005) Based on 
projected total out-of-pocket (OOP) expenses during the coverage gap, the impact of 
Medicare Part D coverage gap while not considerable for an average beneficiary (OOP 
during gap $722); beneficiaries with diabetes (OOP during gap $1,581), chronic lung 
disease (OOP during gap 1,435) and mental illness (OOP during gap $1,844) would still 
have considerable out-of-pocket costs during the coverage gap.(Stuart, et al., 2005) 
However, it is important to note that the results of this study are projected values and the 
study does not control for drug benefits that might be provided by health plans during the 
coverage gap, low income and employer sponsored subsidies.  
Lichtenberg and Sun, (2007) analyzed a 50% sample of Walgreen’s pharmacy 
claims data for the period September 2004 through December 2006 to assess the impact 
of Medicare Part D by evaluating changes in the ratio of elderly to nonelderly costs and 
prescription drug utilization before and after  January 1st, 2006. (F. R. Lichtenberg & 
Sun, 2007) Using difference-in-difference analysis, the authors report that over the period 
2005-2006, the nonelderly patient’s average costs per day of therapy decreased by 0.4 
percent compared to 18.8 percent decrease in elderly patients average costs per day of 
therapy. With respect to prescription drug utilization, a nonelderly patient’s number of 
days of therapy increased by 6.8 percent compared to a 19.5 percent increase in the 
number of days of therapy for elderly patients. These results indicate that Medicare Part 
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D reduced elderly patients out-of-pocket expenses by 18.4 % and increased prescription 
drug utilization by about 12.8 %.  
However, Yin et al., (2008) reported lower values of utilization and out-of-pocket 
expenses after using the same Walgreens database.(Yin, et al., 2008) After selecting a 5% 
random sample of beneficiaries from Walgreens database for the period (September 
2004-April 2007), Yin et al, indicate that during the ramp-up post-Part D period (January 
to May 2006 - penalty free enrollment in Part D) average monthly prescription drug 
utilization increased by 1.1% (95% CI: 0.5-1.7; P < 0.001) and out-of-pocket expenditures 
decreased by 8.8% (95% CI: 6.6-11.0; P < 0.001). During the stable post-Part D period 
(June 2006 to April 2007 - after the deadline for penalty-free enrollment) the effect of 
Part D coverage translates into 5.9% (CI: 5.1-6.7; P < 0.001) increase in prescription 
utilization and a 13.1% (CI, 9.6-16.6%; P = 0.003) decrease in out-of-pocket 
expenditures.  
The study also estimated the effect of Part D, by comparing out-of-pocket costs 
and utilization among seniors eligible for the benefit (Part D eligible group - age 66 to 79 
years) to a control group of seniors not eligible to receive Medicare benefits (Part D 
ineligible group - age 60 to 63 years). The results of the study indicate that during the 
pre-Part D period (September 2004-December 2006), no significant differences in  trends 
in out-of-pocket expenditures and prescription drug utilization were observed between 
the Part D eligible group and Part D ineligible group. During the ramp up and the stable 
post-Part D period, the eligible group had a comparatively greater decrease in out-of-
pocket expenditures and slightly greater increase in prescription drug utilization, than the 
ineligible group in each period.  
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Yin et al., list lack of methodological controls in the Lichtenberg study as 
potential reasons for differences in utilization and costs between their study and the study 
conducted by Lichtenberg and Sun, although both studies employ the same 
database.(Yin, et al., 2008) Yin et al., suggest the following drawbacks associated with 
the Lichtenberg and Sun study: i) analysis was based on a random sample of pharmacy 
claims, rather than selecting every claim for a random sample of beneficiaries ii) used all 
nonelderly persons as a control group without matching and controlling for trends in 
utilization and expenditures among the control participants  and iii) used log-transformed 
ordinary least-squares regressions compared to a GEE log-link model used by Yin et al. 
(Yin, et al., 2008) Despite methodological differences, both studies indicate a 
considerable impact of Medicare Part D on prescription drug utilization. However, both 
these studies did not assess the impact of the Part D coverage gap on medication 
adherence and more importantly the resulting impact on health outcomes. 
Using prescription claims data from Wolters Kluwer Health’s database, for the 
period December, 2004-December, 2007, Ketchman and Simon (2008) compare the 
impact of Medicare Part D on prescription drug utilization and out-of-pocket for the 
elderly (age over 66 years as of 2007) compared to the near elderly (age 58-64 as of 
2007). (Ketcham & Simon, 2008) After using difference-in-difference analysis and 
controlling for pure cash transactions, the results of the study indicate that compared to 
the non-elderly, elderly beneficiaries had 4.7% increase in prescription drug utilization 
and 21.7% reduction in OOP costs per day’s supply of medication for the study period.  
Schneeweiss et al., (2009) assessed the impact of Medicare prescription drug 
coverage and Medicare Part D coverage gap on prescription drug utilization and out-of-
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pocket spending for statins, warfarin, clopidogrel and PPIs for seniors who previously 
lacked drug coverage. (Schneeweiss et al., 2009) It is important to note that in the 
absence of health plan data, the authors assigned an individual’s insurance status as 
uninsured, based on their costs. Individuals were considered uninsured if they paid 60% 
or more of the drug price for 80% or more of prescription fills. Using pharmacy claims 
data from three pharmacy chains for the period January 2005 to December 2006, the 
authors report that about 12% of the study population hit the coverage gap. Using time-
trend analyses, and controlling for demographics and health status measures, the results 
of the study indicate that compared to baseline period (January 1st to December 31st, 
2005), the introduction of Medicare Part D significantly increased utilization of statins by 
22 %, of clopidogrel by 11% and PPIs by 37 % for previously uninsured individuals. No 
significant changes in warfarin use were observed. A decrease in utilization of 5.0 
percentage points per month (95% CI: 3.2–6.8) for clopidogrel; decrease in 4.8 (95% CI: 
3.8–5.7) for warfarin and decrease of 6.3 (95%CI: 4.8–7.8) for statin use was observed 
for individuals who hit the coverage gap in 2006.  Hitting the coverage gap resulted in 
out-of-pocket expenses increase of $12 per thirty days supply for warfarin (95% CI: $11–
$14) to $65 for clopidogrel (95% CI: $59– $70). Due to the lack of conformation of 
insurance status, lack of information on health plan data such as the generosity of 
prescription drug coverage and lack of a control group to account for temporal changes, 
the results of this study should be interpreted with caution. (Schneeweiss, et al., 2009) 
Chen et al., (2008) assessed the effect of Medicare Part D on prescription drug 
utilization and out-of-pocket spending of psychotropic medications (antidepressants, 
antipsychotics, and benzodiazepines) using pharmacy claims from a retail pharmacy 
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chain for the period September 2005 to August 2006.(Chen et al., 2008) Using 
interrupted time series, the study investigators report that introduction of Medicare Part D 
resulted in 18% decrease in out-of-pocket payment for antidepressants and 21% decrease 
in out-of-pocket payment for antipsychotics.(Chen, et al., 2008) However, out-of-pocket 
expenditure for benzodiazepines increased by 19% after the implementation of Medicare 
Part D. Following the implementation of Medicare Part D, utilization of antidepressant 
increased by 7% (from 273,166 to 293,590 prescriptions per month, p<.001) and 
antipsychotic prescriptions increased by 18% (from 41,079 to 48,276 prescriptions per 
month, p<.001). However, utilization of benzodiazepine decreased by 5% (from 238,961 
to 226,622 prescriptions per month, p<.001) after the introduction of Medicare Part 
D.(Chen, et al., 2008)  
Madden and colleagues (2008) assessed the impact of Medicare prescription drug 
coverage on cost related medication non-adherence (CRN) by using data from the 
Medicare Current Beneficiary Survey for the period 2004-2006. (Madden et al., 2008) 
Self-reports of CRN were used as a measure of adherence and adherence was compared 
for the period before Medicare Part D implementation (2005) and after Medicare Part D 
implementation (2006). In addition to controlling for demographics and health status 
measures, the investigators controlled for historical year-to-year changes in cost-related 
medication adherence in the absence of Part D. This was accomplished by first 
calculating odds ratio (OR) of CRN in 2005 compared to CRN in 2004. Next, an OR of 
CRN in 2006 compared to CRN in 2005 was calculated. Finally, a ratio of these 2 ORs 
(2006 vs. 2005 relative to 2005 vs. 2004) was calculated to reflect CRN before and after 
Medicare Part D implementation. Overall, results of the study indicate significant 
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decreases in the odds of CRN after Medicare Part D implementation (Ratio of OR’s = 
0.85; 95% CI = 0.74-0.98). Specifically, for beneficiaries in excellent to good health, 
significant differences in CRN were observed after Medicare Part D implementation 
(Ratio of OR’s = 0.77; 95% CI = 0.63-0.95). However, no significant differences in CRN 
were reported for beneficiaries with fair to poor health.(Madden, et al., 2008) The study 
results also indicate that CRN was strongly associated with poorer self-reported health, 
lower income and higher number of co-morbidities. When interpreting results, it is 
important to note that this study uses self-reported medication adherence as its outcome 
measure. Further, while this study assesses the impact of Medicare Part D on medication 
adherence, it does not assess the impact of the Medicare Part D coverage gap on 
medication adherence. 
Using a Medicare Part D satisfaction survey and retrospective chart reviews, Kim 
et al., (2008) assessed diabetic Medicare beneficiaries’ (n=81) satisfaction with their 
decision to enroll or not enroll in the Medicare Part D program, and levels of 
glycosylated hemoglobin (HbA1c), low-density lipoprotein (LDL) and blood pressure 
before (July 1- December 31, 2005) and after (May 1- October 31, 2006) their decision to 
enroll in Medicare Part D. (Kim, Touchette, Stubbings, Schullo-Feulner, & Pater, 2008) 
The study results indicated that, of the 60 patients enrolled in Part D, 80.0% were 
satisfied with their decision to enroll. Using paired t-test, the authors report no significant 
differences in mean HbA1c, LDL or blood pressure before and after enrollment in 
Medicare Part D.(Kim, et al., 2008) However, the results of this might not be reliable due 
to the use of cross-sectional data, very small sample and no controls for confounding 
demographic or health status variables.   
68 
 
Hsu et al., (2008) used data collected from telephone interviews of 1040 
beneficiaries’ enrolled in Kaiser Permanente-Northern California’s MA-PD plan for the 
full year in 2006 to assess their knowledge about the Part D benefit structures and 
techniques used to cope with medication costs incurred by them.(Hsu et al., 2008)  About 
8% of all beneficiaries in Kaiser Permanente-Northern California’s MA-PD plan hit the 
coverage gap in 2006. The study results indicate that about 40% (95% CI, 35%-45%) of 
the interviewed beneficiaries were aware of the coverage gap in their drug plan. Further, 
as the costs incurred by beneficiaries increased, so did there awareness of the existence of 
the coverage gap. Results of multivariate logistic regression analyses, controlling for 
demographic and health status measures, indicate that compared to those who did not hit 
the coverage gap,  beneficiaries who hit the coverage gap had a greater awareness about 
the coverage gap (difference of 40.3 percentage points, 95% CI: 33.4-47.1). More than a 
third (36%) beneficiaries reported using at least one form or other of a cost-coping 
mechanism, 26% reported decreased adherence to prescribed drug use and 9 % reported 
experiencing financial burden due to their out-of-pocket costs. Of the cost-coping 
behavior’s reported, about 15% (95% CI: 12-18%) indicated switching to a cheaper drug; 
about 7% (95% CI: 5-10%) split pills under physician’s advice; 6% (95% CI:3-9%) went 
to a non-Kaiser pharmacy; 4% (95% CI: 5-10%) used OTC drugs; 2% (95% CI: 0.4-4%) 
received samples; 2% borrowed drugs (95% CI:0.3-1.1%); and  0.3 % (95% CI: 0-0.6%) 
received help from pharmaceutical assistance programs.  
Of the decreased adherence reported behaviors, 8% (95% CI: 6-11) reported not 
refilling a prescription; about 7% (95% CI: 5-9%) reported taking less than prescribed; 
and 5% (95% CI: 3-7%) reported not filling a new prescription. Among those reporting 
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financial burden due to high OOP costs,  5% reported going without a necessity (95% CI: 
3-7%) and about 4% (95% CI: 3-6%) reported borrowing money to pay for drugs. As 
expected, the frequency of cost-coping behaviors increased with increased OOP costs. 
Further, beneficiaries with incomes below $40,000 were significantly more likely to 
report using a cost-coping technique, reduced adherence and increased financial burden 
compared to beneficiaries with incomes greater than or equal to $40, 000. While this 
study provides good descriptive estimates of cost-coping behaviors, the study is limited 
by its cross-sectional design, potential recall bias, and exclusion of beneficiaries who 
could not speak English. (Hsu, et al., 2008) 
In summary, Medicare Part D coverage is associated with an approximately 6% 
increase in prescription drug utilization and a 13% decrease in out-of-pocket expenses, 
with higher amounts reported for specific drug classes. 
 
Medicare Part D coverage gap  
Based on an IMS report, it is estimated that, in 2006, about 6 percent (1.5 million) 
of Medicare Part D enrollees reached the coverage gap. (Hoadley J, et al., 2007) 
However, due to the fact that a considerable number of beneficiaries were enrolled in Part 
D for less than the full year in 2006, it is important to note that more than twice the 
number of beneficiaries hit the coverage gap  in subsequent years.  
 Using nation wide pharmacy claims data for 1.9 million Medicare beneficiaries, 
from IMS Health, a Kaiser Family Foundation study reported that among Part D enrollees 
who used at least one prescription drug and did not qualify to receive low income 
subsidiaries (LIS), more than a quarter (26%) reached the coverage gap in 2007. 
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(Hoadley, et al., 2008) Only 4% of the beneficiaries reached the catastrophic coverage. 
However, it is important to note that Medicare beneficiaries who did not take any 
prescription drug were excluded from this study, thus potentially overestimating the 
numbers. To estimate the number of beneficiaries who hit the coverage gap, in the total 
Medicare Part D population, it is important to account for 9% of Medicare beneficiaries 
who do not take any prescriptions. Including beneficiaries who do not take any 
prescription drugs, the authors estimate that about 14% of the total population of Part D 
enrollees, that is, about 3.4 million Medicare beneficiaries reached the coverage gap in 
2007.  
Thus, despite the prescription drug benefit, about 14-15% of Medicare 
beneficiaries who have a disproportionate need for prescription drugs, are faced with 
increased cost-sharing and few plans offer comprehensive coverage during the coverage 
gap.(Dalen & Hartz, 2005; Hoadley, et al., 2008; S. B. Soumerai & Ross-Degnan, 1999) 
The findings of this literature review have implications for this study, as the objective of 
this study is to assess the impact of the coverage gap on Medicare beneficiaries’ 
prescription drug utilization and medication adherence.  
 
F) Impact of Medicare Part D coverage gap on Medicare beneficiaries’ prescription 
drug utilization, medication adherence and health care utilization 
  The studies conducted with Medicare prescription drug coverage caps conducted 
before the initiation of Medicare Part D provide a good estimate of the impact of capped 
benefits. However, most plans had prescription drug coverage caps in the range of 
$1,000. Standard Medicare Part D plans have a prescription drug cap of $3,000. Only a 
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few studies have thus far directly assessed the impact of Medicare Part D coverage gap. 
 The Kaiser Family Study (2008) based on the IMS Health data assessed the 
impact of Medicare Part D coverage gap on medication use and out-of-pocket costs for 
enrollees taking one of following eight classes of medications: (1) ACE Inhibitors, (2) 
drugs used in the treatment of  Alzheimer’s disease; (3) anti-depressants; (4) ARBs; (5) 
oral anti-diabetics; (6) drugs used in the treatment of  osteoporosis; (7) Proton Pump 
Inhibitors (PPIs); and (8) statins.(Hoadley, et al., 2008) 
Coverage gap: In this study, more than a quarter (26%) of the study population 
reached the coverage gap in 2007. On average, based on an analysis of the above 
mentioned 8 drug classes, about 20 percent of beneficiaries who reached the coverage 
gap made some change in their prescription drug utilization - about 15% stopped taking 
their medications; about 5% switched to another medication (most often a generic drug) 
in the same class; and about 1% reduced the number of medications they were taking 
within the same therapeutic class. (Hoadley, et al., 2008)  
Stopped Medications: Specifically, for each class, the percent of beneficiaries 
who stopped taking medications after hitting the coverage gap include: 20% on PPIs, 
15% on anti-depressants, 18% on osteoporosis medications, 16% on ACEI, 14% on 
ARB’s, 13% on statins, 10% on oral anti-diabetics, and 8% on Alzheimer’s medications.  
Reduced Medications: About 5% of beneficiaries on oral anti-diabetics, 1% on 
osteoporosis medications and anti-depressants, and 2% on Alzheimer’s medications 
reduced their medication use by stopping at least one of the multiple drugs (within the 
same class) that they were taking before hitting the coverage gap.  
Switched Medications: Specifically, for each class, the percent of beneficiaries 
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who switched medications after hitting the coverage gap include 8% on oral anti-
diabetics, 6% on PPIs and anti-depressants, 5% on statins, 4% on ACEI and Alzheimer’s 
medications, and 3% on ARB’s and osteoporosis medications.  
Catastrophic coverage: Of the 26% in the study who reached the coverage gap in 
2007, only 4% had expenses high enough to receive catastrophic coverage. Among the 
beneficiaries who stopped taking their medications in the coverage gap and then reached 
catastrophic coverage, on average, across all 8 classes, about 57% remained off the 
medications, 37% resumed the medications and 7% started taking new medications after 
receiving catastrophic coverage. (Hoadley, et al., 2008) Specifically, for each class, the 
percent of beneficiaries who did not resume taking their stopped medications even after 
reaching catastrophic coverage include: 66% on ACEI, 60% on osteoporosis and 
Alzheimer’s medications, 58% on PPIs and ARB’s, 57% on anti-depressants and oral 
anti-diabetics, and 47% on statins.(Hoadley, et al., 2008)  
Total and out-of-pocket spending: On average, Medicare beneficiaries who did 
not hit the coverage gap spent about $745, beneficiaries who hit the coverage gap but not 
the catastrophic coverage spent $3,364 and beneficiaries who hit the catastrophic 
coverage spent $8,635 in total spending in 2007. Out-of-pocket expenses, on average, for 
Medicare beneficiaries who did not hit the coverage gap were about $312, for 
beneficiaries who hit the coverage gap but not the catastrophic coverage were about 
$1,572 and for beneficiaries who hit the catastrophic coverage were $3,732 in 2007. 
(Hoadley, et al., 2008)  
 The results of this study raise considerable concerns for Medicare beneficiaries 
who hit the coverage gap and stop taking their medications. Of particular concern are 
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beneficiaries stopping drugs like oral anti-diabetics which could cause serious adverse 
health consequences. When interpreting the results from this study, it is important to note 
that this study does not include prescriptions filled by mail-order pharmacies and does 
not account for free samples received from physicians. This study only provides a 
descriptive analysis of the impact of Medicare Part D data.  
Raebel et al., (2008) assessed the impact of the coverage gap on medication 
adherence, hospitalizations, emergency department (ED) visits, and outpatient medical 
office visits for Medicare beneficiaries in two Kaiser Permanente Colorado health plans. 
One health plan offered the standard Medicare Part D benefit structure with the coverage 
gap and the other (for retiree beneficiaries) health plan included a benefit structure with 
no coverage gap. (Raebel, et al., 2008) Health care utilization of beneficiaries who hit the 
coverage gap was compared with utilization of those who did not hit the coverage gap, 
for beneficiaries in the standard Medicare Part D benefit structure. To account for 
seasonal variations, the authors assessed health care utilization for the period after 
beneficiaries hit the coverage gap in 2006 and compared it with their health care 
utilization for the same period in the previous year (in 2005). For  example if a 
beneficiary hit the coverage gap in September 2006, then utilization during September to 
December 2006 would be compared with utilization during September-December 2005. 
To account for confounding due to age, similar calculations comparing 2005 and 2006 
utilizations were conducted for a matched control group which included retiree Medicare 
beneficiaries who hit the coverage gap in 2006 but were enrolled in a plan with full 
coverage during the gap.  
The results of the study indicated that about 6% of the beneficiaries reached the 
74 
 
coverage gap in 2006. Compared to beneficiaries who did not reach coverage gap, 
beneficiaries who reached the coverage gap were older, had greater morbidity, received 
more medications, and had more medical office visits (P < 0.001). After controlling for 
demographics and health status, using Poisson regression, those who reached the 
coverage gap were reported to have 85% greater likelihood of inpatient hospitalizations 
(Incidence Rate Ratio (IRR) = 1.85; 95% CI: 1.64–2.09); 60% greater likelihood of ED 
visit (IRR = 1.60; 95% CI: 1.40-1.83); and 12% greater likelihood of office visit (IRR = 
1.12; 95% CI: 1.07-1.16). Comparing 2006 and 2005 utilizations, for both beneficiaries 
in the standard Medicare plan and those in plan with no coverage gap, the authors report 
that after reaching the coverage gap, there was no change in hospitalizations and ED 
visits, while total office visits in 2006 decreased compared to the same time in 2005 
(Standard plan IRR = 0.90; 95% CI: 0.86-0.95; Retiree plan IRR =.90; 95% CI: 0.87-
0.92). (Raebel, et al., 2008)  
Medication adherence in this study was calculated using the medication refill 
adherence (total days supply/number of days in the study period*100) method. Using 
Wilcoxon Signed Rank test to compare difference in medication adherence between pre-
period (1 year before coverage gap) and post-period (1 year after coverage gap), for 
beneficiaries enrolled in the standard plan, significant reduction in adherence was 
observed for anti-hyperlipidemics (3.6 ± 22.4; p=0.038); anti-hypertensives (5.3± 24.7; 
p=0.003); anti-depressants (6.8± 26.3; p<0.001); and diuretics (8.3± 29.2; p<0.001). No 
significant changes were observed for beneficiaries taking anti-diabetics.  For retiree 
beneficiaries with no coverage gap (matched group), significant differences were found 
only in adherence to anti-hyperlipidemics (p=0.031) and anti-hypertensives (p = 0.006). 
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(Raebel, et al., 2008) 
 It is important to note that the authors do not report any measures to accommodate 
oversupply of medications due to early refills, change in drugs within same class or to 
generics. Further, the authors only report health care utilization in a control group; they 
do not compare the results of the study group to a control group. Also of significance is 
the authors note that absence of differences in ED visits and hospitalizations after 
reaching the coverage gap may be due to lack of power in detecting this difference. 
(Raebel, et al., 2008)  
Impact of the coverage gap on prescription drug utilization has been assessed by 
Sun and Lee (2007) using prescription claims data collected from a pharmacy benefit 
management database for 90,615 patients. The study assessed the impact of the coverage 
gap on  prescription drug utilization and costs during two periods- pre period (January 1 
to June 30, 2006) and post-period (July 1 to December 31, 2006).(F. R. Lichtenberg & 
Sun, 2007) The study group, which included beneficiaries in standard PDP plans who 
reached the coverage gap in June 30, 2006, but not catastrophic coverage in 2006, was 
compared with a control group which included beneficiaries in non-Part D commercial 
plans.  
Similar to reports from earlier studies, the authors report that individuals who 
reach the coverage gap (study group) were significantly older (76.34 vs. 73.04 years), 
sicker (5.39 vs. 3.66 disease conditions), and had high out-of-pocket (OOP) expenses 
($2,354 vs. $598) compared to beneficiaries who did not reach the coverage gap (control 
group). After reaching the coverage gap, average prescription days of therapy decreased 
in the study group by 15.85% from (1,104 to 929, p<0.0001) but increased by 1.77% 
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(from 680 to 692, p<0.0001) in the control group. It is interesting to note that for 
beneficiaries who hit the coverage gap, while the average total costs decreased by about 
28% (from $2,441 to $929, p<0.0001), out-of-pocket expenses increased by 88.94% 
($8777 to $1,657, p<0.0001). However, completely opposite results were reported for the 
control group: a 2.19 % increase (from $1,322 to $1,351, p<0.0001) in total costs and 
5.54% decrease (from $307 to $290, p<0.0001) in OOP costs. Rate of utilization of 
generic drugs was reported to increase by 25.32% (from 39.77% to 49.84%, p<0.0001) in 
the study group and only 5.32% (from 51.55% to 54.29%, p<0.0001) in the control 
group.  
 Results of a difference in difference analysis indicated that, Medicare Part D 
coverage gap decreased prescription drug utilization by 187.49 days of therapy 
(p<0.0001); increased OOP expenses by $796.49 (p<0.0001), and increased rate of 
generic drug utilization by 7.33% (p<0.0001). While this study provides some evidence 
of the impact of coverage gap on medication utilization, it only includes patients enrolled 
in PDP plans, uses non-part D beneficiaries as a control group, only includes 
beneficiaries who hit the coverage gap in June and does not assess impact of the coverage 
gap on medication adherence.  
Zhang et al., (2009) compared prescription drug utilization for beneficiaries with 
coverage during the coverage gap (employer-sponsored plan) with prescription drug 
utilization for beneficiaries with no coverage or some with generic coverage (MA-PD 
plan) during the coverage gap by using data from a large health plan in Pennsylvania, for 
the year 2006. (Zhang, et al., 2009) About 25% of beneficiaries in the MA-PD plan and 
40% of the beneficiaries in the employer-sponsored plan reached the coverage gap in 
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2006. After controlling for demographics and health status, the study results indicate that 
prescription drug utilization of beneficiaries with no coverage in the coverage gap was 14 
% lesser (decrease of 0.3 brand names and 0.4 generic prescriptions/month) compared to 
beneficiaries with full coverage during the gap. Beneficiaries with generic drug coverage, 
decreased use of their brand-name drugs (decrease of 0.5 brand name 
prescriptions/month) but increased use of generic medications (increase of 0.36 generic 
prescriptions/month) compared to beneficiaries with full coverage during the gap. 
However, caution should be exercised when interpreting these results since the study is 
based on cross-sectional data with no control for selection bias.  
A survey of 915 Medicare beneficiaries enrolled in a Kaiser Permanente Colorado 
Medicare Advantage plan indicated that beneficiaries with no gap coverage were nearly 
three times more likely (42% vs. 14%, p<0.001) than beneficiaries with gap coverage to 
report using a medication cost-lowering strategy such as using less medication than was 
prescribed, stop taking a medication, not fill a prescription, etc during the coverage 
gap.(Cronk, et al., 2008) Further, beneficiaries with no gap coverage, younger 
beneficiaries, those in poor health, more than high school education, annual income < 
30,000 (excluding LIS),  and those who had previously purchased a second-generation 
anti-psychotic were more likelyto use a cost-lowering strategy. However, the study did 
not report the impact of the coverage gap on medication adherence.  
 In summary, as reported in detail above, few studies published in the literature 
indicate that the Medicare Part D coverage gap decreases prescription drug utilization by 
about 15%,  decreases medication adherence and increases OOP expenses of Medicare 
beneficiaries. However, it is important to note that these studies are limited by 
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methodological flaws. Two studies assessing the impact of coverage gap are descriptive 
in nature. (Cronk, et al., 2008; Hoadley, et al., 2008) Studies which are based on 
retrospective claims data either include health plan data and lack direct comparison with 
a control group (Raebel, et al., 2008); or include a control group and lack plan related 
data and are limited to beneficiaries hitting coverage gap in a particular month as against 
comparing utilization during different months of the year; (F. R. Lichtenberg & Sun, 
2007) or do not control for selection bias. (Zhang, et al., 2009) 
 Thus, although few studies have been conducted to assess the impact of 
prescription drug coverage gap on utilization and medication adherence, their results need 
to be interpreted with caution. The objective of this study is to present results describing 
the impact of the coverage gap on prescription drug utilization and medication adherence 
by using a methodologically sound research design. Details of the methods used to 
accomplish this will be presented in Chapter 3.  
PART III: MEDICATION ADHERENCE  
Definition of adherence 
 
The National Council on Patient Information and Education (NCPIE) defines 
compliance as “following a medicine treatment plan developed and agreed on by the 
patient and his/her health professional”. (P. G. Rogers & Bullman, 1996) The NCPIE 
includes within this definition the term adherence, including two-way communication, 
patient-centered treatment planning, constant monitoring and agreed-upon dosage or 
medication adjustments, and cooperative specification of what compliance means for 
each medication. A more commonly used definition of medication adherence developed 
by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 
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Medication Compliance and Persistence Work Group, refers to the extent to which a 
patient acts in accordance with the prescribed interval and dose of a medication regimen. 
(Cramer JA, et al., 2008)  
The NCIPE refers to non-compliance as the acts of omission and commission 
caused due to inadvertent error or intentional decisions. (P. G. Rogers & Bullman, 1996) 
Included in the acts of omission are behaviors associated with under use of medications 
such as taking less medicine than prescribed; taking it less frequently than prescribed; 
taking medicine ‘‘holiday’’; or not taking the prescribed medications at all. Acts of 
omission also include behaviors such as not obtaining initial or refill prescriptions; and 
stopping a medicine earlier than prescribed. The NCPIE refers to acts of commission as 
behaviors related to the dosing of medications. This includes behaviors such as overuse 
of medications by taking a higher than prescribed dose or taking doses too frequently; 
mistiming of doses; taking lower than prescribed doses or  skipping doses; sharing 
medicines with family members and knowingly consuming a food, beverage, or drug that 
can interact with prescribed medications.  
 
Factors affecting Medication Adherence 
The literature cites numerous studies assessing the underlying factors associated 
with the medication adherence. A review of the literature by Balkrishnan succinctly lists 
the factors affecting elderly patients' medication adherence.(Rajesh Balkrishnan, 1998) 
These include: race, drug and dosage form, number of medications, cost of medications, 
insurance coverage, and physician-patient communication. The review reports an 
inconsistent association between medication adherence and an elderly patients’ age, sex, 
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socioeconomic status, living arrangement, co-morbidities, number of physician visits, and 
knowledge, attitudes, and beliefs about health. In another review of determinants of 
medication adherence in the elderly, Vik et al report that while number of medications 
and poor patient-healthcare provider relationships (including the use of multiple 
providers) have been consistently shown to affect non-adherence, most socio-
demographic factors may have a limited effect. (Vik, Maxwell, & Hogan, 2004) The 
authors attribute inconsistent findings in the factors affecting adherence to the numerous 
methods of used in measuring adherence.  
Based on the results of these literature reviews assessing the factors affecting 
medication adherence in the elderly, a theoretical framework and available data, the 
factors affecting medication adherence will be controlled for in this study statistically by 
using these variables as covariates.   
Measurement of adherence 
 
 Measurement of medication adherence can be best described by classifying 
them as direct or indirect methods of adherence measurement. Direct methods of 
adherence measurement include methods such as directly observed therapy, assessment 
of serum concentrations of the drug or its metabolite in blood or urine, and detection or 
measurement of pharmacologic tracers added to drug formulations.(Osterberg & 
Blaschke, 2005) Direct methods while providing an accurate measure of adherence can 
be inconvenient and time consuming for the patient and very expensive for the 
investigator.  
 Indirect methods of adherence measurement include using patient self-reports 
(questionnaires, medication diaries), assessing clinical response, pill counts, electronic 
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medication monitors and prescription refill rates.(Osterberg & Blaschke, 2005)  
 Patient self-reports, aided by the use of questionnaires and asking patients to 
maintain diaries, have been widely used as a measure medication adherence. While 
patient self-reports are convenient and easy to use, they might not be accurate due to poor 
patient recall or incorrect representations by patients. Patient self-reports have been 
reported to overestimate adherence by as much as 200% compared to adherence 
measured using biochemical measures and over estimate by 1.3 to 2.0 times when 
compared to adherence measured using pill counts. (Krueger, Berger, & Felkey, 2005) 
 Assessment of clinical response, while easy to perform, might not be truly 
reflective of adherence as clinical response to medications might be affected by factors 
not related to medication taking behavior.  
 A commonly used measure of medication adherence is pill counts (counting the 
number of pills that remain in the patient's medication bottles or vials). Although 
relatively inexpensive, objective and quantifiable, this method of adherence measurement 
may not be valid as patients can easily manipulate it (by discarding pills before visits) 
and this method does not provide information on dose or the time that the medication was 
ingested.  
 Electronic medication monitoring overcomes the problems of pill counts with 
the use of digital monitors installed in the caps of bottles, eye drop dispensers, canisters, 
etc, to record the time and amount of drug dispensed from the bottle. This method is very 
accurate, provides information about time and dosing and prevents the problem of 
patient’s discarding drugs before a visit. However, these monitors are expensive and the 
act of taking a pill out of the bottle does not confirm consumption. (Osterberg & 
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Blaschke, 2005)  
  Pharmacologic tracers, pill counts and electronic compliance monitors are 
commonly used in randomized clinical trials. Patient self-reports, clinician assessments, 
and serum drug levels have been used in clinical settings. However, for studies involving 
large populations or for health services research, where direct adherence measurement is 
not feasible, pharmacy refill records have been used extensively. With the availability of 
electronic records, refill records provide a quick and inexpensive method of adherence 
assessment. However, refill records might provide an inaccurate adherence estimate 
given that medication acquisition does not necessarily imply medication consumption. 
But medication acquisition is an important step for medication consumption. Further, the 
validity of refill records as a measure of adherence has been assessed in a number of 
studies. Significant correlations between adherence measured using refill records and 
other measures of adherence like appointment keeping, medication taking, provide some 
evidence of convergent validity. (Steiner & Prochazka, 1997) 
  Moderate correlations have been reported when refill adherence measures are 
compared with serum drug levels or drug effects such as blood pressure control. 
Association between partial adherence and adverse health outcomes provides some 
evidence of discriminant validity. Since one of the objectives of this study is to assess 
Medicare beneficiaries adherence to medications, pharmacy refill records would be the 
most appropriate and valid method to measure medication adherence in this study.  
Adherence from refill records can be assessed either as a continuous or a 
dichotomous measure. A continuous measure of adherence may be defined as “one which 
offers three or more ordered response categories, or is based on multiple adherence 
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criteria, or uses a reliable, validated continuous measure to assess adherence.” (DiMatteo 
MR, et al., 2002) A dichotomous measure, as the name suggests, involves two categories 
(eg. adherent versus non-adherent, etc) based on cut-off values decided by researchers to 
define the extent of adherence or non-adherence. The results of a meta-analysis of 63 
studies analyzing patient adherence to medications, indicated that compared to 
dichotomous measures, continuous measures should be used to measure adherence. 
(DiMatteo MR, et al., 2002)  
After an extensive review of the literature, Hess et al., (2006), compiled a list of 
eleven most commonly used adherence measures, described in Table 1. (Hess, Raebel, 
Conner, & Malone, 2006) These include Continuous, Single-Interval Measure of 
Medication Availability (CSA);Continuous Measure of Medication Acquisition (CMA); 
Compliance rate (CR); Days Between Fills Adherence Rate (DBR); Continuous Measure 
of Medication Gaps (CMG); Continuous Multiple Interval Measure of Oversupply 
(CMOS); Medication Possession Ratio (MPR);  Refill Compliance Rate (RCR); 
Medication Possession Ratio, modified (MPRm); Medication Refill Adherence (MRA); 
and Proportion of Days Covered (PDC). Hess et al., calculated and compared medication 
adherence values derived by using each of these methods on data from the LOSE Weight 
(Long-term Outcomes of Sibutramine Effectiveness on Weight) study. 
 Medication adherence calculations using all eleven measures indicated that, of 
the eleven, CMA, MPR and MRA provided the same adherence value of 63.5%. 
Calculations based on PDC resulted in a slightly lower adherence value of 63.0%. CMG 
and CMOS, the gap measures resulted in adherence of 0.365 and 0.370 respectively. 
Higher adherence values were reported with the use of CR (84.4%), MPRm (86.6%), 
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RCR (104.8%), and CSA (109.7%), as methods to measure adherence. (Hess, et al., 
2006)  
The authors note several important points about each method of calculation. They 
indicate that when medication adherence calculations include more than one refill per day 
and if refills occur close to the study completion date, CSA can be biased. CMG and 
CMOS are essentially treatment gap measures and maybe difficult to interpret. The 
biggest limitation of using the MPR is the inconsistency in the terminology used in the 
literature to describe it. Numerous published measures of adherence with different 
formulae used for calculations have been termed “MPR”. The biggest limitation of using 
CR, RCR, DBR and MRA as measures of adherence is that the period from last 
dispensation until study completion is disregarded. The MPRm method overcomes this 
limitation by adding a number of days to the evaluation period which is equal to the days’ 
supply obtained at the last fill. However, due to the assumption that each individual will 
be 100% adherent during the last dispensation period, use of MPRm results in higher 
values of adherence. (Hess, et al., 2006)  
Using North Carolina Medicaid claims of 7069 patients (aggregated for each 
person as person-quarters) suffering from Schizophrenia, Martin et al compared 
medication adherence when measured using the PDC and two variants of MPR (MPR 
and truncated MPR- MPR capped at 1.0). (Martin et al., 2009) The proportion of days 
covered (PDC) measures the proportion of days a patient has a drug available, in the 
study interval, by assigning a simple binary measure indicating the presence or absence of  
the study drug for each day in the study period. Drug oversupplies from early refills are 
thus not included in PDC calculations. MPR is calculated by adding the total days' supply  
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Table 1: Measures of Medication Adherence 
 
Measure 
 
Formula 
 
Continuous Measure of 
Medication Acquisition (CMA) 
 
cumulative days’ supply of medication 
obtained / total days to next fill or to end of 
observation period 
Continuous Measure of 
Medication Gaps (CMG)  
total days of treatment gaps / total days to 
next fill or end of observation period 
Continuous Multiple Interval 
Measure of Oversupply 
(CMOS)  
total days of treatment gaps (+) or surplus (–) 
/ total days in observation period 
Compliance rate (CR)   
 
(total days supplied – last days’ supply) / 
(last claim date – first claim date) × 100 
Continuous, Single-Interval 
Measure of Medication 
Availability (CSA) 
days’ supply obtained at beginning of 
interval/days in interval  
Days Between Fills Adherence 
Rate (DBR)  
 
 
1 – [(last claim date – first claim date) – total 
days’ supply] / (last claim date – first claim 
date) × 100 
Medication Possession Ratio 
(MPR)   days’ supply: days in period  
Medication Possession Ratio, 
modified (MPRm)  
[total days supply / (last claim date – first 
claim date + last days’ supply)] × 100 
Medication Refill Adherence 
(MRA)  
 
(total days’ supply / total number of days 
evaluated) × 100 
Proportion of Days Covered 
(PDC)  
 
total days supply (medication availability) / 
total number of days evaluated × 100%, 
capped at 1.0 
Refill Compliance Rate (RCR)  
 
 
[(sum of quantity dispensed over interval / 
quantity to be taken per day) × 100] / number 
of days in interval between first and last refill
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for all medications and dividing by the number of days in the study period. Therefore, in 
this study, the numerator for PDC included the number of days one or more 
antipsychotics was available and the MPR numerator included the total days' supply of 
antipsychotics. The denominator for both MPR and PDC were total days in each person 
quarter. The results of the study indicated that PDC provides a more conservative 
estimate of medication adherence compared to medication adherence when calculated by 
using the MPR (mean PDC= 0.607, mean truncated MPR= 0.640, and mean MPR 
=0.695; p < 0.001) The differences between medication adherence measured using the 
PDC and MPR were more pronounced when calculated for patients who switched therapy 
(mean PDC=0.562, mean MPR =0.690, and mean truncated MPR=0.624; p < 0.001) and 
for patients with prescribed therapeutic duplication (mean PDC=0.669, mean truncated 
MPR=0.774, and mean MPR=1.238; p < 0.001).  In these cases, compared to the PDC, 
medication adherence was overestimated by nearly 11% when measured using the MPR 
and overestimated by nearly 60% when measured using the truncated MPR. The authors 
reported that in certain cases with therapeutic duplication, use of MPR as a measure of 
adherence resulted in adherence values nearly 85% higher than values obtained when 
measured using the PDC.  
Adherence measures used in this study 
 
Based on the review of studies described above, established validity and 
recommendations from the ISPOR task force on compliance, the two most commonly 
used and validated measures of adherence in studies involving pharmacy refill records – 
the Medication Possession Ratio (MPRm) and the Proportion of Days covered (PDC) will 
be used in this study. (Hess, et al., 2006; Martin, et al., 2009; Peterson AM et al., 2007)  
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The MPRm is calculated by summing the number of days supplied for all but the 
last refill, divided by the number of days between the first and the last refill. The PDC is 
calculated by dividing the total days a medication is available by total number of days 
evaluated in the study period.  The MPR and PDC have a range of 0-1, with a higher 
number indicating higher adherence. A ratio of greater than 1.0 is possible when 
adherence is measured using the MPR, with values greater than 1 indicating an 
oversupply, switching, etc. The PDC on the other hand is capped at 1.0 and is not 
affected by oversupply of medications. Adherence calculation related details associated 
with over supplies, switching, etc will be described at length in Chapter 3.   
 
SECTION IV: THEORETICAL FRAMEWORK 
 
The objectives of this study will be analyzed using the framework provided by one of the 
most widely used model to study health service’s use - the Andersen's Behavioral Model 
of Health Services Use as a guide. The model originally developed in 1968, has been 
modified multiple times. (Andersen, 1995) The 1995 modification model, which is most 
frequently used in studies assessing health service use, will be used in this 
study.(Andersen, 1995) The model as depicted in figure 1 is based on the premise that 
outcomes (health status and satisfaction) are dependent on environment factors, 
population characteristics and health behavior factors. 
Environment factors refer to a composite measure of health care system factors 
and external environment factors. Health care system factors include factors related to 
national health policy, health care resources available and their organization in the health 
care system that impact health services use. External environment factors refer to 
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Figure 1 The Andersen's Behavioral Model of Health Services Use* 
 
Enviornment   Population Characteristics      Health Behavior        
Outcomes 
 
 
                                                                                                              
 
                          
 
 
 
 
 
*Source: Andersen, 1995  
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physical, political and economic components in a health care system that impact use of 
health care services. (Andersen, 1995) 
Population characteristics include predisposing factors, enabling resources and 
need. Predisposing factors include demographic variables such as age, gender, marital 
status, education, race/ethnicity, and occupation, as well as an individual’s health beliefs 
and attitudes. Enabling resources refer to availability and accessibility of family and 
community resources such as income, insurance status, etc. Need factors refer to an 
individual’s perceptions of their health status and their need for medical care. (Andersen, 
1995) 
Health behavior factors are a composite measure of personal health practices 
such as diet, exercise, etc and measures of health services use including type, site, 
purpose and coordinated services in an episode of illness.(Andersen, 1995) 
Outcomes include perceived and evaluated health status and consumer 
satisfaction. Perceived health status as the name suggests reflects the health status, as a 
population perceives it while evaluated health status refers to the health status as 
evaluated by professionals. (Andersen, 1995) Consumer satisfaction, an explicit outcome 
of health services includes convenience, availability, financing, provider characteristics 
and quality of care. The feedback loops in the model reflect the dynamic and recursive 
nature of a health services model. (Andersen, 1995)  
Andersen’s model is a comprehensive model which presents a complete 
framework of various factors influencing health services utilization. While it is desirable 
that all variables described in the model be measured to adequately assess health care 
utilization, this study uses data from a pre-existing database and data required to assess 
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each variable might not be available. For the purposes of this study, the Andersen’s 
model framework is used as a theoretical guide to assess the impact of the Medicare Part 
D coverage gap on Medicare beneficiaries’ prescription drug utilization and medication 
adherence, based upon the data available. Figure 2 represents the variables assessed in 
this study based on the availability of data. Environment factors which refer to a 
composite measure of health care system factors and external environment factors, 
assessed in this study, include the month in which the coverage gap starts and an 
individual’s receipt of MTM services. The month in which an individual’s coverage gap 
starts is dependent on the coverage gap limit set by CMS and thus represents a healthcare 
system factor. Acceptance to receive MTM services are an individual’s choice. However, 
eligibility requirements determining receipt of MTM services are preset by the CMS. 
Thus, receipt of MTM services is also considered as a healthcare system factor. 
 Predisposing factors, which refer to the demographic variables assessed in this study, 
include age, gender and co-morbidities. Data representing other predisposing factors such 
as marital status, education, race/ethnicity, occupation, and an individual’s health beliefs 
and attitudes was not available. Enabling resources refer to availability and accessibility 
of family and community resources. Income will be considered as an enabling resource in 
this study, as an individual’s income might influence their decision on the type of the 
prescription drug coverage plan that they choose to enroll (generic/full/no coverage 
during the gap). Need factors refer to an individual’s perceptions of their health status 
and their need for medical care. While the data does not provide a direct measurement of 
need factors, an individual’s choice to enroll in a HMO or PPO plan might be reflective  
of their perception of their health status and their need for medical care. Therefore, HMO 
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Figure 2: The Andersen's Behavioral Model of Health Services Use (with variables 
used in the study) * 
 
Enviornment       Population Characteristics     Health Behavior    Outcomes   
 
 
                                                                                                              
 
                          
 
 
 
 
 
 
  
 
 
*Source: Andersen, 1995  
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vs. PPO enrollment will be included as a need factor in this study. 
Health behavior factors are a composite measure of personal health practices such 
as diet, exercise, etc and measures of health services use. Data related to individual’s 
personal health practices was not available. The health behavior assessed in this study 
refers to an individual’s prescription drug utilization and medication adherence before 
and after hitting the coverage gap. Health behavior assessment thus reflects the desired 
outcome to be measured in this study.  The outcomes represented in Andersen’s model 
include health status and satisfaction. The data available for this study did not lend 
support to measure the outcomes listed in the Andersen’s health behavior model and were 
truncated at measurement of health services use. 
 
SUMMARY OF LITERATURE REVIEW 
 
Medicare, a federal insurance program established in 1965, provides health 
insurance to Americans aged 65 and older and to individuals under age 65 with certain 
disabilities or end-stage renal disease. Medicare consists of four parts: Part A, B, C and 
D. Medicare Part A covers inpatient care in hospitals; Medicare Part B covers physicians’ 
services and outpatient care; and Medicare Part C, in addition to covering Part A and B 
services, typically includes additional benefits such as vision, dental, prescription drug 
coverage, etc.  
 To increase Medicare beneficiaries’ access to medications and help lower their 
prescription drug costs, the Medicare Prescription Drug, Improvement, and 
Modernization Act (MMA) of 2003 introduced a prescription drug benefit, for all 
Medicare beneficiaries, referred to as ‘Medicare Part D’. A review of the literature 
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indicates that Medicare Part D coverage is associated with an approximately 6% increase 
in prescription drug utilization and a 13% decrease in out-of-pocket expenses, with 
higher amounts reported for specific drug classes. However, it is also important to note 
that Medicare Part D has been structured to include substantial cost-sharing from 
beneficiaries in the form of deductibles, co-payments, and tiered payments. 
 A significant body of literature has been dedicated to understanding the impact of 
cost-sharing on Medicare beneficiaries’ prescription drug utilization, medication 
adherence and health outcomes before Medicare Part D was initiated. With Medicare Part 
D data not released by CMS, findings from these studies may provide reasonable 
estimates of the impact of cost-sharing in Medicare Part D on health care utilization. A 
review of the literature indicates that cost-sharing in the form of increased co-insurance 
rates decreases prescription drug utilization in the elderly by 2-6%, with larger decreases 
for specific drug classes. Cost-sharing has also been associated with decreased adherence, 
increased costs, and increased out-of-pocket expenses. Further, cost-sharing in the form 
of prescription benefit caps have been reported to decrease Medicare beneficiaries’ 
prescription utilization by about 8-30%, increase hospitalizations and emergency room 
visits, and increase total costs by 13-30%, on average.  
 While the studies assessing the impact of cost-sharing on Medicare beneficiaries, 
conducted before the initiation of Medicare Part D, provide a reasonable estimate of the 
impact of cost-sharing in Medicare Part D, most studies are based on plans with 
prescription drug coverage caps in the range of $1,000.  Standard Medicare Part D plans 
in 2007 had cost sharing in the amount of approximately up to $4,000. Medicare Part D 
coverage gap, the largest cost-sharing component of the Part D structure, has been 
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estimated to affect approximately 14-15% of Medicare beneficiaries in 2007.  Only a few 
studies have thus far directly assessed the impact of Medicare Part D coverage gap. 
Results of these studies indicate that the Medicare Part D coverage gap decreases 
prescription drug utilization by about 15%, decreases medication adherence and increases 
OOP expenses of Medicare beneficiaries. However, it is important to note that these 
results are based on studies which are either descriptive in nature or are limited by 
methodological flaws (lack of control groups, lack of health plan data, inaccurate 
estimation of coverage gap status, etc). Thus, although few studies have been conducted 
to assess the impact of prescription drug coverage gap on utilization and medication 
adherence, their results need to be interpreted with caution. 
The objective of this study is to assess the impact of the Medicare Part D 
coverage gap on prescription drug utilization and medication adherence by using a 
methodologically sound research design which is theoretically guided by the Andersen's 
Behavioral Model of Health Services Use, accurately assesses the coverage gap status, 
incorporates health plan data, includes a control group, accounts for confounding 
variables, uses two validated measures of adherence and uses robust econometric 
techniques for data analyses. Details of the methods to assess the study objectives are 
provided in chapter 3.  
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CHAPTER 3 
METHODS 
 
This chapter presents a detailed description of the methods used to conduct the 
study. The chapter begins with a description of the Human Research Review Committee 
approval to conduct this study, followed by an overview of the study research design, and 
a description of the study participants. Next, the study inclusion and exclusion criteria are 
discussed followed by a description of sample size calculations. Cost calculations used to 
determine if a beneficiary remains in the initial coverage limit, hits the coverage gap or is 
covered under catastrophic coverage followed by validity checks of the cost calculations 
are presented. 
The steps involved in data cleaning are described, followed by a description of the 
independent variables used in this study. Definitions and steps involved in measuring 
prescription drug utilization and medication adherence are described next, followed by 
examples of medication adherence calculations for three hypothetical cases and a 
description of the ten drug classes selected for medication adherence calculations. A 
description of the covariates used in the study is provided including a description of the 
measure and validation of the co-morbidity score, income assessment for beneficiaries in 
the study and MTM services provided by XYZ health care services. Following this is a 
description of the description of sample clinics and the data available on utilization of 
Medicare Part A and B services by beneficiaries who hit the coverage gap and total 
medical costs incurred pre- and post-coverage gap. The last section of the chapter 
describes the statistical data analyses planned for this study.   
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Human research review committee approval 
 
The University of New Mexico Health Sciences Center Human Research Review 
Committee (HRRC) reviewed and granted approval for the study after an expedited 
review. A copy of the HRRC approval letter is included in Appendix A. A waiver of 
HIPPA authorization and a waiver for informed consent were obtained.  
Data required for this study was abstracted from the electronic data repository 
from a large managed care organization in New Mexico, henceforth referred to as XYZ 
health care services. Information from electronic medical and pharmacy records was used 
for this study. These data include detailed information on pharmacy claims (prescription 
fills, costs of prescription drugs, etc), demographic data (e.g., age, gender, ZIP codes etc), 
medical claims (e.g. diagnostic codes, etc), and data from XYZ health care services’ 
sample clinics (information about prescriptions obtained by beneficiaries from sample 
clinics). Full compliance with the Health Insurance Portability and Accountability Act 
(HIPPA) regulations as required by UNM HRRC was maintained when conducting this 
research.  
 
Research design 
 
A quasi-experimental, cross-sectional, retrospective, pre-post with control group study 
design was used to assess the study objectives. The study objectives examined 
prescription drug utilization and medication adherence, before and after hitting the 
coverage gap, of beneficiaries enrolled in a health plan with no prescription drug 
coverage during the coverage gap (study group) was compared with that of beneficiaries 
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enrolled in a plan with generic drug coverage and full prescription drug coverage during 
the coverage gap (control group). Pharmacy and medical claims data from a large 
managed care organization in New Mexico were used to answer the study objectives. 
Data was abstracted for the period January 1 to December 31, 2007.  
 
Study participants 
 
Study participants included Medicare beneficiaries enrolled in Medicare Advantage 
prescription drug (MA-PD) plans offered by XYZ health care services. MA-PD plan 
beneficiaries can choose between two plans offered by the XYZ health care services - the 
Senior Care plan (HMO) and the Medicare Preferred Provider Organization (PPO) plan 
to receive Medicare Part D benefits. The Senior Care HMO plan only covers services 
obtained from providers associated within the plans network while the Medicare PPO 
plan covers services obtained from both in-network and out-of-network providers. 
However, with respect to Part D benefits, both the HMO and the PPO plans provide the 
same prescription drug benefits. Beneficiaries enrolled in the Senior Care (HMO) plan 
and the Medicare PPO plans further have an option to choose between two plans referred 
to as plan 2 and plan 3. The primary difference between plan 2 and plan 3 (for both 
Senior Care and PPO plan) is coverage of prescription drugs during the coverage gap. 
Plan 2, hence forth referred to as the ‘no coverage’ plan, does not offer any coverage of 
prescription drugs during the coverage gap. Medicare beneficiaries enrolled in plan 2, 
represent the study group. Plan 3 hence forth referred to as the ‘generic coverage’ plan is 
a plan which covers all preferred generics during the coverage gap. Medicare 
beneficiaries enrolled in the generic coverage plan represent one control group. Medicare 
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beneficiaries enrolled in an employer-sponsored plan, which covers both brand name and 
generics in the coverage gap, hence forth referred to as the ‘full coverage’ plan, will be 
used as a second control group. Details about premiums, deductibles, and coverage for no 
coverage, generic coverage and full coverage plans are listed in Table 2.  
 In 2007, XYZ healthcare services’ Medicare Senior Care Plan had 18,731 
enrollees and Medicare PPO plan had 4,608 enrollees and the employer-sponsored plan 
had 2,232 enrollees. Medicare beneficiaries who met the study eligibility criteria were 
thus selected from a pool of 25,571 beneficiaries in Medicare Senior care, PPO and 
employer sponsored plans. 
 
Inclusion criteria 
 
Medicare beneficiaries who were at least 65 years of age, non-institutionalized, 
continuously enrolled in a XYZ health care services MA-PD plan from January 1, 2007 
to December 31, 2007 were included in the study.  
 
Exclusion criteria 
 
Medicare beneficiaries who received any form of financial assistance from external 
sources were excluded from the study. Medicare beneficiaries who were dual eligible (i.e. 
eligible for both Medicare and Medicaid), beneficiaries with low income subsidies, 
beneficiaries eligible for military retirement benefits (TRICARE), beneficiaries eligible 
for Veteran benefits (VA), beneficiaries eligible for federal retiree benefits, and 
beneficiaries in long term care facilities were excluded from the study.  
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Table 2: Coverage details for no coverage, generic coverage and full coverage plans 
 
Benefits No Coverage 
Plan 
Generic Coverage Plan Full Coverage Plan 
Premium No additional 
premium beyond 
the Medicare Part 
B premium of 
$93.50 each 
month 
A $57.00 monthly 
premium in addition to 
Medicare Part B 
premium of $93.50 each 
month 
Variable 
Deductible No deductible 
Initial 
Coverage  
Generic/Preferred Brand /Non-Pref. Brand Generic/Preferred Brand 
/Non-Preferred Brand 
Retail Pharmacy  Retail Pharmacy  
$4/33/55 for 30 days supply (DS) $5/20/45 for 30 DS 
Specialty: $100 Specialty: $100 
Mail Order Mail Order 
$8/83/165 for 90 DS $10/50/145 for 90 DS 
Coverage 
Gap  
No gap coverage All generics covered All drugs covered  
Beneficiaries pay 
100% of 
prescription drug 
costs 
  
 
 
Retail Pharmacy Retail Pharmacy
Generic Gen/Pref Brand /Non-
Pref Brand 
$4 for 30 DS 
$12 for 90 DS 
 
$5/20/45 for 30 DS 
$15/105/165 for 90 DS 
Specialty: $100 
Mail Order Mail Order 
$8 for 90 DS $10/50/145 for 90 DS 
Beneficiaries pay 100% 
for all other prescription 
drug costs. 
 
Catastrop
hic 
Coverage  
Beneficiaries pay the greater of: $2.25 for Generic/$5.60 for all other 
drugs or 5% co-insurance 
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Sample size calculations  
 
 Sample size calculations are based on the primary objective of the study, which is to 
assess the impact of the Medicare Part D coverage gap on prescription drug utilization 
and medication adherence. Due to lack of available information required to calculate the 
sample size based on multivariate tests, univariate paired t-tests were used to conduct the 
sample size calculations. Additionally, since multivariate tests have higher power 
compared to univariate tests, sample size estimates based on univariate tests provide 
more conservative estimates compared to sample size estimates based on multivariate 
tests. (Stevens, 2002) The NCSS/PASS software was used for sample size calculations. 
(NCSS/PASS, 2008) 
 
a) Impact of the coverage gap on prescription drug utilization 
 In order to estimate the sample size required to compare Medicare beneficiaries’ 
prescription drug utilization before and after hitting the coverage gap, results from the 
study conducted by Sun and Lee (2007) were used. The authors report that after reaching 
the coverage gap, Medicare beneficiaries’ average prescription days of therapy decreased 
by 15.85% (from 1,104 to 929 days of therapy, p<0.0001). Standard deviation (SD) 
values are not reported as a part of the Sun and Lee study results. For the purposes of this 
study, sample size was estimated for a range of possible standard deviation (100, 500, 
and 1000) values. By using a standard deviation of 1000, which is nearly as large as the 
reported mean, a very conservative estimate of sample size is provided. Using a paired t-
test, at a level of significance=0.05, power=80%, effect size=0.18 (calculated based on 
pre-period mean prescription drug utilization=1104 and post-period mean prescription 
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drug utilization =929, SD = 1000), the most conservative estimate of sample size was 259 
beneficiaries. Sample size estimates based on a range of SD values are presented in Table 
3.  
Table 3: Sample Size Estimation for Prescription Drug Utilization 
 
N 
Prescription days therapy 
SD 
Effect 
Size Power 
Pre-coverage 
gap mean* 
Post-coverage 
gap mean* 
5 
 
1104 
 
929 
 
100 
 
1.75 
 
0.83 
 
67 
 
1104 
 
929 
 
500 
 
0.35 
 
0.80 
 
259 
 
1104 
 
929 
 
1000 
 
0.18 
 
0.80 
 
*Estimates reported in the study conducted by Sun and Lee (2007)  
 
b) Impact of the coverage gap on medication adherence 
In order to estimate the sample size required for comparing Medicare 
beneficiaries’ medication adherence before and after the coverage gap, results from the 
study conducted by Raebel et al., (2008) were used. (Raebel, et al., 2008) Raebel et al., 
calculated medication adherence using the medication refill adherence (total days 
supply/number of days in the study period*100) method. Medication Possession Ratio 
(MPRm) and the Proportion of Days covered (PDC) are used as measures of medication 
adherence for the purposes of our study. As reported in detail in the literature review, 
medication adherence calculated using MPR is equivalent to medication adherence 
calculated using MRA. Thus, although Raebel et al., used a different measure of 
medication adherence, adherence values reported in their study provide reasonable 
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estimates for sample size calculations.  
Based on the results of the Raebel et al study, the pre-period (before the coverage 
gap) and post-period (after the coverage gap) medication adherence means and SD values 
for drug classes relevant to our study (statins, anti-hypertensive and oral anti-diabetic 
medications) are reported in table 4. Using a paired t-test, at a level of significance=0.05, 
power=80%, effect size=0.17 (calculated based on pre-period mean adherence=91 and 
post-period mean adherence=87.3, SD=22.4), the most conservative estimate of the 
sample size was 290 beneficiaries.  
 Table 4 : Sample Size Estimation for Medication Adherence 
*Estimates reported in the study conducted by Raebel et al (2007) 
Determination of initial coverage limit, coverage gap and catastrophic coverage  
 
Total costs and true out-of-pocket (TrOOP) costs are used to assess if a Medicare 
beneficiary remains in the initial coverage limit, hits the coverage gap or is covered under 
catastrophic coverage. Total costs represent the costs associated with filling a prescription 
drug and include the amount XYZ health care services pays and the amount a beneficiary 
Drug class N 
Medication Refill Adherence 
SD 
Effect 
Size 
Pre-coverage 
gap mean 
adherence* 
Post-coverage 
gap mean 
adherence* 
Statins 290 91 87.3 22.4 0.17 
Anti-
hypertensives 173 89.8 84.5 24.7 0.22 
Oral anti-
diabetics 245 95.1 91.7 18.9 0.18 
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pays (co-pay) after filling a prescription drug.  
True out-of-pocket costs, on the other hand, only include costs incurred by the 
beneficiary. TrOOP costs are the prescription drug costs that count toward the annual out-
of-pocket threshold that beneficiaries must reach before catastrophic drug coverage 
begins. (Centers for Medicare and Medicaid Services, 2006) Deductibles, co-payments, 
and co-insurance amounts that a beneficiary pays contribute towards TrOOP. More 
specifically, the payments that count toward TrOOP costs include the beneficiary’s own 
out-of-pocket spending; payments made by a family member or official charity on behalf 
of the beneficiary; payments by a qualified charity; and payments made by a State 
Pharmaceutical Assistance Program.(Centers for Medicare and Medicaid Services, 2006) 
Payments that do not count toward TrOOP costs include premiums paid by the 
beneficiary; payments made by a group health plan (e.g., employer or retiree plan); 
payments made by government programs (e.g., Veterans Affairs or TRICARE); 
payments covered by an automobile insurer; and payments made by Part D plans as part 
of an enhanced plan benefit package. (Department of Health and Human Services, 2007) 
For beneficiaries enrolled in standard Part D plans, TrOOP costs in 2007 included $265 
deductible, $535 coinsurance during initial coverage and $3050 during the coverage gap, 
which add up to $3,850.  
Medicare beneficiaries enrolled in XYZ health care services MA-PD plans are not 
required to pay any deductible. Details about co-payment amounts that beneficiaries are 
required to pay during the initial coverage limit, coverage gap and catastrophic coverage 
are listed in table 2. The following steps were taken to assess if a beneficiary remains in 
the initial coverage limit, hits the coverage gap or is covered under catastrophic coverage: 
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1) Total drug costs (ingredient cost + dispensing fee) were calculated for each 
beneficiary. The next step involved determining beneficiaries who had total costs less 
than $2,400 and beneficiaries who had total costs greater than $2,400. Beneficiaries 
who had total costs less than $2,400 represented beneficiaries who remained in the 
initial coverage limit. Beneficiaries who had total costs greater than $2,400 were 
beneficiaries who hit the coverage gap. 
2) For beneficiaries with total drug costs greater than $2,400, their true out-of -pocket 
costs were calculated. Beneficiaries who incurred TrOOP costs less than or equal to 
$3,850 and beneficiaries who incurred TrOOP costs greater than $3,850 were 
identified. Beneficiaries with TrOOP costs less than or equal to $3,850 represented 
beneficiaries who remained in the coverage gap through the entire year. Beneficiaries 
with TrOOP costs greater than $3,850 represented beneficiaries who were covered 
under the catastrophic coverage limit. 
 
 
Validity of Cost Calculations 
 
XYZ health care services use a pharmacy benefit management (PBM) company that 
follows each MA-PD plan enrollee’s costs to determine if they are in the initial coverage 
limit, have hit the coverage gap or are covered under the catastrophic coverage limit. 
However, a comprehensive listing of beneficiaries who hit the coverage gap and their 
respective total and TrOOP costs for 2007was not available from the PBM. Only by 
accessing each patient’s record through the PBM system, available only on the health 
plan computer systems, would it be possible to identify these patients. Further these costs 
from individual records could not be transferred into a database for additional analyses. 
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Thus, for the purposes of this study, total and TrOOP costs were calculated for each 
beneficiary by tracking costs associated with all their claims for the year 2007 from XYZ 
healthcare services pharmacy claims database. To ensure that the cost calculations 
performed for the purposes of this study were accurate, costs listed in the PBM records 
for 250 patients were cross checked with costs calculated for the purposes of this study. 
 
Data Cleaning 
The following steps were taken to clean the data before analyzing it: 
1. Medicare beneficiaries who were at least 65 years of age, non-institutionalized, 
enrolled in a Medicare Advantage prescription drug plan, enrolled in an employer 
sponsored benefit plan and received no additional financial assistance from external 
sources (eg LIS, TRICARE, etc) were identified. 
2. Only members who had a full year of coverage (January 1–December 31, 2007) 
were included. Members who died before the end of the year were also excluded. 
3. All claims for drugs covered under Medicare Part B were deleted based on GPI 
numbers. A list of all Part B drugs deleted and their GPI numbers is included in 
Appendix B.  
4. XYZ health care services covers Prilosec® for all Medicare beneficiaries. Since 
Prilosec® is an OTC medication and does not contribute towards TrOOP costs, all 
Prilosec claims® were deleted for the purposes of cost calculations. 
5. Reversed claims: A large number of duplicate claims existed in the data base due to 
multiple processes and reversals for one claim. The following steps were taken to 
ensure that only one valid claim existed for each fill.  
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a) Each claim has a distinct claim number. All claims for each member were ordered 
by claim number.  
b) Each claim had a claim status associated with it. A claim status of ‘P’ indicates that 
the claim was processed and a claim status of ‘R’ indicates that the claim was 
reversed. If the same claim appeared more than once during the entire year, then 
three possible scenarios can occur:  
i) The number of times a claim is processed (P) is greater than the number of times a 
claim is reversed (R), i.e. P>R. This implies that the claim was eventually processed. 
Therefore, the claim was included. 
ii) The number of times a claim is processed (P) is less than the number of times a claim 
is reversed (R), i.e., P<R. This implies that the claim was eventually reversed. 
Therefore, the claim was deleted. 
iii) The number of times a claim is processed (P) is equal to the number of times a claim 
is reversed (R), i.e., P = R. In this case, there can be two scenarios – 1) claims are 
resolved on a date, which occurs after the date that the claim was originally submitted 
and 2) claims are resolved on the same date that the claim was originally submitted. 
Different date: If a claim was processed on one date and reversed on another date, 
then the claim status listed for the latter date was accepted. For example, let us 
consider a claim which was processed on 1/10/07 and then the claim was reversed on 
1/15/07. This claim was considered as reversed.  
Same date: The data does not include a time stamp that reflects the time a claim was 
processed or reversed. For scenarios where a claim was processed and then reversed 
on the same day, it was difficult to judge whether the claim was eventually processed 
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or reversed. These claims were deleted from the analyses. 
 
Description of study variables 
 
a) Independent Variable 
The independent variable in this study was the coverage gap status, measured at two 
levels: pre-coverage gap and post-coverage gap. Pre-coverage gap refers to the period 
before an individual hits the coverage gap and post-coverage gap refers to the period 
during the coverage gap.  
 
b) Dependent Variables or Outcome Measures 
Prescription drug utilization 
Prescription drug utilization refers to a measure of how many and how often, plan 
members use prescription medications in a given year. The standard and most widely 
used measure of prescription drug utilization, included in the Health Plan Employer Data 
and Information Set (HEDIS®) is the outpatient drug utilization measured as the total 
number of prescriptions per member per year. (Chawla AJ, Hatzmann MR, & Long SR, 
2001) For the purposes of this study, prescription drug utilization was assessed using per 
member total number of prescriptions. (Khan, et al., 2008; Klepser, Huether, Handke, & 
Williams, 2007; F. R. Lichtenberg & Sun, 2007) Prescription drug utilization was 
calculated before a beneficiary hits the coverage gap (pre-coverage utilization) and 
during the coverage gap (post-coverage utilization). Prescription drug utilization included 
claims filled in mail order and retail pharmacies. Claims that had a 90 days’ supply were 
adjusted to reflect a 30 days supply. For example, a claim with a 90 days’ supply was 
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adjusted to reflect 3 claims. This approach has been used in the literature. (Klepser, et al., 
2007)   
 
Medication Adherence 
Based on established validity and recommendations from the ISPOR task force on 
compliance, the two most commonly used and validated measures of adherence in studies 
involving pharmacy refill records – the Medication Possession Ratio (MPRm) and the 
Proportion of Days Covered (PDC) were used in this study. (Hess, et al., 2006; Peterson 
AM, et al., 2007) The MPRm is calculated by summing the number of days supplied for 
all but the last refill, divided by the number of days between the first and the last refill. 
The PDC is calculated by dividing the total days a medication is available by total 
number of days evaluated in the study period.   
 
Steps and Assumptions considered for medication adherence calculation 
The following steps and assumptions were considered to calculate medication adherence: 
1) Two adherence values, the pre-MPR/PDC and the post-MPR/PDC, were calculated 
for each Medicare beneficiary. The pre-MPR/PDC reflects adherence before a 
beneficiary hits the coverage gap and the post-MPR/PDC reflects adherence during 
the coverage gap.  
2) The day a beneficiary’s total costs are equal to $2400, was considered as the day a 
beneficiary hits the coverage gap. Since the data does not include time stamps, all 
prescriptions filled on the day a beneficiary hits the coverage gap were considered as 
prescriptions filled before hitting the coverage gap. 
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3) Medication adherence was calculated by using December 31st as the end date. To 
understand the importance of using December 31st as the end date and not the last 
claim filled by the beneficiary, let us consider the following example. Suppose a 
beneficiary John hits the coverage gap on 8/15/07. John fills his prescription for 
simvastatin on the first of every month from 1/1/07 through 8/1/07. However, John 
fills no prescriptions for simvastatin from 9/1/07 through 12/31/07. If we use 8/1/07 
as the end date, John’s adherence would be 100% although John does not fill any 
prescriptions for 4 months after hitting the coverage gap. This is the time period we 
are most interested in analyzing and hence 12/31/07 was used as the end date.  
4) If a beneficiary’s days supply for their last fill was greater than the number of days in 
the calendar year, then the days supply was updated to reflect the number of days left 
in the calendar year. For example, if a beneficiary filled a 30 days’ supply on 
12/18/07, then the days’ supply for the claim was updated to 14 days (12/31/07-
12/18/07 = 14).  
5) The variable days supply associated with dosage forms such as injectables, inhalers, 
etc might result in incorrect estimates. Thus, as is frequently done in studies assessing 
medication adherence, only oral dosage forms were considered for the purposes of 
medication adherence calculations.  
6) Medication adherence was calculated per drug class and not for specific drugs. As 
long as a beneficiary filled a medication in a drug class, the beneficiary was 
considered adherent. For example, a beneficiary’s adherence to statins is reported, not 
his adherence to simvastatin or pravastatin in particular.  
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7) It is assumed that a beneficiary is prescribed only one medication per drug class. For 
example, it is assumed that a beneficiary on statin will be prescribed either 
simvastatin or pravastatin but not both. 
Medication Possession Ratio (MPRm) Calculation 
 
The MPRm is calculated by summing the number of days supplied for all but the 
last refill, divided by the number of days between the first and the last refill.(Hess, et al., 
2006) Days supply is an estimate of how many days a prescription is intended to last and 
is calculated by dividing the number of doses in the prescription by the number of doses 
per day. For example, a prescription of 30 tablets twice a day equals to 15 days’ supply. 
The MPR is a ratio with a range of 0-1, with a higher number indicating higher 
adherence. A ratio of greater than 1.0 is also possible, indicating an oversupply.   
MPRm = total days supply   × 100 
   (last claim date – first claim date) + last days’ supply 
 
This formula is traditionally used to calculate the MPRm. However, this formula does not 
account for medication oversupply - an important aspect to be considered while 
calculating medication adherence. (Peterson AM, et al., 2007) Beneficiaries’ might have 
an oversupply of medication due to early refills, switching to different medications or 
switching to a different dose. Therefore, for the purposes of this study, two values of 
MPRm will be reported. One MPRm, henceforth referred to as “Traditional MPR”, was 
calculated without accounting for medication oversupply. Another value referred to as 
updated MPRm, henceforth referred to as “Updated MPR” was calculated by accounting 
for medication oversupply. The following steps were taken to account for oversupply 
required for the updated MPR calculations.  
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1. Oversupply due to early refills: XYZ health care services allow patients to refill 
prescriptions once they have exhausted 75% of their medications. Thus, for 
prescriptions with 30 days’ supply, a beneficiary can fill a prescription with 8 days 
supply left. To understand the importance of adjusting for this oversupply due to early 
refills, let us consider the following example. Let us consider a beneficiary John who 
refills his prescription for Simvastatin each month when he is left with 8 day’s 
supply. Suppose John continues his pattern of refilling 8 days before his supply is 
exhausted for 10 months. Over a period of 10 months, John would have 80 extra 
days’ supply. Now suppose John hits the coverage gap on October 30th. With 80 extra 
days supply accrued over time, John has enough medication to cover the remaining 2 
months. Thus, in John’s case, absence of a refill after hitting the coverage gap, does 
not necessarily imply that he is non-adherent.  
Further, oversupply of medications accrued in the pre-coverage gap period was 
carried forward to the post-coverage gap period. Medication oversupply was assessed 
by comparing a beneficiary’s total days supply for the entire pre-coverage gap period 
with the days between first and last fill in the pre-coverage gap period. To understand 
this better, let us consider claims for a beneficiary listed in table 5.  
Total days supply for the period from 03/27/07 to 5/22/07 = 60.  
Days between 03/27/07to 5/22/07 = 56.  
Oversupply = Days supply-days between 03/27/07to 5/22/07 
  = 60-56 = 4  
Therefore, 4 days will be subtracted from the numerator in the pre-coverage gap 
period and added to the numerator of the post-coverage gap period.  
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Table 5: Example of claims to assess oversupply due to early refills for MPR 
calculation 
 
Statin Date Filled Days Supply 
simvastatin  03/27/07 30 
simvastatin 05/22/07 30 
 
2. Oversupply due to switching within the same class: A beneficiary might be 
switched to a different medication in the same drug class for reasons such as side-
effects or costs (availability of a cheaper alternative). For example, let us consider all 
claims for statins for a beneficiary John, listed in table 6. 
 
Table 6: Example of claims to assess oversupply due to switching within the same 
class for MPR calculation 
 
Statin Date Filled Days supply  
simvastatin  02/16/07 30 
simvastatin  03/10/07 30 
pravastatin 03/27/07 30 
pravastatin 04/18/07 30 
pravastatin 5/22/07 30 
   
 John is prescribed a 30 days’ supply of Simvastatin on 02/16/07. John then refills a 
30 days’ supply for simvastatin on 3/10/07. Thus, John has simvastain which would 
last him until 4/8/2007. However, John is switched to pravastatin on 3/27/2007. Thus, 
for the period between 3/27/07 and 4/10/2007 John has both simvastatin and 
pravastatin in his possession. As a result of the switch, has 13 days of oversupply (30 
days’ supply available - 17 days’ supply used). There are two options to deal with this 
oversupply of 13 days due to switching. Either we assume that John might use the 
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excess medication at some later point in time or assume that John will discard the 13 
days oversupply of simvastatin. The more conservative estimate, that John will use 
the oversupply at a later time will be used for this study. Therefore, as described in ‘a’ 
above, 13 days will be subtracted from the numerator in the pre-coverage gap period 
and added to the numerator of the post-coverage gap period. However, alternative 
calculations based on the assumption that John will discard the oversupply will also 
be conducted and results compared. 
 
Therefore, to accurately calculate  medication adherence, the PDC and two MPR 
values will be calculated. The traditional MPR will be calculated without accounting 
for medication oversupply and the updated MPR will be calculated by accounting for 
the oversupply. 
 Traditional Pre-MPR = TDS  
                            (last claim date – first claim date) + last days’ supply 
 
Traditional Post-MPR = TDS  
                    (last claim date – first claim date) + last days’ supply 
 
Updated Pre- MPR = TDS-OS  
                                (last claim date – first claim date) + last days’ supply 
 
Updated Post-MPR = TDS+ OS  
                               (last claim date – first claim date) + last days’ supply 
 
 
Proportion of Days Covered Calculation 
The proportion of days covered (PDC) measures the proportion of days a patient has a 
drug available, in the study interval, by assigning a simple binary measure indicating 
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the presence or absence of the study drug for each day in the study period. Drug 
oversupplies from early refills are thus not included in PDC calculations.  The PDC is 
a ratio with a range of 0-1, with a higher number indicating higher adherence. A ratio 
of greater than 1.0 is not possible, as the PDC is capped at 1.0. (Martin, et al., 2009)  
 
PDC = total days medication is available × 100      
            total number of days evaluated 
 
The following steps were used to calculate PDC:  
 
1. The numerator in the PDC is calculated by checking if a beneficiary has 
medication coverage for each day in the study period. Dummy variables with 
values of 0 or 1 are created for each day in the period. If a beneficiary has 
prescription drug coverage for a particular day he is given a value of 1. If he does 
not have prescription drug coverage for a particular day he is given a value of 0. 
The sum of all days that a beneficiary has medication coverage will provide the 
numerator for the PDC calculation. This approach is very useful when measuring 
PDC for a therapeutic class, where beneficiaries are concurrently prescribed more 
than one medication from the same therapeutic class. It is also useful to account 
for drug switches, addition of drugs within a class, etc. Counting medications per 
day prevents over-estimation of adherence values. 
2. Oversupply due to switching: Oversupply due to switching to a different drug is 
automatically accounted for in the PDC calculations. To understand how 
oversupply is accounted for in the PDC calculations, let us consider, all claims for 
statins for a beneficiary John, listed in table 7.  
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Table 7:  Example of claims to assess oversupply due to switching for PDC 
calculation 
 
 
 
 
 
 
 
 
 
John is prescribed a 30 days’ supply of Simvastatin on 02/16/07. John refills a 30 days’ 
supply for his Simvastatin on 3/10/07. Thus, John has simvastain which would last him 
until 4/8/2007. However, John is switched to pravastatin on 3/27/2007. Thus, for the 
period between 3/27/07 and 4/10/2007 John has both Simvastatin and Pravastatin in his 
possession. As described in step 1, when calculating PDC, dummy variables indicating a 
presence or absence of a drug are assigned for each day.  As is depicted in table 8, one 
dummy variable assessing days supply for simvastatin and one dummy variable assessing 
days supply for pravastatin are created. John has values of 1 for both simvastatin and 
pravastatin for the period from 3/27/07 to 4/8/07. As depicted in table 8, the dummy 
variable for total medications available will reflect a value of 1 on days that a beneficiary 
has both simvastatin and pravastatin, thus automatically accounting for the oversupply.  
The numerator for the PDC reflects the total days medications are available, irrespective 
of whether it was a simvastatin or a pravastatin. 
Drug Date Filled DS 
simvastatin 02/16/07 30 
simvastatin 03/10/07 30 
pravastatin 03/27/07 30 
pravastatin 04/18/07 30 
pravastatin 05/22/07 30 
pravastatin 06/21/07 30 
pravastatin 07/21/07 30 
pravastatin 08/23/07 30 
pravastatin 09/20/07 30 
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Table 8:  Example for claims to assess oversupply due to early refills for PDC 
calculation 
 
3. Oversupply due to early refills: As described in the MPR calculations, when a 
beneficiary has an oversupply due to early refills, it is important to carry forward 
the oversupply from the pre-PDC period to the post-PDC period. At the end of 
each claim, an assessment is made to check if the days supply is greater than the 
days between that claim and the next claim. For example, let us consider two 
consecutive claims on 2/16/07 on 3/10/07 (table 7). The days supply for the period 
between 3/10/07 to 2/16/07 is 30 days while there are only 22 days between 
3/10/07 to 2/16/07. Thus the beneficiary has 8 days oversupply. This oversupply of 
8 days will be carried forward to the next fill period on 3/10/07. Similarly any 
oversupply from the fill on 3/10/2007 will be added to the 8 days oversupply from 
the fill on 2/16/07 and this process is continued for each fill in the study period. If 
a beneficiary continues filling his prescriptions in a timely manner then all 
oversupply accumulated at the end of the study period is discarded and PDC is 
capped at 1. If a beneficiary has gaps between fills, then days supply from the 
oversupply, sufficient to cover the gap period will be added and the remainder 
carried forward. 
  2/16 
2/17
-
3/09 
3/10
-
3/26 3/27 
3/28
-
4/08 
4/09
- 
9/20 Total  
simvastatin  1 1 1 1 1 0 60 
pravastatin  0 0 0 1 1 1 177 
Total days supply              237
Total days statin avail 1 1 1 1 1 1 221 
117 
 
4. Denominator in the PDC calculation is the number of days in the study period. 
   
Examples of Traditional MPR, Updated MPR and PDC calculations  
In order to better understand steps involved in MPR and PDC calculations three cases 
where beneficiaries either have oversupply or undersupply of medications or are switched 
to medications in the same class are depicted below.  
 
CASE 1: BENEFICIARY WITH NO SWITCHING 
Medication Possession Ratio (MPR) 
i) Pre-MPR 
Step1:  Let us consider a beneficiary who is prescribed simvastatin. Table 9 below lists 
all claims filled by the beneficiary from January1 –December 31, 2007.  
Table 9: Example of all claims considered for MPR calculation 
 
 
 
 
 
 
 
Step 2: The beneficiary hits the coverage gap on 7/11/07. Thus, the pre-period includes 
all claims filled before 7/11/07 (as depicted in table 10). The Pre-period MPR is 
calculated as follows: 
Drug Date filled 
 
Days’ Supply 
(DS) 
simvastatin  01/23/07 30 
simvastatin  02/21/07 90 
simvastatin  05/22/07 90 
simvastatin  08/28/07 30 
simvastatin  12/18/07 30 
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Table 10: Example of pre-period claims considered for MPR calculation 
 
 
 
 
 
Traditional Pre-MPR = TDS  
                     Days between 05/22/07 to 01/23/07 + Days’ supply of 5/22/07 
 
Total Days Supply = 30+90+90 = 210 
Days between 05/22/07- 01/23/07 = 120 
Days’ supply of 5/22/07=90 
 
Pre-MPR = 210  
                   119+90 
 
     = 210 
        209 
 
Traditional Pre-MPR = 1.004 
 
Step 3: Oversupply (OS) for the period 05/22/07-01/23/07 is assessed by calculating the 
difference between the total DS till 5/22/07 and the days between 05/22/07-01/23/07. 
OS = total DS till 5/22/07–Days between 05/22/07-01/23/07 
OS= 120-119 =1 
Updated Pre- MPR=   TDS- OS  
                     Days between 05/22/07 to 01/23/07 + Days’ supply of 5/22/07 
= 210-1 
                 209 
= 209 = 1 
                 209 
Date filled DS 
01/23/07 30 
02/21/07 90 
05/22/07 90 
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Updated Pre- MPR = 1 
 
ii) Post- MPR  
Step 1: The post-period includes all claims filled after 7/11/07.  
Step 2:The beneficiary’s last claim is updated to reflect the number of days from the date 
filled to 12/31/07. (Updated days supply is bold faced)  
Table 11: Example of post-period claims considered for MPR calculation 
 
Date filled DS Updated DS  
08/28/07 30 30 
12/18/07 30 13 
 
Step 3: The oversupply from the pre-period is added to the numerator of the post-period 
MPR calculation. Therefore, 
Traditional Post- MPR = TDS                         
                        Days between 12/31/07 to 08/28/07+ Days supply of 12/18/07 
 
Updated Post-MPR = TDS +OS                        
                     Days between 12/31/07 to 08/28/07+ Days supply of 12/18/07 
 
Total Days Supply = 30+13 = 43 
Days between 12/31/07 to 08/28/07= 125 
Oversupply (OS) from the Pre-period =1 
Last days supply = Days supply of 12/18/07 = 13 
Therefore,  
Traditional Post- MPR = 43                         
120 
 
                       125+13 
Traditional Post-MPR = 0.312 
 
Updated Post-MPR = 43+1 
                              125+13              
 
Updated Post-MPR = 0.319 
 
Proportion of Days Covered (PDC) 
i) Pre- PDC 
Step 1: The beneficiary hits the coverage gap on 7/11/07. Thus, the pre-period includes 
all claims till 7/11/07. (as shown in table 10) 
Table 12: Example of all claims considered for PDC calculation 
 
 
 
 
 
Step2: 
Total Days Medication Available from 1/23/07 to 7/11/07 = 169 (as shown in table 12) 
Days between 1/23/07 to 7/11/07 =169 
PDC = total days medication is available 
            total number of days evaluated, capped at 1.0 
 
         = 169 
             169 
  1/23 
1/24-
2/20 2/20 
2/21-
5/21 5/22
5/23-
7/10 7/11 Total  
simvastatin  1 1 1 1 1 1 1 169 
Total days supply                170 
Total days meds. 
available   1 1 1 1 1 1 1 169 
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Pre-PDC = 1.00 
Oversupply (OS) for the pre-period (07/11/07-01/23/07) is difference between the total 
days medications available and days supply. 
 OS = 170-169 =1 
 
ii) Post- PDC 
Step 1: The beneficiary hits the coverage gap on 7/11/07. The post-period includes all 
claims from 7/12/07 to 12/31/07 as shown in the table 13. 
Table 13: Example of pre-period claims considered for PDC calculation 
 
Step 2: 
Total days medication is available from 7/12/07 to 12/31/07= 84 
Days between 12/31/07 to 7/12/07 =172 
Post-PDC = total days medication is available 
                    total number of days evaluated, capped at 1.0 
           
      = 84 
                    172 
 
Post-PDC = 0.488 
  7/12 
7/13 -
8/19 
 
8/20
8/21 8/21-
8/27 
8/28-
9/26 
9/27-
12/17 
12/18-
12/31 Total 
simvastatin  1 1 1 0 0 1 0 1  84 
Total days 
supply      
   
      84 
Total days 
meds. 
available   1 1 
 
 
1 
 
 
1 
 
 
0 1 0 1 84 
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In summary, table 14 lists the adherence values when calculated using different measures 
of adherence. 
 
Table 14: Summary of pre- and post coverage gap medication adherence for a 
beneficiary with no switching 
 
 Pre-Coverage gap Post-Coverage Gap 
Traditional MPR 1.004 0.312 
Updated MPR 1.000 0.319 
PDC 1.000 0.488 
 
CASE II: MPR and PDC for beneficiary with switching 
Step 1: Let us consider a beneficiary who is switched from simvastatin to pravastatin on 
3/27/07, as depicted in table 15. The beneficiary utilizes only 17 days supply of 
simvastatin (3/10/07 -3/27/07) and therefore has 13 days oversupply which will be 
carried forward.  
 
i) Pre- MPR 
Step 2: 
 The beneficiary hits the coverage gap on 9/25/07. Thus, the pre-period includes all 
claims filled before 9/25/07 (as depicted in table 16) and post-period includes all claims 
filled after 9/25/07.  
 
 
123 
 
Table 15: Example of all claims considered for MPR calculation 
 
 
 
 
 
 
 
 
 
 
 
Table 16: Example of pre-period claims considered for MPR calculation 
 
Drug Date Filled DS 
simvastatin 02/16/07 30 
simvastatin 03/10/07 30 
pravastatin 03/27/07 30 
pravastatin 04/18/07 30 
pravastatin 05/22/07 30 
pravastatin 06/21/07 30 
pravastatin 07/21/07 30 
pravastatin 08/23/07 30 
pravastatin 09/20/07 30 
 
Traditional MPR = TDS  
                              Days between 09/20/07 to 02/16/07 + Days’ supply of 09/20/07 
 
Days between 09/20/07 to 02/16/07 = 216 
Total Days Supply = 270 
Drug Date Filled DS 
simvastatin 02/16/07 30 
simvastatin 03/10/07 30 
pravastatin 03/27/07 30 
pravastatin 04/18/07 30 
pravastatin 05/22/07 30 
pravastatin 06/21/07 30 
pravastatin 07/21/07 30 
pravastatin 08/23/07 30 
pravastatin 09/20/07 30 
pravastatin 10/18/07 30 
pravastatin 11/23/07 30 
pravastatin 12/22/07 30 
pravastatin 12/31/07 0 
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Last days supply = Days supply of 09/20/07 = 30 
Traditional Pre-MPR = 270 
                     216+ 30 
                = 270 
                   246 
 
Traditional Pre-MPR = 1.098 
 
Step 3: 
OS = DS from 2/16/07 till 9/20/07–Days between 9/20/07-2/16/07  
OS= 240-216=24 
Updated Pre-MPR = TDS -OS 
                                     Days between 09/20/07 to 02/16/07 + Days’ supply of 09/20/07 
       = 270-24 
           246 
 
Updated Pre-MPR = 1 
 
ii) Post- MPR  
Step 1: The post-period includes all claims filled after 9/20/07 (table 17).  
Step 2:The beneficiary’s last claim is updated to reflect the number of days from the date 
filled to 12/31/07. (Updated days supply is bold faced)  
Table 17: Example of post-period claims considered for MPR calculation 
 
Drug Date Filled DS Updated DS  
pravastatin 10/18/07 30 30 
pravastatin 11/23/07 30 30 
pravastatin 12/22/07 30 9 
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Total Days Supply = 30+30+9=69 
Days between 12/31/07 to 10/18/07= 74 
Last days supply = Days supply of 12/22/07 = 9 
Traditional Post- MPR = TDS  
                                    Days between 12/31/07 to 10/18/07+ Days supply of 12/22/07 
 
Traditional MPR = 69 
                               74+9 
   
Traditional post-MPR = 0.831 
 
 
Step 3: The oversupply from the pre-period is added to the numerator of the post-period 
MPR calculation. Therefore, 
Post- MPR = TDS +OS                        
                      Days between 12/31/07 to 10/18/07+ Days supply of 12/22/07 
 
Oversupply (OS) from the Pre-period =24 
Post-MPR = 69+24 
                     74+9 
 
Updated Post-MPR = 1.120 
 
Proportion of Days Covered (PDC) 
i) Pre-PDC 
Step 1: The beneficiary hits the coverage gap on 9/25/07. Table 18 reflects all claims 
filled by the beneficiary for the pre-period.  
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Table 18: Example of pre-period claims considered for PDC calculation 
 
 
 
 
 
 
 
 
 
 
 
Step 2:  
 
Total Days Medication Available from 2/16/07 to 9/25/07 = 221 
Days between 2/16/07 to 9/25/07 =221 
PDC = total days medications available 
            total number of days evaluated, capped at 1.0 
PDC = 221   
            221 
 
Pre-PDC = 1.00 
 
Step 3: OS = DS from 2/16/07 till 9/25/07–Days between 9/25/07-2/16/07  
OS= 242-221=21 
 
ii) Post-Period PDC 
Step 1: The beneficiary hits the coverage gap on 9/25/07. The post-period includes all 
claims from 9/26/07 to 12/31/07 shown in the table 19 below.  
 
  2/16 
2/17-
3/09 
3/10-
3/26 
3/2
7 
3/28-
4/08 
4/09- 
9/25 Total  
simvastatin  1 1 1 1 1 0 60 
pravastatin  0 0 0 1 1 1 182 
Total days supply              242 
Total days 
medication (statin)  
is available   1 1 1 1 1 1 221 
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Table 19: Example of post-period claims considered for PDC calculation 
 
Step2: 
Total Days Medication Available from 9/26/07 to 12/31/07 = 94  
Days between 12/31/07 to 9/26/07 =96 
Post-PDC = total days medications available 
                    total number of days evaluated, capped at 1.0 
 
Post-PDC = 96 
                    96 
 
Post-PDC = 1 
In summary, table 20 lists the adherence values when calculated using different measures 
of adherence. 
Table 20: Summary of pre- and post coverage gap medication adherence measures 
for a beneficiary with switching 
 
 Pre-Coverage gap Post-Coverage Gap 
Traditional MPR 1.098 0.831 
Updated MPR 1.000 1.120 
PDC 1.000 1.000 
 
 
  9/26 
10/18- 
11/16 
11/17- 
11/23 
11/24- 
12/21 
12/22-
12/31 Total  
pravastatin  1 1 0 1 1 94 
Total days supply       94
Total days medication 
is available 1 1 
 
1 1 1 96 
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CASE III: Beneficiary with under supply  
i) Pre-MPR 
Step1:  Let us consider a beneficiary who is prescribed Simvastatin. Table 21 below lists 
all claims filled by the beneficiary from January1 –December 31, 2007.  
Table 21: Example of all claims considered for MPR calculation 
 
 
 
 
 
 
 
 
Step 2: The beneficiary hits the coverage gap on 11/29/07. Thus, the pre-period includes 
all claims filled before 11/29/07 (table 22). 
Table 22: Example of pre-period claims considered for MPR calculation 
 
 
 
 
 
 
 
 
Drug Date 
Filled DS 
simvastatin 01/09/07 30 
simvastatin 02/03/07 30 
simvastatin 03/06/07 30 
simvastatin 04/10/07 30 
simvastatin 05/11/07 30 
simvastatin 06/08/07 30 
simvastatin 07/10/07 30 
simvastatin 08/28/07 30 
Drug Date 
Filled DS 
simvastatin 01/09/07 30 
simvastatin 02/03/07 30 
simvastatin 03/06/07 30 
simvastatin 04/10/07 30 
simvastatin 05/11/07 30 
simvastatin 06/08/07 30 
simvastatin 07/10/07 30 
simvastatin 08/28/07 30 
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Traditional Pre-MPR = TDS  
                     Days between 08/28/07 to 01/09/07 + Days’ supply of 08/28/07 
 
Total Days Supply = 240 
Days between 08/28/07 to 01/09/07 = 231 
Last days supply = Days supply of 08/28/07 = 30  
Pre-MPR = 240  
                  231+ 30 
 
               = 240 
                  261  
 
Traditional Pre-MPR = 0.919 
Step 3: Oversupply (OS) for the period 08/28/07 to 01/09/07 is assessed by calculating 
the difference between the total DS till 08/28/07 and the days between 08/28/07 to 
01/09/07.  
OS =210-231= -21 
Since the days supply is less than the days between, there is no oversupply for this period.  
Further, since there is no oversupply, for this case,  
 Traditional Pre-MPR = Updated Pre-MPR = 0.919 
 
ii) Post- MPR  
The post-period includes all claims filled after the day the beneficiary hits the coverage 
gap, that is after 11/29/07. Since the beneficiary has no claims after 8/28/07 and no 
oversupply, the post-period MPR for the beneficiary is 0.  
Traditional Post-MPR = Updated Post-MPR = 0 
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Proportion of Days Covered 
i) Pre- PDC 
Step 1: The beneficiary hits the coverage gap on 11/29/07. Table 23 reflects all claims 
filled by the beneficiary for the pre-period.  
Table 23: Example of pre-period claims considered for MPR calculation 
 
Step2: 
 
Total Days Medication Available from 1/9/07 to 11/29/07 = 240 
Days between 1/9/07 to 11/29/07 =324 
PDC = total days medications available 
            total number of days evaluated, capped at 1.0 
 
Pre-PDC = 240  = 0.741 
                  324 
 
Pre-PDC = 0.741 
 
ii) Post- PDC 
The post-period includes all claims filled after the day the beneficiary hits the coverage 
gap, that is, after 11/29/07. Since the beneficiary has no claims after 8/28/07 and no 
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oversupply,the post-period PDC for the beneficiary is 0. 
 Post-PDC = 0 
In summary, table 24 lists the adherence values when calculated using different measures 
of adherence  
Table 24: Summary of pre- and post coverage gap medication adherence measures 
for a beneficiary with under supply 
 
 Pre-Coverage Gap Post-Coverage Gap 
Traditional MPR 0.919 0 
Updated MPR 0.919 0 
PDC 0.741 0 
 
Drug classes selected for medication adherence calculations 
Prescription drug utilization was calculated for all medications that a beneficiary was 
prescribed. However, adherence calculations were limited to ten classes of medications 
identified as drugs used to treat commonly occurring chronic conditions in the Medicare 
population. (Brenson & Horvath, 2002; Hoadley, et al., 2008; Moxey ED, O'Connor JP, 
Novielli KD, Teutsch S, & Nash DB, 2003) Except for PPI’s, these drug classes have 
also been previously classified as “essential” and not typically dispensed “as needed”. 
(Tamblyn, et al., 2001a)  Further, a geriatric clinical pharmacist identified these drugs as 
drugs most commonly used in the Medicare population and indicated that an analysis of 
their utilization and adherence would have clinical significance. The ten drug classes 
include- statins, ACEI, beta-blockers, ARB’s, CCB, thiazide diuretics, SSRI’s, PPIs, 
thyroid hormones, and biguanides.  
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Co-variates 
 
Based on the Andersen's Behavioral Model of Health Services Use as described in depth 
in chapter 2 and a review of the literature citing factors affecting medication adherence, 
the following variables were used as covariates: age, gender, income, month in which the 
coverage gap starts, plan (HMO vs. PPO), MTM and co-morbidity score.(Andersen, 
1995; Rajesh Balkrishnan, 1998; Vik, et al., 2004) Data on age, gender, month in which 
the coverage gap starts and HMO versus PPO plan enrollment were readily available 
from the data set. The data did not provide for a direct calculation of the co-morbidity 
score. Therefore, an individual’s risk score reported by the health plan for each enrolled 
beneficiary was used as a proxy for the co-morbidity score. Detailed description of the 
risk score and validity of using the risk score as a measure of co-morbidity are provided 
below. The data also did not provide an assessment of an individual’s income but was 
derived based on zip-codes.  Detailed description of income estimation based on zip-code 
date is provided below. While the CMS mandates provision of MTM services for eligible 
Medicare beneficiaries, the type and extent of MTM services offered by health plans is 
not established by the CMS. Details of MTM services provided by XYZ healthcare 
services are listed below.  
 
a) Co-morbidity score assessment 
With administrative databases, Charlson’s co-morbidity index or Diagnostics Cost Group 
are commonly used for assessing co-morbidities. (de Groot, Beckerman, Lankhorst, & 
Bouter, 2003; Pope et al., 2000) However, due to mis-communications to the health plan 
computing personnel, ICD9-CM codes required to calculate Charlson’s co-morbidity 
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index or Diagnostic Cost Groups were available only for a sample of the study population 
(633 beneficiaries). For the purposes of this study, clinical episodes based risk scores 
assigned to each member by XYZ health services, to identify high risk patients and to 
measure health risk for a member, were used as a measure of co-morbidity. A member’s 
risk score is a measure of the relative resources expected to be required for their medical 
care.(Ingenix, 2009)A member’s risk score is calculated based on their clinical episodes 
of care, utilization of prescription drugs and medical services over the previous year. A 
member’s risk scores for 2008 reflects his/her 2007 utilization. XYZ healthcare services 
uses a product developed by a large professional organization which specializes in this 
field of work, to generate this score for its beneficiaries. The following steps are used to 
calculate a beneficiary’s risk score: 
1. Episodes of care: All medical and pharmacy claims for a member are classified into 
mutually exclusive categories referred to as “episodes of care”. These episodes of care 
describe a member’s observed mix of conditions and underlying co-morbid conditions 
and/or complications. A member’s episodes of care and the services provided within 
those episodes describe a member’s mix of clinical conditions, the severity of those 
conditions, and the member’s overall level of risk. The episodes of care are then 
classified into one of 22 categories (Infectious Diseases, Endocrinology, Hematology, 
Psychiatry, Chemical Dependency, Neurology, Ophthalmology, Cardiology, 
Otolaryngology, Pulmonology, Gastroenterology, Hepatology, Nephrology, Urology, 
Obstetrics, Gynecology, Dermatology, Orthopedics & Rheumatology, Neonatology, 
Preventative & Administrative, Late Effects, Environmental Trauma & Poisoning, 
Isolated Signs & Symptoms). (Ingenix, 2009) 
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2. Base Markers: The episodes of care for each member are further grouped into 
homogeneous risk categories (episodes with similar clinical and risk characteristics are 
combined into the same group) called base markers. Two types of base markers are 
used. The first type of base marker derives directly from a member’s episodes of care. 
Episodes with similar clinical and risk characteristics are combined into the same 
group. A total of more than 120 episode-related base markers are identified. Examples 
of  this type of base-markers include AIDS/HIV; CHF, with co-morbidity; benign 
hypertension; and other endocrinology. The second type of base marker focuses on a 
small number of higher risk, chronic conditions. Patients with these conditions are 
identified separately from other patients with the same mix of episodes, providing a 
more accurate measurement of future risk. Examples of these higher risk conditions 
include ALS, cystic fibrosis, and multiple sclerosis.  Finally, for some clinically-
related base markers hierarchies  are applied, which allow focus on a single clinical 
condition most responsible for future risk. As a result of this, episodes best describing 
a patient’s underlying medical condition within a general disease category are 
identified. For example, a patient with both coronary artery disease (CAD) and 
congestive heart failure (CHF) episode activity would only receive a base marker for 
CHF. Demographic markers of risk, describing a member’s age and gender are also 
created in this step.  
3. Service-Based Risk Markers: Each member’s medical services utilization, observed 
within an episode of care, are used to generate service-based risk markers. These 
markers are generated based on a beneficiaries utilization of services such as inpatient 
stay, ER, significant contacts with a physician, and use of pharmacy services. Service 
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based markers capture relevant utilization related to a disease or condition by 
describing the prior use of medical services for a member related to those episodes of 
care included in a base marker. While base markers identify a patient with a given 
condition, the service-based markers supplement base markers by providing an 
indicator of differences in patient severity within that condition.  
In addition to base and service based markers, pharmacy based markers are 
also created as a means to both identify patients with diseases or conditions or provide 
an indicator of severity for patients with the same base marker. Pharmacy markers are 
assigned using the presence of a therapeutic agent within specific episodes of care. For 
example, patients identified with an episode for major depression who also receive 
anti-depressant/anti-anxiety medications are identified. (Ingenix, 2009) 
4. Member Clinical Profiles:  An episode-based, clinical profile is created for each 
member after collecting all markers for a member. This profile describes whether each 
member had (or did not have) each of the more than 450 markers of risk. All members 
are also assigned an age-sex marker.  
5. Weighting of the clinical Profile: Weights describing the contribution of each marker 
to overall patient risk are applied to each member. These weights were estimated using 
enrollment and medical and pharmacy claims data for a large managed care population 
(including more than twenty health plans enrolling more than 17 million lives).  
6. Risk Computation: The clinical profile and weights are combined to compute a 
member’s risk score. A person’s risk score is based on the sum of risk weights for each 
marker observed. The formula used to compute risk can be described as: Risk o,i = 
Σbr,o* Marker i,r ; where Risk o,i is the risk score for outcome o for individual i; 
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Marker i,r indicates the individual’s risk marker (r) assignments, and the b’s are the 
risk weights – one for each marker. The markers are a series of 0,1 variables (1 
=marker is observed, 0= marker is not observed). The risk score is a measure of the 
member’s future relative risk for an inpatient stay and a predictor of their future health 
care costs. (Ingenix, 2009) 
7. Interpretation of risk score: Risk is generally measured in reference to a “standard 
population” that is assigned a risk score of 1.00. An individual or group with a risk 
score of 1.15 would be expected to require 15% more healthcare resources than the 
standard population.  A member with a risk score of 0.85 would be expected to 
consume 15% fewer resources. 
Validation of risk score: To ensure that the risk score is a valid measure of co-
morbidity, Charlson’s co-morbidity score was calculated for members for whom ICD-9 
codes were available and was co-related to the risk score assigned to the beneficiary. A 
significant, positive co-relation between the Charlson’s co-morbidity score and the 
member’s risk score will provide some evidence of construct validity. Charlson’s co-
morbidity index is calculated by assigning a weight of 1, 2, 3, or 6 to nineteen disease 
conditions. A sum of all the weights provides the Charlson’s co-morbidity 
index.(Charlson, Pompei, Ales, & MacKenzie, 1987) For  the purposes of this study, 
Charlson’s co-morbidity score was calculated using the algorithm developed by Quan et 
al. (Quan et al., 2005) Further, the risk score is based on a predictive modeling technique 
similar to the technique used to calculate the Diagnostic Cost Groups, a commonly used 
and validated measure of co-morbidity calculated using administrative databases. (Pope, 
et al., 2000) 
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b) Income 
Data about median household income levels based on a beneficiary’s ZIP code of 
residence, reported in the 2000 US Census data base, were used as a proxy of the 
beneficiary’s income. This approach of using ZIP codes based socio-economic 
characteristics as a proxy for an individual’s characteristics has been validated and is 
widely used in utilization studies. (Geronimus, Bound, & Neidert, 1995; Gornick et al., 
1996; Krieger, 1992; Smith, Ben-Shlomo, & Hart, 1999) 
 It is important to note that, for the purposes of this study, 2000 US census data are 
used. Thus, there is an assumption that there have not been significant changes in the 
income of the population by ZIP code between 2000 and 2007. The most current Census 
Bureau data available are 2007 American Community Survey (ACS) data. ACS data are 
not available at the ZIP Code level. ACS data are available only for Metropolitan 
Statistical Areas and cities and counties of a certain minimal size.(US Census Bureau, 
2009) Since we do not have access to metropolitan area data, 2000 Census data for ZIP 
Code geography are used for this study. Further, ZIP code data cannot be aggregated to 
counties or metro areas, as ZIP Codes do not recognize county boundaries and they can 
even cross state lines.(Compton, 2009) 
 
c) Medication Therapy Management 
Medication therapy management (MTM) has been defined as “a distinct service or group 
of services that optimize therapeutic outcomes for individual patients”. Medicare 
beneficiaries who have multiple chronic diseases (such as diabetes, asthma, hypertension, 
hyperlipidemia, COPD and congestive heart failure); take multiple covered Part D drugs; 
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and are likely to incur greater than $4,000 annually in total drug costs are eligible to 
receive MTM services. MTM encompasses a broad range of professional activities and 
responsibilities which include but are not limited to formulating a medication treatment 
plan; performing a comprehensive medication review to identify, resolve, and prevent 
medication-related problems, including adverse drug events; and providing information, 
support services and resources designed to enhance patient adherence with his/her 
therapeutic regimens.  
XYZ health care services sends MTM eligible members an invitation to schedule 
an appointment with a clinical pharmacist. The clinical pharmacist evaluates a member’s 
medication record prior to appointment. As a part of MTM services, the clinical 
pharmacist identifies opportunities for the member to lower average monthly pharmacy 
costs by suggesting strategies such as switching to generic, tablet splitting, more cost 
effective formulary alternatives, eliminating duplicate or unnecessary prescriptions, 
prescription to over-the-counter switches, etc. The clinical pharmacist also identifies 
medication related problems such as overdosage, underdosage, adverse drug reaction, 
untreated medical condition, failure to receive medication, drug interaction, drug use 
without an indication, etc. Finally, the clinical pharmacist documents the number of 
changes accepted by the beneficiary to the number of recommended changes and 
documents patient safety related problems identified and the results. With all the MTM 
services available to beneficiaries, it is possible that, beneficiaries who receive MTM 
services may have higher adherence rates compared to those do not receive MTM 
services. Therefore, for the purposes of this study, utilization of MTM services was 
statistically controlled for by including it as a covariate. 
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Sample Clinics 
 
XYZ health care services have a sample clinic where beneficiaries, upon referral from 
their physician, can receive free medication samples. Medications obtained by 
beneficiaries through the sample clinic are recorded in a database. However, due to 
manual entry of data in a manner inconsistent with the pharmacy claims, despite best 
efforts, it was not possible to connect this database to the pharmacy claims database. 
Additional Outcomes assessed in the study 
 
a) Utilization of Medicare Part A and B services by beneficiaries who hit the 
coverage gap 
XYZ health care services provided data on emergency room visits, inpatient and 
outpatient hospitalizations and ICD-9 codes for 633 beneficiaries who hit the coverage 
gap. However, XYZ healthcare services did not provide the date that these services were 
provided. Thus, it was not possible to assess if the utilization of these services occurred 
before a beneficiary hit the coverage gap or after hitting the coverage gap. This data was 
however used to calculate the Charlson’s co-morbidity index for the 633 beneficiaries. 
 
b) Medical Costs incurred by beneficiaries who hit the coverage gap 
XYZ health care services provided data on medical costs associated with Medicare Part 
A and B services for beneficiaries who hit the coverage gap. Medical costs refer to the 
costs that were associated with medical claims (all claims except for pharmacy claims) 
and paid by XYZ healthcare services for the beneficiary. It is important to note that these 
costs were calculated based on the month in which a beneficiary hit the coverage gap and 
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are not a very accurate representation of pre-coverage gap and post-coverage gap medical 
costs. For example, a beneficiary who hit the coverage gap on the 25th of June would be 
classified as hitting the coverage gap in June and all costs incurred by the beneficiary 
before 25th June were also included as costs incurred after hitting the coverage gap. 
XYZ healthcare services provided charts comparing a) differences in medical 
costs between the entire XYZ Senior Care population enrolled in MA-PD plans with 
costs of beneficiaries who reached the coverage gap in 2007; b) the difference in medical 
costs per member per month (PMPM) incurred before the beneficiary reached the 
coverage gap and after the beneficiary reached the coverage gap; and c) for beneficiaries 
whose medical costs were higher after reaching the Part D gap, the difference in PMPMs 
before and after reaching the coverage gap, in specific utilization categories [emergency 
room visits, inpatient hospitalizations, outpatient hospitalizations, and other (all costs not 
included in the previous 3 categories)].   
 
Data Analysis 
Descriptive statistics (mean, SD, median, minimum, maximum) were analyzed for all 
study variables. In order to detect any outliers or miscoded data, frequencies were 
analyzed for each variable. Baseline demographics were assessed by using univariate 
tests such as independent t-tests, paired t-tests, ANOVA or chi-square where appropriate. 
All tests were analyzed at a 0.05 level of significance. 
 
 Difference-in-Difference Analysis 
In order to assess the impact of the Medicare Part D coverage gap on prescription drug 
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utilization and medication adherence a difference-in-difference analysis was used. 
Difference-in-difference (DiD) analysis has been widely used to assess the impact of 
natural experiments, such as health care policy changes, where researchers have no 
control on the allocation of individuals to a control group (not affected by a change in 
environment) or a treatment group (affected by a change in environment). DiD analysis 
estimates the difference between the before and after outcome for the treatment group 
and the before and after outcome for the control group.  
DiD analysis used to assess the impact of a policy change can best be described using the 
following equation:  
DiD = (outcome after policy change in treatment group – outcome before policy change 
in treatment group) – (outcome after policy change in control group – outcome 
before policy change in control group) 
If we define μit to be the mean of the outcome in group i at time t. Let i=0 for the control 
group and i=1 for the treatment group and t=0 to be a pre-treatment period and t=1 to be 
the post-treatment period. Then,  
D = ( μ11 −μ10 ) −( μ01 −μ00) 
Where, 
 D = DiD estimator 
  μ11  = is mean of the outcome in treatment group in the post-period 
  μ10  = is mean of the outcome in treatment group in the pre-period 
  μ01  = is mean of the outcome in control group in the post-period 
  μ00  = is mean of the outcome in control group in the pre-period 
In order to use the difference-in-difference analysis it is important to ensure that the 
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underlying trend in the outcome variable is the same for both treatment and control 
group. This assumption was checked by comparing the outcome variable in the control 
and treatment group in the pre-treatment period. Using the difference-in-difference 
approach eliminates biases that result from inherent pre-treatment differences between 
the control and treatment group, which are constant over time. In addition to elimination 
of biases due to observed or unobserved pre-treatment differences, biases as a result of 
time based comparisons are also eliminated. Addition of regressors further helps 
eliminate effects of confounding factors. For the purposes of this study, the outcome 
variable y which represents MPR or prescription drug utilization can be defined as  
Y = β0 + β1*Time+ β2*Group + β3*(Time*Group) + β4*Age ……. + βn*Covariates+ e 
 
 
Time 0 = Pre – Coverage Gap 
  1 =  Post – Coverage Gap 
Group 0 =  Employer / Generic Coverage 
  1 =  No Coverage 
β3 DID estimator (Interaction coefficient) 
 
The difference-in-difference analysis was conducted three times to address the study 
objective. The first analysis included comparing prescription drug utilization and 
medication adherence between beneficiaries enrolled in a plan providing no gap coverage 
with beneficiaries enrolled in a plan with full prescription drug coverage. The second 
analysis included comparing prescription drug utilization and medication adherence 
between beneficiaries enrolled in a plan providing no gap coverage with beneficiaries 
enrolled in a plan with generic drug coverage. The third analysis included comparing 
prescription drug utilization and medication adherence between beneficiaries enrolled in 
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a plan providing generic drug coverage with beneficiaries enrolled in a plan with full 
prescription drug coverage. As a result of conducting three different analyses within the 
same dataset, an alpha-slippage occurs. In order to correct the alpha-slippage, a 
Bonferroni’s correction was applied and all analyses were tested at a level of significance 
of 0.017 (0.05/3).  
 
 
Data analyses required to address study objectives:  
1. To compare prescription drug utilization of a sample of New Mexico Medicare 
beneficiaries enrolled in a Medicare Part D plan with full prescription drug coverage 
during the coverage gap with prescription drug utilization of Medicare beneficiaries 
enrolled in a plan providing no gap coverage. 
- Data: Medicare beneficiaries enrolled in plans with full prescription drug 
coverage and no prescription drug coverage during the coverage gap. 
- Difference-in difference analysis with prescription drug utilization as the 
dependant variable was used to compare prescription drug utilization pre- and 
post- coverage gap between Medicare beneficiaries enrolled in plans with full 
prescription drug coverage and no prescription drug coverage during the coverage 
gap. All covariates listed in the covariates section were controlled for.  
 
2. To compare prescription drug utilization of a sample of New Mexico Medicare 
beneficiaries enrolled in a Medicare Part D plan covering generic drugs during the 
coverage gap with prescription drug utilization of Medicare beneficiaries enrolled in a 
plan providing no gap coverage. 
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- Data: Medicare beneficiaries enrolled in plans with generic drug coverage and no 
prescription drug coverage during the coverage gap. 
- Difference-in difference analysis with prescription drug utilization as the dependant 
variable was used to compare prescription drug utilization pre- and post- coverage 
gap between Medicare beneficiaries enrolled in plans with generic drug coverage 
and no prescription drug coverage during the coverage gap. All covariates listed in 
the covariates section were controlled. 
 
3. To compare prescription drug utilization of a sample of New Mexico Medicare 
beneficiaries enrolled in a Medicare Part D plan with full prescription drug coverage 
during the coverage gap with prescription drug utilization of Medicare beneficiaries 
enrolled in a plan covering generic drugs during the coverage gap. 
-  Data: Medicare beneficiaries enrolled in plans with full prescription drug coverage 
and generic drug coverage during the coverage gap. 
- Difference-in difference analysis with prescription drug utilization as the dependant 
variable was used to compare prescription drug utilization pre- and post- coverage 
gap between Medicare beneficiaries enrolled in plans with full prescription drug 
coverage and generic drug coverage during the coverage gap. All covariates listed 
in the covariates section were controlled. 
 
4. To compare medication adherence (to select drug classes) of a sample of New 
Mexico Medicare beneficiaries enrolled in a Medicare Part D plan with full 
prescription drug coverage during the coverage gap with medication adherence of 
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Medicare beneficiaries enrolled in a plan providing no prescription drug coverage 
during the coverage gap. 
- Data: Medicare beneficiaries enrolled in plans with full prescription drug 
coverage and no prescription drug coverage during the coverage gap. 
- Difference-in difference analysis with medication adherence as the dependant 
variable was used to compare medication adherence pre- and post- coverage gap 
between Medicare beneficiaries enrolled in plans with full prescription drug 
coverage and no prescription drug coverage during the coverage gap. 
 
5. To compare medication adherence (to select drug classes) of a sample of New 
Mexico Medicare beneficiaries enrolled in a Medicare Part D plan covering generic 
drugs during the coverage gap with medication adherence of Medicare beneficiaries 
enrolled in a plan providing no prescription drug coverage during the coverage gap. 
- Data: Medicare beneficiaries enrolled in plans with generic drug coverage and no 
prescription drug coverage during the coverage gap. 
- Difference-in difference analysis with medication adherence as the dependant 
variable was used to compare medication adherence pre- and post- coverage gap 
between Medicare beneficiaries enrolled in plans with generic drug coverage and 
no prescription drug coverage during the coverage gap. 
 
6. To compare medication adherence (to select drug classes) of a sample of New 
Mexico Medicare beneficiaries enrolled in a Medicare Part D plan with full 
prescription drug coverage during the coverage gap with medication adherence of 
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Medicare beneficiaries enrolled in a plan covering generic drugs during the coverage 
gap. 
- Data: Medicare beneficiaries enrolled in plans with full prescription drug 
coverage and generic drug coverage during the coverage gap. 
- Difference-in difference analysis with medication adherence as the dependant 
variable was used to compare medication adherence pre- and post- coverage gap 
between Medicare beneficiaries enrolled in plans with full prescription drug 
coverage and generic drug coverage during the coverage gap. 
 
SUMMARY 
 
This study focuses on Medicare beneficiaries enrolled in Medicare Advantage 
prescription drug (MA-PD) plans offered by XYZ health care services. A quasi-
experimental, cross-sectional, retrospective, pre-post with control group study design was 
used to assess the impact of Medicare Part D coverage gap on prescription drug 
utilization and medication adherence. Medicare beneficiaries who met the study 
eligibility criteria and were enrolled in a plan with full prescription drug coverage, a plan 
with generic drug coverage or a plan with no prescription coverage during the coverage 
gap were selected from a pool of 25,571 beneficiaries. Total costs and true out-of-pocket 
(TrOOP) costs were used to assess if a Medicare beneficiary remained in the initial 
coverage limit, hit the coverage gap or was covered under catastrophic coverage. 
Beneficiaries with total drug costs greater than $2,400 and true out-of -pocket (TrOOP) 
costs less than or equal to $3,850 represented beneficiaries who remained in the coverage 
gap through the entire year. Beneficiaries with total drug costs greater than $2,400 and 
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TrOOP costs greater than $3,850 represented beneficiaries who were covered under the 
catastrophic coverage limit. 
Pre- and post-coverage gap prescription drug utilization was assessed using per 
member total number of prescriptions. Medication Possession Ratio (MPRm) and the 
Proportion of Days Covered (PDC) were used as measures of medication adherence in 
this study. Descriptive statistics were analyzed for all study variables. Difference-in 
difference analysis, with prescription drug utilization and medication adherence as the 
dependant variables, was used to compare prescription drug utilization pre- and post-
coverage gap between: a) Medicare beneficiaries enrolled in plans with full prescription 
drug coverage and no prescription drug coverage during the coverage gap; b) Medicare 
beneficiaries enrolled in plans c) Medicare beneficiaries enrolled in plans with generic 
prescription drug coverage and no prescription drug coverage during the coverage gap 
and with full prescription drug coverage and generic prescription drug coverage during 
the coverage gap. The DiD analysis controlled for age, gender, income, month in which 
the coverage gap starts, plan (HMO vs. PPO), MTM and co-morbidity score as 
covariates. The next chapter presents the results obtained after conducting the data 
analyses.  
 
 
 
 
148 
 
CHAPTER 4 
RESULTS 
 
The study results are described in chapter 4.  The chapter begins with a description of the 
study population and study sample, followed by results of the number of beneficiaries 
who hit the coverage gap in 2007 and results of the data validity check as related to 
accuracy of the cost calculations and validity of using the risk score as a measure of co-
morbidity. Next, demographics of the study sample are presented, followed by a 
description of the number of beneficiaries who hit the coverage gap in each month 
(January-December) of 2007. In the next section, results of univariate analysis comparing 
overall prescription drug utilization among beneficiaries enrolled in the three Medicare 
Advantage plans and a descriptive analysis of pre-and post-coverage gap prescription 
drug utilization and medication adherence for ten select drug classes is provided. 
Following the descriptive analyses, are results of the difference-in-difference analysis 
assessing the impact of the coverage gap on prescription drug utilization and medication 
adherence for the ten selected drug classes. Finally, per member per month total medical 
costs incurred before and after beneficiaries hit the coverage gap are provided.  
Study population and sample selection 
 
The study sample was selected from 23,339 Medicare beneficiaries enrolled in XYZ 
health services’ senior care HMO and PPO plans and 2,232 beneficiaries enrolled in 
employer-sponsored health plans. A total of 14,846 beneficiaries, accounting for 436,087 
claims, met the study inclusion and exclusion criteria. Of these, 7,684 members were 
enrolled in a plan which provided no prescription drug coverage during the coverage gap, 
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henceforth referred to as ‘no coverage’ plan; 5,777 were enrolled in a plan which covered 
generic drugs during the coverage gap, henceforth referred to as the ‘generic coverage’ 
plan and 1,385 were enrolled in an employer sponsored plan which provided full 
prescription drug coverage during the coverage gap, henceforth referred to as the ‘full 
coverage’ plan.  The 14,846 beneficiaries who met the study inclusion and exclusion 
criteria were analyzed further to identify beneficiaries who hit the coverage gap in 2007.  
Coverage Gap  
 
Of the 14,846 beneficiaries who met the study inclusion and exclusion criteria, 2,661 
beneficiaries (17.92%) hit the coverage gap in the year 2007. Nearly seventeen percent or 
2,494 beneficiaries remained in the coverage gap and less than 1% or 117 beneficiaries 
reached the catastrophic coverage limit in the year 2007. This study will focus on the 
2,494 beneficiaries who hit the coverage gap and remained in the coverage gap in 2007. 
Of these 2,494 beneficiaries, 791 (31.72%) were enrolled in the plan with no coverage, 
1284 (51.48%) were enrolled in the plan with generic coverage and 419 (16.80%) were 
enrolled in the plan with full coverage. Figure 4 presents the study sample and number of 
beneficiaries who reached the coverage gap in 2007.  
Data validity: Accuracy of cost calculations 
 
The most critical aspect of this study was the identification of beneficiaries who hit the 
coverage gap. Total costs and true out-of-pocket (TrOOP) costs are used to assess if a 
Medicare beneficiary remains in the initial coverage limit, hits the coverage gap or is  
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Figure 3:  Study sample and number of beneficiaries who reached the coverage gap 
in 2007 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XYZ Health Care Services MA-PD plans  
Senior Care HMO 
& PPO  
Employer 
Group (Full 
Coverage) 
No 
Coverage 
n=7,684 
Inclusion & 
Exclusion
  
Generic 
Coverage 
n=5,777
Coverage 
gap Coverage 
gap 
791 hit the 
coverage gap 1,284 hit the 
coverage gap 
Employer Group 
(Full Coverage) 
419 hit the 
coverage gap  
151 
 
covered under catastrophic coverage. As described in chapter 3, to ensure that cost 
calculations were accurate, total costs calculated for  the purposes of this study were 
compared with total costs reported by the health plan for 250 (~10%) beneficiaries. 
The comparison indicated discrepancy in costs for 11 out of the 250 beneficiaries. 
Further examination indicated that the cost discrepancy stemmed from truncating the 
number of digits in the GPI numbers used to identify drugs covered under Medicare Part 
B. For example, 10 digits of a GPI number “9940407000****” were used instead of 12 
digits “994040700001**”. To ensure that this discrepancy did not result in inaccurate 
identifications, each GPI number used to identify drugs covered under Medicare Part B 
was then reviewed by a clinical pharmacist employed at XYZ healthcare services. 
Following all corrections, costs were recalculated and the costs for the 11 beneficiaries 
were rechecked to confirm that accurate costs calculations were conducted for this study. 
No further discrepancy provided an assurance that all costs calculated for the purposes of 
this study were accurate. 
 
Validity of using risk score as a measure of co-morbidity 
Medical claims with ICD-9 codes required for the assessment of the Charlson’s co-
morbidity score were available only for 633 beneficiaries. Therefore, Charlson’s co-
morbidity score was calculated only for these 633 beneficiaries. As described in chapter 
3, the risk score was used as a measure of co-morbidity. To ensure that the risk score is a 
valid measure of co-morbidity, risk scores for 633 members were correlated with 
Charlson’s co-morbidity score calculated for these beneficiaries. Significant positive 
correlations (r = 0.614, p = 0.01) between the risk scores and Charlson’s co-morbidity 
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scores calculated for 633 members provides some evidence of construct validity.  
Demographics of beneficiaries who hit the coverage gap 
Table 24 and table 25 present the demographic characteristics of members who hit the 
coverage gap in 2007. The mean age of beneficiaries who hit the coverage gap was 72.59 
±9.20 and nearly 60% of the beneficiaries were females. Their mean co-morbidity score 
was 6.55±6.27 and less than 10% of the beneficiaries received MTM services. The 
average income of beneficiaries who hit the coverage gap was $39,602.00 ± 11,465.12 
and three-quarters of the beneficiaries were enrolled in HMO plans. Average total cost 
incurred by beneficiaries who hit the coverage gap in the year 2007 was $3,002.38 
±2,222.39 with average TrOOP expenses amounting to $1,075.06 ±709.74. 
Demographics of beneficiaries enrolled in no coverage, generic coverage and full 
coverage plans 
Table 25 and table 26 present a comparison of demographic characteristics of 
beneficiaries enrolled in no coverage, generic coverage and full coverage plans. An 
analysis of variance indicated that significant difference in age existed between 
beneficiaries in no coverage and full coverage plans (F (2, 2491) = 10.98, p <0.05, mean 
difference = 2.49; and between generic and full coverage plan (mean difference = 2.12) 
beneficiaries. Similarly, significant difference in total costs existed between beneficiaries 
in no coverage and full coverage plans (F (2, 2491) = 80.56, p <0.05; mean difference 
=1,581.51) and generic and no coverage plan beneficiaries (mean difference = 1,351.87). 
Total costs were highest for beneficiaries in the full coverage plan but very similar for 
beneficiaries in the no coverage and generic coverage plans. Significant differences in co-  
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Table 25: Demographics (continuous variables) 
* Significant differences between three groups at p ≤ 0.05 
 
Table 26: Demographic Information (categorical variables) 
*Significant differences across three groups at p ≤ 0.05 
 
 All 
Mean (S.D.) 
No 
Coverage 
Plan 
Generic 
Coverage 
Plan  
Full 
Coverage 
Plan  
N 2494 791 1284 419 
Age*   
 
72.59  
(9.20) 
73.20  
(9.83) 
72.83  
(9.18) 
70.71 
 (7.73) 
Income  
(median) 
39,602.00  38,370.00 39,670.00 39,375.69  
Co-morbidity* 
risk score 
6.55 
(6.27) 
6.25  
(5.74) 
7.00 
(4.90) 
5.72 
(4.12) 
Total cost* 
(median) 
3,002.38  2,857.94 
 
2,949.11 
 
3,775.00 
 
Total OOP 
(median) 
1,075.06 
 
1,194.11 
 
1,107.65 
 
768.85 
 
 All 
n (%) 
No Coverage 
Plan 
n (%) 
Generic 
Coverage 
Plan n (%) 
Full 
Coverage 
Plan n (%) 
Male* 1004  
(40.32) 
320 
(40.46) 
483 
(37.62) 
201 
(47.97) 
Female* 1490 
(59.84) 
471 
(59.54) 
801 
(62.38) 
218 
(52.03) 
Received 
MTM* 
234 
(9.40) 
57 
(7.21) 
165 
(12.85) 
12 
(2.86) 
PPO* 640  
(25.70) 
197 
(24.91) 
218 
(16.98) 
225 
(53.70) 
HMO* 1,854 
 (74.46) 
594 
(75.09) 
1066 
(83.02) 
194 
(46.30) 
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morbidity risk scores were found between beneficiaries in no coverage and generic 
coverage plans (F (2, 2491) =7.95, p <0.05; mean difference = 0.75) and beneficiaries in  
generic and full coverage (mean difference=1.28). Co-morbidity scores were highest for 
beneficiaries enrolled in generic coverage plans followed by beneficiaries enrolled in no 
coverage plans and lowest for beneficiaries in full coverage plans. A comparison of 
categorical demographic variables conducted by using a chi-square analysis (Table 26) 
indicates that the number of male and female Medicare beneficiaries’ differed 
significantly across the three plans (χ2(2, N = 2494) = 14.10, p<0.05). Similarly the 
number of beneficiaries receiving MTM services (χ2(2, N = 2494) = 43.50, p<0.05) and 
the number of beneficiaries enrolled in HMO and PPO plans (χ2(2, N = 2494) = 147.32, 
p<0.05) varied significantly across the three plans. 
Coverage gap month 
 
Figure 5 represents the number of beneficiaries who hit the coverage gap from January-
December of 2007. Nearly 90% (2243) of the beneficiaries hit the coverage gap during 
the period June–December 2007. 
 Figure 4 Beneficiaries who hit the coverage gap from January-December of 2007 
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Univariate analysis comparing prescription drug utilization among three plans 
 
Figure 6 presents mean pre-utilization (utilization before a beneficiary hits the 
coverage gap) and post-utilization (utilization after a beneficiary hits the coverage gap) 
rates for beneficiaries enrolled in each of the three plans. As is evident from the figure, 
overall pre-utilization is higher in all three groups compared to the post-utilization. Post-
utilization is lowest for beneficiaries enrolled in the no coverage followed by 
beneficiaries enrolled in the generic coverage plan and with post-utilization being highest 
for beneficiaries enrolled in the plan with full coverage. Paired t-tests indicate significant 
differences in pre- and post-prescription drug utilization (mean difference = 32.74 ± 
23.32) for beneficiaries enrolled in the no coverage plan (t (790) =39.48, p = 0.05); 
generic coverage plan (mean difference = 31.30 ± 27.95, t (1283) =39.91, p = 0.05); and 
the full coverage plan (mean difference = 19.05 ±34.43, t (418) =11.32, p = 0.05).  
 
Figure 5 Mean pre-and post-utilization rates for beneficiaries enrolled in the three 
plans 
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Descriptive analyses of pre- and post- utilzation and medication adherence for select 
drug classes 
Tables 27-36 represent mean (S.D.) pre- and post-utilization and pre- and post- 
medication adherence of beneficiaries in all groups (overall), beneficiaries enroled in no 
coverage, generic coverage and full coverage plans for select ten classes of prescription 
drugs. These ten drug classes include: statins, ACEI, beta-blockers, ARB’s, CCB, 
thiazide diuretics, SSRI’s, PPIs, thyroid hormones, and biguanides.  
 
Pre- and post-utilization: As is evident in tables 27-36, descriptive analyses of pre- and 
post-utilization of statins, ACEI, beta-blockers, ARB’s, CCB, thiazide diuretics, SSRI’s, 
PPIs, thyroid hormones, and biguanides indicates that utilization decreased overall and 
for beneficiaries in all three plans (full coverage, generic coverage and no coverage) after 
they hit the coverage gap.  
 
Medication adherence: With respect to medication adherence, descriptive anlayses 
indicated that pre-post medication adherence differred based on the measure of 
medication adherence (tables 27-36). Medication adherence when measured using the 
PDC decreased overall and for beneficiaries in all three groups after beneficiaries hit the 
coverage gap. However, when measured using the MPR (Updated MPR and traditional 
MPR), descriptive analyses indicate that medication adherence increased overall and for 
beneficiaries in all three groups after beneficiaries hit the coverage gap. This trend was 
observed for all ten drug classes of statins, ACEI, beta-blockers, ARB’s, CCB, thiazide 
diuretics, SSRI’s, PPIs, thyroid hormones, and biguanides. 
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Table 27: Pre- and post- utilzation and medication adherence of beneficiaries on 
statins 
 
 
 
 
 
 
 
 
 
 
 
Statins 
Overall Full Coverage 
Generic 
Coverage No Coverage 
 
N 
Mean 
(SD) N 
Mean 
(SD) N 
Mean 
(SD) N 
Mean 
(SD) 
Pre-
Utilization 
1291 
 
51.403 
(18.294) 
221 48.760 
(18.103) 
684 
 
52.838 
(18.976) 
386 50.376 
(16.926) 
Post-
utilization 
1291 19.520 
(21.009) 
221 27.970 
(28.087) 
684 
 
19.168 
(20.135) 
386 15.303 
(15.807) 
Pre-PDC 1256 0.864 
(0.195) 
213 
 
0.884 
(0.179) 
666 
 
0.861 
(0.192) 
377 
 
0.859 
(0.207) 
Post-PDC 1256 0.748 
(0.337) 
213 
 
0.805 
(0.316) 
666 
 
0.747 
(0.333) 
377 
 
0.717 
(0.350) 
Updated Pre-
MPR 
856 0.938 
(0.104) 
160 
 
0.952 
(0.080) 
451 
 
0.937 
(0.101) 
245 
 
0.930 
(0.121) 
Updated 
Post-MPR 
856 1.157 
(1.870) 
160 
 
1.159 
(0.778) 
451 
 
1.055 
(0.403) 
245 
 
1.345 
(3.392) 
Traditional 
Pre-MPR 
856 0.964 
(0.143) 
160 
 
0.992 
(0.148) 
451 
 
0.960 
(0.138) 
245 
 
0.952 
(0.147) 
Traditional 
Post-MPR 
856 0.974 
(0.178) 
160 
 
0.977 
(0.120) 
451 
 
0.980 
(0.206) 
245 
 
0.960 
(0.151) 
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Table 28: Pre- and post- utilzation and medication adherence of beneficiaries on 
ACEI 
 
 
 
 
 
 
 
 
 
 
 
 
ACEI 
Overall Full Coverage 
Generic 
Coverage No Coverage 
 
N 
Mean 
(SD) N 
Mean 
(SD) N 
Mean 
(SD) N 
Mean 
(SD) 
Pre-Utilization 886 54.595 
(18.172)
297 52.90 
(18.537) 
464 55.87 
(18.692) 
125 53.32 
(17.074) 
Post-utilization 886 20.113 
(20.867)
297 27.08 
(28.935) 
464 21.09 
(20.476) 
125 15.66 
(15.918) 
Pre-PDC 845 0.855 
(0.210) 
     
117 
0.855 
(0.233) 
446 
0.845 
(0.215) 
282 
0.872 
(0.191) 
Post-PDC 845 0.753 
(0.351) 
117 
0.809 
(0.308) 
446 
0.737 
(0.369) 
282 
0.756 
(0.338) 
Updated Pre-
MPR 
592 0.937 
(0.113) 
87 
0.933 
(0.134) 
314 
0.934 
(0.115) 
191 
0.944 
(0.099) 
Updated Post-
MPR 
592 1.149 
(1.144) 
87 
1.197 
(0.592) 
314 
1.068 
(0.310) 
191 
1.259 
(1.932) 
Traditional 
Pre-MPR 
592 0.969 
(0.164) 
87 
0.966 
(0.170) 
314 
0.960 
(0.149) 
191 
0.984 
(0.182) 
Traditional 
Post-MPR 
592 0.984 
(0.150) 
87 
0.986 
(0.142) 
314 
0.984 
(0.154) 
191 
0.981 
(0.147) 
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Table 29: Pre- and post- utilzation and medication adherence of beneficiaries on 
CCI 
 
CCI Overall 
 
Full Coverage 
 
Generic 
Coverage 
No Coverage 
 
 N 
 
 
Mean 
(SD) 
 
N 
 
 
Mean 
(SD) 
 
N 
 
 
Mean 
(SD) 
 
N 
 
 
Mean 
(SD) 
 
Pre-Utilization 832 55.905 
(18.888) 
132 54.917 
(19.638) 
436 56.817 
(19.116) 
264 54.894 
(18.106) 
Post-utilization 832 20.772 
(21.335) 
132 29.129 
(27.356) 
436 21.248 
(20.812) 
264 15.807 
(16.99) 
Pre-PDC 802 
 
0.852 
(0.211) 
126 
 
0.909 
(0.178) 
420 
 
0.843 
(0.213) 
256 
 
0.839 
(0.219) 
Post-PDC 802 0.757 
(0.341) 
126 
 
0.848 
(0.292) 
420 
 
0.734 
(0.348) 
256 
 
0.751 
(0.345) 
Updated Pre-
MPR 562 
0.926 
(0.130) 
95 
0.957 
(0.108) 
 
292 
0.915 
(0.141) 
175 
0.929 
(0.117) 
Updated Post-
MPR 
562 
1.244 
(1.718) 
95 
1.530 
(2.231) 
292 
1.085 
(0.510) 
175 
1.353 
(2.509) 
Traditional Pre-
MPR 562 
0.958 
(0.171) 
95 
0.999 
(0.158) 
 
292 
 
0.950 
(0.191) 
175 
0.949 
(0.137) 
Traditional Post-
MPR 
562 
 
0.981 
(0.200) 
95 
1.019 
(0.316) 
292 
0.971 
(0.176) 
175 
  0.977 
(0.149) 
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Table 30: Pre- and post- utilzation and medication adherence of beneficiaries on 
beta-blockers 
 
 
 
 
 
 
 
 
 
 
 
 
Beta-blockers Overall 
 
Full Coverage 
 
Generic 
Coverage 
No Coverage 
 
 
N 
Mean 
(SD) N 
Mean 
(SD) N 
Mean 
(SD) N 
Mean 
(SD) 
Pre-Utilization 884 
 
55.825 
(18.886) 
135 
54.689 
(19.502) 
464 
 
56.597 
(19.210) 
285 
 
55.105 
(18.049)
Post-utilization 
884 
20.433 
(21.091) 
135 
28.956 
(27.268) 
464 
21.056 
(20.615) 
285 
15.382 
(16.693)
Pre-PDC 
852 
0.849 
(0.216) 
129 
0.911 
(0.177) 
447 
 
0.841 
(0.216) 
276 
 
0.832 
(0.226) 
Post-PDC 852 
 
0.752 
(0.346) 
129 
 
0.852 
(0.289) 
447 
 
0.732 
(0.349) 
276 
 
0.736 
(0.357) 
Updated Pre-
MPR 593 
0.927 
(0.128) 
97 
0.958 
(0.107) 
310 
 
0.917 
(0.140) 
186 
 
0.928 
(0.115) 
Updated Post-
MPR 
593 
1.244 
(1.685) 
97 
1.556 
(2.228) 
310 
1.081 
(0.497) 
186 
1.354 
(2.446) 
Traditional  
Pre-MPR 
593 
0.960 
(0.172) 
97 
1.005 
(0.166) 
310 
0.952 
(0.190) 
186 
0.950 
(0.139) 
Traditional 
Post-MPR 593 
0.981 
(0.197) 
97 
1.023 
(0.314) 
310 
0.971 
(0.174) 
186 
0.977 
(0.145) 
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Table 31: Pre- and post- utilzation and medication adherence of beneficiaries on 
ARB’s 
 
 
 
 
 
 
 
 
 
 
 
 
ARB’s Overall Full Coverage 
 
Generic Coverage No Coverage 
 
N 
Mean 
(SD) N 
Mean 
(SD) 
N Mean 
(SD) N 
Mean 
(SD) 
Pre-Utilization 
356 52.919 
(18.141)
75 49.347 
(17.554) 
191 55.764 
(18.456) 
90 49.856 
(17.079) 
Post-utilization 
356 20.472 
(19.520)
75 29.720 
(24.857) 
191 19.079 
(17.635) 
90 15.722 
(15.592) 
Pre-PDC 340 0.863 
(0.188) 
71 0.896 
(0.164) 
185 0.855 
(0.192) 
84 0.853 
(0.195) 
Post-PDC 340 0.703 
(0.359) 
71 0.836 
(0.288) 
185 0.682 
(0.357) 
84 0.636 
(0.389) 
Updated Pre-
MPR 
216 0.943 
(0.090) 
57 0.950 
(0.091) 
114 0.941 
(0.088) 
45 0.938 
(0.096) 
Updated Post-
MPR 
216 1.066 
(0.361) 
57 1.031 
(0.179) 
114 1.086 
(0.450) 
45 1.059 
(0.266) 
Traditional 
Pre-MPR 
216 0.974 
(0.138) 
57 0.974 
(0.119) 
114 0.976 
(0.149) 
45 0.970 
(0.134) 
Traditional 
Post-MPR 
216 0.967 
(0.157) 
57 0.990 
(0.135) 
114 0.955 
(0.185) 
45 0.969 
(0.096) 
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Table 32: Pre- and post- utilzation and medication adherence of beneficiaries on 
thiazide diuretics 
 
 
 
 
 
 
 
 
 
 
Thiazide  
Diuretics 
Overall 
 
Full Coverage 
 
Generic Coverage 
 
No Coverage 
 
 N 
 
 
Mean 
(SD) 
 
N 
 
 
Mean 
(SD) 
 
N 
 
 
Mean 
(SD) 
 
N 
 
 
Mean 
(SD) 
 
Pre-Utilization 421 56.240 
(18.751) 
78 53.910 
(17.193) 
217 58.364 
(19.013) 
126 54.024 
(18.932) 
Post-utilization 421 20.862 
(19.510) 
78 28.167 
(24.055) 
217 21.106 
(18.911) 
126 15.921 
(15.702) 
Pre-PDC 380 0.781 
(0.277) 
69 0.790 
(0.286) 
200 0.778 
(0.270) 
111 0.782 
(0.285) 
Post-PDC 380 
 
0.623 
(0.406) 
69 0.642 
(0.400) 
200 0.605 
(0.409) 
111 0.643 
(0.408) 
Updated Pre-
MPR 
225 0.934 
(0.124) 
41 0.957 
(0.086) 
119 0.925 
(0.136) 
65 0.935 
(0.120) 
Updated Post-
MPR 
225 1.130 
(0.717) 
41 1.218 
(0.784) 
119 1.084 
(0.479) 
65 1.159 
(0.990) 
Traditional Pre-
MPR 
225 0.967 
(0.178) 
41 0.984 
(0.122) 
119 0.963 
(0.204) 
65 0.965 
(0.155) 
Traditional 
Post-MPR 
225 0.976 
(0.172) 
41 1.006 
(0.146) 
119 0.971 
(0.210) 
65 0.966 
(0.086) 
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Table 33:Pre- and post- utilzation and medication adherence of beneficiaries on 
SSRI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SSRI 
Overall 
 
Full Coverage 
 
Generic 
Coverage 
 
No Coverage 
 
 N 
 
 
Mean 
(SD) 
 
N 
 
 
Mean 
(SD) 
 
N 
 
 
Mean 
(SD) 
 
N 
 
 
Mean 
(SD) 
 
Pre-Utilization 668 50.295 
(19.383) 
101 46.950 
(18.432) 
359 51.763 
(20.289) 
208 49.385 
(18.012) 
Post-utilization 668 22.204 
(22.234) 
101 34.436 
(31.280) 
359 21.816 
(20.891) 
208 16.933 
(16.254) 
Pre-PDC 623 0.810 
(0.247) 
93 0.865 
(0.184) 
334 0.800 
(0.255) 
196 0.801 
(0.256) 
Post-PDC 623 0.659 
(0.385) 
93 0.767 
(0.332) 
334 0.649 
(0.389) 
196 0.623 
(0.394) 
Updated Pre-
MPR 
414 0.924 
(0.121) 
72 0.942 
(0.095) 
217 0.921 
(0.127) 
125 0.918 
(0.126) 
Updated Post-
MPR 
414 1.102 
(0.728) 
72 1.192 
(1.345) 
217 1.086 
(0.574) 
125 1.079 
(0.389) 
Traditional 
Pre-MPR 
414 0.954 
(0.161) 
72 0.970 
(0.125) 
217 0.948 
(0.164) 
125 0.954 
(0.174) 
Traditional 
Post-MPR 
414 (0.975) 
(0.169) 
72 (0.999) 
(0.152) 
217 (0.975) 
(0.163) 
125 (0.961) 
(0.186) 
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Table 34: Pre- and post- utilzation and medication adherence of beneficiaries on PPI 
 
 
 
 
 
 
 
 
 
 
 
 
 
PPI Overall Full Coverage 
Generic 
Coverage No Coverage 
 
N 
Mean 
(SD) N 
Mean 
(SD) N 
Mean 
(SD) N 
Mean 
(SD) 
Pre-
Utilization 
628 48.632 
(18.671) 
150 45.167 
(18.472) 
310 50.058 
(19.282) 
168 49.095 
(17.371) 
Post-
utilization 
628 22.490 
(23.754) 
150 32.200 
(29.985) 
310 21.716 
(22.048) 
168 15.250 
(16.682) 
Pre-PDC 559 0.754 
(0.280) 
133 0.853 
(0.223) 
277      0.730 
(0.280) 
149 0.712 
(0.306) 
Post-PDC 559 0.555 
(0.416) 
133 0.784 
(0.321) 
277 0.495 
(0.419) 
149 0.461 
(0.411) 
Updated Pre-
MPR 
301 0.919 
(0.139) 
104 0.940 
(0.113) 
134 0.906 
(0.145) 
63 0.913 
(0.164) 
Updated 
Post-MPR 
301 1.161 
(1.558) 
104 1.121 
(0.415) 
134 1.073 
(0.799) 
63 1.412 
(3.162) 
Traditional 
Pre-MPR 
301 0.954 
(0.195) 
104 0.987 
(0.196) 
134 0.941 
(0.201) 
63 0.927 
(0.175) 
Traditional 
Post-MPR 
301 0.969 
(0.196) 
104 0.999 
(0.181) 
134     0.949 
(0.199) 
 
63 0.963 
(0.208) 
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Table 35: Pre- and post- utilzation and medication adherence of beneficiaries on 
thyroid hormones 
 
 
 
 
 
 
 
 
 
 
 
 
Thyroid 
Overall Full Coverage 
Generic 
Coverage No Coverage 
 
N 
Mean 
(SD) N 
Mean 
(SD) N 
Mean 
(SD) N 
Mean 
(SD) 
Pre-
Utilization 
720 53.410 
(19.103)
122 50.934 
(18.477) 
398 54.889 
(19.408) 
200 51.975 
(18.689) 
Post-
utilization 
720 21.275 
(22.016)
122 31.959 
(29.357) 
398 19.977 
(20.436) 
200 17.340 
(17.470) 
Updated Pre-
PDC 
693 0.899 
(0.158) 
117 0.927 
(0.129) 
382 0.885 
(0.170) 
194 0.908 
(0.145) 
Updated 
Post-PDC 
693 0.828 
(0.280) 
117 0.888 
(0.250) 
382 0.800 
(0.302) 
194 0.848 
(0.245) 
Pre-MPR 521 0.940 
(0.104) 
102 0.966 
(0.070) 
274 0.930 
(0.114) 
145 0.940 
(0.100) 
Post-MPR 521 1.287 
(1.369) 
102 1.251 
(1.110) 
274 1.321 
(1.488) 
145 1.246 
(1.303) 
Traditional 
Pre-MPR 
521 0.989 
(0.199) 
102 1.021 
(0.167) 
274 0.980 
(0.216) 
145 0.983 
(0.185) 
Traditional 
Post-MPR 
521 1.005 
(0.193) 
102 1.036 
(0.171) 
274 1.010 
(0.210) 
145 0.974 
(0.167) 
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Table 36: Pre- and post- utilzation and medication adherence of beneficiaries on 
biguanides 
 
 
 
 
 
 
 
 
 
 
 
 
Biguanides Overall Full Coverage Generic Coverage No Coverage 
 
N 
Mean 
(SD) N 
Mean 
(SD) N 
Mean 
(SD) N 
Mean 
(SD) 
Pre-
Utilization 
413 54.884 
(19.550) 
75 48.933 
(18.386) 
238 56.475 
(19.900) 
100 55.560 
(18.880) 
Post-
utilization 
413 22.988 
(22.470) 
75 34.040 
(26.971) 
238 22.391 
(22.148) 
100 16.120 
(15.560) 
Pre-PDC 392 0.841 
(0.212) 
71 0.926 
(0.102) 
227 0.830 
(0.220) 
94 0.803 
(0.236) 
Post-PDC 392 0.732 
(0.333) 
71 0.840 
(0.233) 
227 0.718 
(0.341) 
94 0.682 
(0.363) 
Updated Pre-
MPR 
281 0.917 
(0.135) 
60 0.956 
(0.066) 
165 0.901 
(0.156) 
56 0.922 
(0.114) 
Updated 
Post-MPR 
281 1.044 
(0.379) 
60 1.069 
(0.436) 
165 1.058 
(0.401) 
56 0.977 
(0.208) 
Traditional 
Pre-MPR 
281 0.944 
(0.179) 
60 0.987 
(0.113) 
165 0.928 
(0.201) 
56 0.945 
(0.162) 
Traditional 
Post-MPR 
281 0.967 
(0.156) 
60 0.974 
(0.119) 
165 0.975 
(0.174) 
56 0.934 
(0.130) 
167 
 
Difference-in-Difference analysis: Prescription drug utilization 
 
Tables 37-39 reflect results of the difference-in-difference analysis comparing 
prescription drug utilization before and after the coverage gap for beneficiaries enrolled 
in the no coverage plan, generic coverage plan and the full coverage plan. Beneficiaries 
enrolled in the no coverage gap plan filled 14.67 prescriptions less than beneficiaries in 
the full coverage plan, after hitting the coverage gap (p=0.001).  Similar differences were 
noted between beneficiaries enrolled in the generic coverage plan and the no coverage 
plan.  Beneficiaries enrolled in the no coverage plan filled 12.52 prescriptions less than 
beneficiaries in the generic coverage plan, after hitting the coverage gap (p=0.001). 
However, no significant differences in prescription drug utilization, after hitting the 
coverage gap, were noted upon comparison of beneficiaries enrolled in the full coverage 
plan with beneficiaries enrolled in the generic coverage plan. 
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Table 37: Prescription drug utilization: Difference-in-difference analysis: Full 
versus No Coverage Plan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                  
 
 
 
 
 
 
 
 
 
 
Parameter Estimate SE P-value 
N 1210   
Gender -1.38 0.67 0.04 
MTM -1.26 1.42 0.37 
HMO -0.33 0.72 0.64 
Plan type 8.61 0.88 0.001* 
Time 34.14 1.05 0.001* 
Age 0.13 0.04 0.001* 
Income 0.001 0.001 0.02 
Risk 0.36 0.06 0.001* 
Coverage gap 
month 
-3.91 0.14 0.001* 
DiD 
(Plan type* 
time 
interaction) 
-14.67 1.77 0.001* 
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Table 38: Prescription drug utilization: Difference-in-difference analysis: Generic 
versus no coverage plan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter Estimate SE P-value 
N 2075   
Gender -1.24 0.58 0.03 
MTM -2.99 0.97 0.001* 
HMO 1.00 0.70 0.15 
Plan type 5.87 0.88 0.001* 
Time 31.79 0.89 0.001* 
Age 0.07 0.03 0.02 
Income  0.001 0.001 0.29 
Risk 0.44 0.04 0.001* 
Coverage gap 
month 
-3.86 0.13 0.001* 
DiD 
(Plan type* time 
interaction) 
-12.52 1.78 0.001* 
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Table 39: Prescription drug utilization: Difference-in-difference analysis: Generic 
versus full coverage plan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter Estimate SE P-value 
N 1703   
Gender -0.675 0.492 0.170 
MTM -3.839 0.811 0.001* 
HMO 0.576 0.628 0.359 
Plan type -2.390 0.565 0.001* 
Time 31.793 0.787 0.001* 
Age 0.065 0.027 0.014* 
Income  0.000 0.000 0.004* 
Risk 0.324 0.036 0.001* 
Coverage gap 
month 
-3.961 0.114 0.001* 
DiD 
(Plan type* time 
interaction) 
2.088 1.293 0.107 
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Difference-in-Difference Analysis: Medication adherence 
 
Tables 40-69 reflect results of the difference-in-difference (DiD) analysis for the ten drug 
classes. For each drug class, three tables are presented. The first table for each drug class 
compares pre- and post- medication adherence for beneficiaries enrolled in the full 
coverage plan versus beneficiaries enrolled in the no coverage plan. The second table for 
each drug class compares pre- and post- medication adherence for beneficiaries enrolled 
in the generic coverage versus those enrolled in the no coverage plan. The third table for 
each drug class compares pre- and post- medication adherence for beneficiaries enrolled 
in the full coverage versus those enrolled in the generic coverage plan. The DiD analyses 
controls for the following covariates : age, gender, beneficiaries receiving MTM services, 
beneficiaries enrolled in HMO plans, plan type (full versus no coverage plan), time (pre-
coverage gap versus post-coverage gap), risk score (which reflects a beneficiaries co-
morbidities), income and the month in which a beneficiary hit the coverage gap.  
 DiD analyses without discarding oversupply due to drug switches within the same 
medication class were also conducted. However, no differences in results were observed 
when compared to results obtained by discarding the oversupply due to drug switches 
within the same medication class. Therefore, only the results obtained by discarding the 
oversupply due to drug switches within the same medication class are reported. 
 
Statins: Difference-in-Difference analysis - Full versus no coverage plans 
Table 40 compares pre- and post-medication adherence to statins for beneficiaries 
enrolled in full coverage versus no coverage plans. As was noted in the descriptive 
analyses, the impact of the coverage gap on medication adherence varied depending on 
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the method used to measure medication adherence. When medication adherence was 
measured using the PDC method, medication adherence of beneficiaries in the no 
coverage gap compared to beneficiaries in the full coverage plan decreased significantly 
by 0.058 (5.8%, p≤0.017) after hitting the coverage gap. However, when measured using 
the updated MPR and MPR traditional methods, there was no significant difference in 
pre- and post medication adherence for beneficiaries in the no coverage plan compared to 
beneficiaries in the full coverage plan.  
 
Statins: Difference-in-Difference analysis - Generic versus no coverage plans 
Table 41 compares pre- and post-medication adherence to statins for beneficiaries 
enrolled in generic coverage versus no coverage plans. As was observed for the generic 
versus no coverage plans, when medication adherence was measured using the PDC 
method, medication adherence of beneficiaries in the no coverage plan compared to 
beneficiaries in the generic coverage plan decreased significantly by 0.011 (1.1%, 
p≤0.017) after beneficiaries hit  the coverage gap. However, when measured using the 
MPR and MPR traditional methods, there was no significant difference in pre- and post 
medication adherence for beneficiaries in the no coverage plan compared to beneficiaries 
in the generic coverage plan.  
 
Statins: Difference-in-Difference analysis - Full versus generic coverage 
Table 42 compares pre- and post-medication adherence to statins for beneficiaries 
enrolled in full coverage versus generic coverage plans. No significant differences were 
found in medication adherence of beneficiaries in the generic coverage plans compared to 
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beneficiaries in the full coverage plan irrespective of whether adherence was measured 
using the PDC, updated MPR or MPR traditional methods.  
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Table 40: Statins Difference-in-difference analysis: Full versus no coverage plan 
 
 
 
 
 
 
 
 
Param
eter 
PDC MPR  Updated MPR Traditional 
 
 Estima
te 
SE P-
value 
Estim
ate 
SE P-
value 
Estima
te 
SE P-
value 
N 568   390   390   
Gende
r 
0.016    0.017   0.333 0.023   0.013   0.034* 0.011 0.011 0.356 
MTM -0.020 0.033 0.551 -0.011 0.020 0.561 0.008 0.021 0.688 
HMO -0.003  0.018 0.883 -0.002 0.012 0.858 0.004 0.012 0.756 
Plan 
type 
-0.070 0.031 0.023* -0.203 0.283 0.474 0.013 0.015 0.401 
Time 0.138 0.014 0.001* -0.434 0.178 0.015* -0.011 0.012 0.355 
Age -0.020   0.033 0.551 0.001 0.001 0.939 0.000 0.001 0.978 
Risk -0.003   0.018 0.883   -0.002 0.001 0.077* -0.001 0.001 0.586 
Incom
e 
0.001 0.001 0.001* 0.001 0.001 0.001* 0.001 0.000 .001* 
Cover
age 
gap 
month 
-0.013  0.004  0.001* -0.003 0.003 0.150 0.003 0.003 0.226 
DiD 
(Plan 
type* 
time 
interac
tion) 
-0.058 
 
0.024 
 
0.014*
 
0.223 
 
0.282 
 
0.430  
 
0.029 0.019 
 
0.122 
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Table 41: Statins Difference-in-difference analysis: Generic versus no coverage plan 
 
 
 
 
 
 
 
Param
eter 
PDC MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
N 998   668   668   
Gende
r 
0.024 0.013 0.057 0.023 0.009 0.009 0.017 0.010 0.084 
MTM 0.003 0.021 0.876 -0.011 0.013* 0.385 -0.016 0.015 0.277 
HMO -0.010 0.016 0.547 0.009 0.011* 0.428 0.011 0.012 0.362 
Plan 
Type 
-0.028 0.022 0.206 0.302 0.169 0.073 -0.020 0.016 0.192 
Time 0.116 0.011 0.001* -0.120 0.100 0.228 -0.020 0.010 0.056* 
Age 0.000 0.001 0.001* 0.001* 0.001* 0.510 0.001 0.001 0.733 
Risk 0.001 0.001 0.066 -0.003 0.001* 0.001* -0.002 0.001 0.018* 
Incom
e 
-0.003 0.001 0.001* 0.001 0.001* 0.001* 0.001 0.001 0.001* 
Cover
age 
gap 
month 
0.001 0.001 0.001* -0.003 0.002 0.219 0.003 0.003 0.281 
DiD 
(Plan 
type* 
time 
interac
tion) 
-0.011 
 
0.003 
 
0.001*
 
0.313 
 
0.168 
 
0.063 
 
-0.009 
 
0.018 
 
0.604 
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Table 42: Statins Difference-in-difference analysis: Full versus generic coverage 
plan 
 
 
 
 
 
 
Param
eter 
PDC MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estima
te 
SE P-
value 
N 846   663   663   
Gende
r 
0.041 0.020 0.06 0.019 0.004 0.016
* 
0.023 0.050 0.068 
MTM 0.001 0.021 0.887 -0.010 0.018 0.584 -0.014 0.015 0.452 
HMO -0.020 0.014 0.609 0.004 0.011 0.411 0.032 0.022 0.556 
Plan 
type 
0.047 0.027 0.081 -0.001 0.142 0.579 -0.009 0.018 0.574 
Time 0.116 0.011 0.001* 0.167 0.014 0.064 -0.020 0.011 0.058* 
Age 0.001 0.001 0.066 0.001 0.001 0.310 0.000 0.001 0.733 
Risk -0.001 0.001 0.001* -0.001 0.001 0.001
* 
-0.002 0.001 0.018* 
Incom
e 
0.001 0.001 0.001* 0.001 0.001 0.001
* 
0.001 0.001 0.001* 
Cover
age 
gap 
month 
-0.011 0.003 0.001* -0.013 0.004 0.142 0.016 0.001 0.308 
DiD 
(Plan 
type* 
time 
interac
tion) 
-0.022 0.018 0.241 0.418 0.114 0.074 0.135 0.048 0.736 
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ACEI 
 
ACEI: Difference-in-Difference analysis - Full versus no coverage plans 
Table 43 compares pre- and post-medication adherence to ACEI for beneficiaries 
enrolled in full coverage versus no coverage plans. No significant differences were found 
in medication adherence of beneficiaries in the no coverage plan compared to 
beneficiaries in the full coverage plan irrespective of whether adherence was measured 
using the PDC, updated MPR or MPR traditional methods. 
 
ACEI: Difference-in-Difference analysis - Generic versus no coverage plans 
Table 44 compares pre- and post-medication adherence to ACEI for beneficiaries 
enrolled in generic coverage versus no coverage plans. No significant differences were 
found in medication adherence of beneficiaries in the generic coverage plan compared to 
beneficiaries in the no coverage plan irrespective of whether adherence was measured 
using the PDC, updated MPR or MPR traditional methods. 
 
ACEI: Difference-in-Difference analysis - Full versus generic coverage 
Table 45 compares pre- and post-medication adherence to ACEI for beneficiaries 
enrolled in full coverage versus generic coverage plans. No significant differences were 
found in medication adherence of beneficiaries in the generic coverage plans compared to 
beneficiaries in the full coverage plan irrespective of whether adherence was measured 
using the PDC, updated MPR or MPR traditional methods.  
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Table 43: ACEI: Difference-in-difference analysis: Full versus no coverage plan 
 
 
 
 
 
  
 
Param
eter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
N 381   262   262   
Gende
r 
0.906 0.117 0.001* -0.010 0.014 0.488 0.003 0.017 0.857 
MTM 0.036 0.021 0.092 0.038 0.032 0.233 -0.061 0.037 0.104 
HMO -0.004 0.048 0.926 -0.002 0.016 0.914 0.006 0.018 0.741 
Plan 
type  
-0.018 0.026 0.483 0.033 0.062 0.592 0.001 0.021 0.945 
Time -0.168 0.038 0.479 -0.168 0.034 0.001* 0.002 0.014 0.889 
Age 0.113 0.016 0.001* 0.000 0.001 0.599 -0.001 0.001 0.380 
Risk -0.001 0.001 0.362 -0.002 0.001 0.155 -0.001 0.002 0.660 
Incom
e 
-0.003 0.002 0.136 0.000 0.000 0.001* 0.001 0.000 .001* 
Cover
age 
gap 
month 
0.000 0.000 0.001* -0.010 0.003 0.005* 0.001 0.004 0.953 
DiD 
(Plan 
type* 
time 
intera
ction) 
-0.052 
 
0.026 
 
0.042 
 
0.056 
 
0.060 
 
0.351 
 
-0.027 
 
0.025 
 
0.293 
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Table 44: ACEI: Difference-in-difference analysis: Generic versus no coverage plan 
 
  
 
  
 
 
Param
eter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
N 542   387   387   
Gende
r 
0.005 0.019 0.802 -0.017 0.013 0.164 -0.009 0.013 0.454 
MTM 0.037 0.032 0.246 0.017 0.019 0.386 0.025 0.019 0.187 
HMO -0.018 0.024 0.450 0.009 0.015 0.566 0.008 0.015 0.598 
Plan 
type  
0.049 0.038 0.197 0.081 0.046 0.075 -0.006 0.020 0.751 
Time 0.107 0.013 0.001* -0.134 0.020 0.001* -0.022 0.011 0.044 
Age -0.001 0.001 0.279 0.000 0.001 0.917 0.000 0.001 0.626 
Risk -0.003 0.002 0.050* -0.001 0.001 0.224 -0.001 0.001 0.500 
Incom
e 
0.000 0.000 0.001* 0.000 0.000 0.001* 0.000 0.000 .001* 
Cover
age 
gap 
month 
-0.016 0.005 0.001* -0.009 0.003 0.006* -0.002 0.003 0.531 
DiD 
(Plan 
type* 
time 
intera
ction) 
-0.058 
 
0.029 
 
0.046 
 
-0.090 
 
0.043 
 
0.040 
 
-0.001 
 
0.024 
 
0.969 
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Table 45:ACEI: Difference-in-difference analysis: Full versus generic coverage plan 
 
 
 
 
 
 
 
 
 
Param
eter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
N 695   483   483   
Gender 0.022 0.016 0.173 0.004 0.010 0.668 0.005 0.012 0.654 
MTM 0.014 0.027 0.598 0.026 0.016 0.109 0.016 0.019 0.384 
HMO -0.017 0.020 0.393 -0.024 0.013 0.052 -0.025 0.015 0.097 
Plan 
type  
-0.024 0.028 0.389 -0.046 0.035 0.185 0.000 0.015 0.993 
Time 0.114 0.017 0.001* -0.168 0.026 0.001* 0.002 0.014 0.865 
Age -0.001 0.001 0.125 0.000 0.001 0.690 -0.001 0.001 0.146 
Risk -0.003 0.001 0.045 -0.002 0.001 0.019* -0.001 0.001 0.195 
Income 0.000 0.000 0.001* 0.000 0.000 0.001* 0.001 0.000 0.001
* 
Covera
ge gap 
month 
-0.010 0.004 0.010* -0.008 0.003 0.002* -.003 0.003 0.334 
DiD 
(Plan 
type* 
time 
interac
tion) 
-0.007 0.021 0.743 0.034 0.033 0.313 -0.025 0.018 0.165 
181 
 
ARB 
ARB: Difference-in-Difference analysis - Full versus no coverage plans 
Table 46 compares pre- and post-medication adherence to ARB for beneficiaries enrolled 
in full coverage versus no coverage plans. When medication adherence was measured 
using the PDC method, medication adherence of beneficiaries in the no coverage plan 
compared to beneficiaries in the full coverage plan decreased significantly by 0.160 
(16.0%, p≤0.017) after hitting the coverage gap. However, when measured using the 
updated MPR and MPR traditional methods, there was no significant difference in pre- 
and post medication adherence for beneficiaries in the no coverage plan compared to 
beneficiaries in the full coverage plan.  
 
ARB: Difference-in-Difference analysis - Generic versus no coverage plans 
Table 47 compares pre- and post-medication adherence to ARB for beneficiaries enrolled 
in generic coverage versus no coverage plans. Medication adherence of beneficiaries in 
the no coverage plan compared to beneficiaries in the generic coverage plan decreased 
significantly by 0.121 (12.1%, p≤0.017) when measured using the PDC.  However, when 
measured using the updated MPR or the MPR traditional method, there was no 
significant difference in pre- and post medication adherence for beneficiaries in the no 
coverage plan compared to beneficiaries in the generic coverage plan.  
 
ARB: Difference-in-Difference analysis - Full versus generic coverage plans 
Table 48 compares pre- and post-medication adherence to ARB for beneficiaries enrolled 
in generic coverage versus full coverage plans. No significant differences were found in 
182 
 
medication adherence of beneficiaries in the generic coverage plans compared to 
beneficiaries in the full coverage plan irrespective of whether adherence was measured 
using the PDC, updated MPR or MPR traditional methods.  
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Table 46:ARB: Difference-in-difference analysis: Full versus no coverage plan 
  
 
 
 
 
 
Param
eter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estima
te 
SE P-
value 
Estima
te 
SE P-
value 
Estim
ate 
SE P-
value 
N 147   97   97   
Gende
r 
0.022 0.031 0.488 0.043 0.020 0.037 0.045 0.021 0.031 
MTM -0.036 0.055 0.507 -0.045 0.040 0.264 -0.018 0.040 0.665 
HMO 0.027 0.036 0.448 0.018 0.022 0.411 0.009 0.022 0.692 
Plan 
type  
0.202 0.060 0.001* -0.021 0.046 0.648 0.019 0.029 0.507 
Time 0.208 0.032 0.001* -0.117 0.033 0.001* -0.004 0.025 0.869 
Age 0.004 0.002 0.106 0.001 0.001 0.585 0.002 0.002 0.157 
Risk -0.006 0.004 0.200 -0.001 0.003 0.643 -0.001 0.003 0.665 
Incom
e 
0.000 0.000 0.268 0.000 0.000 0.001* 0.000 0.000 0.001
* 
Cover
age 
gap 
month 
-0.007 0.007 0.347 -0.002 0.005 0.680 -0.003 0.005 0.548 
DiD 
(Plan 
type* 
time 
intera
ction) 
-0.160 
 
0.046 
 
0.001*
 
0.033 
 
0.043 
 
0.449 
 
-0.013 
 
0.033 
 
0.700 
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Table 47:ARB: Difference-in-difference analysis: Generic versus no coverage plan 
 
 
 
 
 
 
 
Param
eter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-value Estim
ate 
SE P-
value 
n 250   167   167   
Gende
r 
0.003 0.024 0.900 0.017 0.015 0.234 0.017 0.019 0.354 
MTM 0.106 0.034 0.002 -0.007 0.022 0.740 0.022 0.028 0.448 
HMO 0.027 0.031 0.387 0.018 0.019 0.347 0.012 0.025 0.614 
Plan 
type  
0.114 0.049 0.019 -0.077 0.064 0.232 0.017 0.031 0.574 
Time 0.169 0.022 .001 -0.149 0.035 0.001 0.016 0.020 0.414 
Age 0.007 0.001 .001 0.001 0.001 0.375 0.002 0.001 0.050 
Risk -0.008 0.002 0.001 -0.002 0.001 0.123 -0.002 0.002 0.288 
Incom
e 
0.000 0.000 0.001 0.000 0.000 0.001 0.000 0.000 0.001 
Covera
ge gap 
month 
-0.012 0.005 0.029 -0.008 0.004 0.025 -0.005 0.005 0.285 
DiD 
(Plan 
type* 
time 
interac
tion ) 
-0.121 
 
0.042 
 
0.004*
 
0.065 
 
0.061 
 
0.287 
 
-0.033 
 
0.034 
 
0.335 
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Table 48: ARB: Difference-in-difference analysis: Full versus generic coverage plan 
 
 
 
 
 
Paramet
er 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
n 259   152   152   
Gender 0.015 0.025 0.558 0.024 0.016 0.132 0.012 0.020 0.557 
MTM 0.052 0.033 0.116 -0.023 0.022 0.285 -0.003 0.027 0.920 
HMO 0.027 0.037 0.457 0.010 0.023 0.666 0.021 0.029 0.477 
Plan 
type  
0.070 0.050 0.160 0.049 0.075 0.520 -0.005 0.031 0.860 
Time 0.208 0.036 0.001
* 
-0.117 0.062 0.064 -0.004 0.034 0.904 
Age 0.006 0.002 0.000
* 
0.001 0.001 0.745 0.002 0.001 0.156 
Risk -0.008 0.002 0.001
* 
-0.003 0.002 0.028
* 
-0.002 0.002 0.211 
Income 0.001 0.001 0.001
* 
0.001 0.001 0.001
* 
0.001 0.001 0.001* 
Coverag
e gap 
month 
-0.014 0.006 0.023
* 
-0.006 0.004 0.172 0.001 0.005 0.833 
DiD 
(Plan 
type* 
time 
interacti
on) 
-0.039 0.043 0.368 -0.033 0.073 0.656 0.020 0.040 0.612 
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Beta-blockers: Difference-in-Difference analysis - Full versus no coverage plans 
Table 49 compares pre- and post-medication adherence to beta-blockers for beneficiaries 
enrolled in full coverage versus no coverage plans. No significant differences were found 
in medication adherence of beneficiaries in the full coverage plans compared to 
beneficiaries in the no coverage plan irrespective of whether adherence was measured 
using the PDC, updated MPR or MPR traditional methods.  
 
Beta-blockers: Difference-in-Difference analysis - Generic versus no coverage plans 
Table 50 compares pre- and post-medication adherence to beta-blockers for beneficiaries 
enrolled in generic coverage versus no coverage plans. No significant differences were 
found in medication adherence of beneficiaries in the generic coverage plans compared to 
beneficiaries in the no coverage plan irrespective of whether adherence was measured 
using the PDC, updated MPR or MPR traditional methods.  
 
Beta-blockers: Difference-in-Difference analysis - Full versus generic coverage 
Table 51 compares pre- and post-medication adherence to beta-blockers for beneficiaries 
enrolled in full coverage versus generic coverage plans. No significant differences were 
found in medication adherence of beneficiaries in the generic coverage plans compared to 
beneficiaries in the full coverage plan irrespective of whether adherence was measured 
using the PDC, updated MPR or MPR traditional methods.  
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Table 49: Beta-blockers: Difference-in-difference analysis: Full versus no coverage 
plan 
  
 
 
 
Para
meter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
N 378   254   254   
Gende
r 
-0.006 0.022 0.789 0.004 0.014 0.790 -0.005 0.015 0.740 
MTM 0.004 0.047 0.926 -0.036 0.030 0.230 -0.010 0.032 0.751 
HMO -0.025 0.024 0.302 0.009 0.016 0.564 0.003 0.017 0.867 
Plan 
type  
0.096 0.039 0.014 0.076 0.053 0.158 0.036 0.030 0.238 
Time 0.094 0.016 0.001
* 
-0.136 0.031 0.001
* 
-0.021 0.021 0.322 
Age -0.001 0.001 0.583 -0.001 0.001 0.335 -0.001 0.001 0.576 
Risk -0.003 0.002 0.149 -0.002 0.001 0.088 -0.003 0.002 0.053 
Incom
e 
0.000 0.000 0.001
* 
0.000 0.000 .001* 0.000 0.000 .001* 
Cover
age 
gap 
month 
-0.009 0.005 0.072 -0.003 0.003 0.406 -0.001 0.004 0.693 
DiD 
(Plan 
type* 
time 
intera
ction) 
-0.030 0.029 0.310 -0.059 0.054 0.271 0.003 0.036 0.939 
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Table 50: Beta blockers: Difference-in-difference analysis: Generic versus no 
coverage plan 
 
 
 
 
 
Para
meter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
n 679   467   467   
Gend
er 
0.048 0.042 0.252 -0.013 0.040 0.742 -0.018 0.035 0.610 
MTM -0.135 0.067 0.043 0.055 0.059 0.358 0.038 0.051 0.458 
HMO 0.061 0.053 0.248 0.040 0.050 0.428 0.029 0.043 0.507 
Plan 
type  
-0.053 0.052 0.310 -0.031 0.054 0.562 -0.057 0.047 0.224 
Time -0.179 0.072 0.014 -0.321 0.050 0.001 -0.247 0.052 .001 
Age -0.002 0.002 0.478 0.000 0.002 0.902 0.000 0.002 0.999 
Risk -0.005 0.003 0.043 -0.007 0.003 0.006 -0.007 0.002 0.002 
Incom
e 
0.014 0.020 0.474 0.037 0.019 0.051 0.049 0.016 0.003 
Cover
age 
gap 
mont
h 
0.039 0.010 0.000 0.005 0.011 0.661 0.016 0.009 0.097 
DiD 
(Plan 
type* 
time 
intera
ction) 
0.094 0.092 0.308 0.077 0.062 0.218 0.105 0.065 0.105 
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Table 51:Beta blockers: Difference-in-difference analysis: Full versus generic  
coverage plan 
  
 
 
 
Param
eter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
N 526   275   275   
Gende
r 
-0.024 0.019 0.198 -0.019 0.014 0.177 -0.037 -2.230 0.027 
MTM 0.003 0.029 0.931 0.016 0.020 0.418 -0.001 -0.030 0.973 
HMO 0.024 0.022 0.278 0.008 0.016 0.612 -0.002 -0.110 0.916 
Plan 
type  
0.087 0.035 0.015 0.096 0.048 0.045 0.047 1.650 0.099 
Time 
 
0.103 0.013 0.001 -0.128 0.023 0.001 -0.018 -1.160 0.247 
Age -0.001 0.001 0.306 0.000 0.001 0.697 -0.001 -1.250 0.213 
Risk -0.002 0.001 0.097 0.000 0.001 0.846 0.000 0.040 0.968 
Incom
e 
0.000 0.000 0.001 0.000 0.000 0.001 0.000 0.000 0.001 
Cover
age 
gap 
month 
-0.008 0.004 0.051 0.000 0.003 0.978 0.000 -0.100 0.918 
DiD 
(Plan 
type* 
time 
interac
tion) 
-0.038 0.027 0.157 -0.067 0.047 0.154 -0.004 -0.140 0.889 
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Biguanides 
Biguanides: Difference-in-Difference analysis - Full versus no coverage plans 
Table 52 compares pre- and post-medication adherence to biguanides for beneficiaries 
enrolled in full coverage versus no coverage plans. No significant differences were found 
in medication adherence of beneficiaries in the full coverage plans compared to 
beneficiaries in the no coverage plan irrespective of whether adherence was measured 
using the PDC, updated MPR or MPR traditional methods.  
 
Biguanides: Difference-in-Difference analysis - Generic versus no coverage plans 
Table 53 compares pre- and post-medication adherence to biguanides for beneficiaries 
enrolled in generic coverage versus no coverage plans. No significant differences were 
found in medication adherence of beneficiaries in the generic coverage plans compared to 
beneficiaries in the no coverage plan irrespective of whether adherence was measured 
using the PDC, updated MPR or MPR traditional methods.  
 
Biguanides: Difference-in-Difference analysis - Full versus generic coverage 
Table 54 compares pre- and post-medication adherence to biguanides for beneficiaries 
enrolled in full coverage versus generic coverage plans. No significant differences were 
found in medication adherence of beneficiaries in the generic coverage plans compared to 
beneficiaries in the full coverage plan irrespective of whether adherence was measured 
using the PDC, updated MPR or MPR traditional methods.  
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Table 52: Biguanides: Difference-in-difference analysis: Full versus no coverage 
plan 
 
Para
meter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estima
te 
SE P-
value
n 155   110   110   
Gend
er 
0.062 0.032 0.054 0.003 0.180 0.855 0.016 0.019 0.406 
MT
M 
0.053 0.066 0.423 0.046 1.220 0.224 0.041 0.040 0.312 
HMO 0.032 0.036 0.380 0.022 1.040 0.299 0.025 0.022 0.269 
Plan 
type  
0.142 0.055 0.011
* 
0.063 0.940 0.351 0.033 0.026 0.208 
Time 0.122 0.028 0.001
* 
-0.056 -1.160 0.249 0.015 0.024 0.546 
Age 0.000 0.002 0.966 -0.001 -0.400 0.689 0.000 0.001 0.855 
Risk -0.004 0.003 0.171 -0.002 -1.060 0.293 -0.004 0.002 0.049 
Inco
me 
0.000 0.000 0.986 0.000 0.000 .001* 0.000 0.000 .001* 
Cove
rage 
gap 
mont
h 
-0.009 0.007 0.206 -0.010 -2.230 0.028 -0.003 0.005 0.570 
DiD 
(Plan 
type* 
time 
inter
actio
n) 
-0.041 0.044 0.346 -0.053 -0.800 0.424 -0.005 0.034 0.872 
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Table 53: Biguanides: Difference-in-difference analysis: Generic versus no coverage 
plan 
 
 
 
 
 
 
 
 
Parame
ter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
n 306   218   218   
Gender 0.048 0.026 0.071 0.002 0.020 0.938 0.007 0.018 0.685 
MTM 0.033 0.039 0.409 0.064 0.028 0.024 0.013 0.025 0.598 
HMO -0.001 0.035 0.974 -0.005 0.027 0.861 0.034 0.024 0.152 
Plan 
type  
0.053 0.044 0.224 0.082 0.058 0.161 0.048 0.024 0.050
* 
Time 0.122 0.030 0.001* -0.056 0.051 0.276 0.015 0.032 0.649 
Age 0.000 0.002 0.984 0.000 0.001 0.988 0.000 0.001 0.772 
Risk -0.006 0.002 0.004* -0.002 0.002 0.360 -0.003 0.002 .039* 
Income 0.000 0.000 0.340 0.000 0.000 0.001* 0.000 0.000 .001* 
Covera
ge gap 
month 
-0.011 0.007 0.107 -0.014 0.006 0.020* 0.003 0.005 0.538 
DiD 
(Plan 
type* 
time 
interact
ion) 
-0.013 0.035 0.717 -0.100 0.059 0.089 -0.057 0.037 0.123 
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Table 54: Biguanides: Difference-in-difference analysis: Full versus generic 
coverage plan 
 
 
 
 
 
 
 
 
 
Parame
ter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
n 283   217   217   
Gender 0.013 0.024 0.605 -0.011 0.019 0.578 0.010 0.017 0.554 
MTM 0.028 0.037 0.451 0.066 0.027 0.016 0.025 0.024 0.310 
HMO -0.027 0.032 0.397 -0.011 0.025 0.658 0.026 0.022 0.238 
Plan 
type  
0.093 0.045 0.042 -0.020 0.064 0.750 -0.009 0.024 0.716 
Time 0.109 0.017 0.001* -0.156 0.033 0.001* -0.043 0.018 .017* 
Age 0.000 0.002 0.835 0.000 0.001 0.854 -0.001 0.001 0.564 
Risk -0.006 0.002 0.006 -0.002 0.002 0.373 -0.003 0.002 0.124 
Income 0.000 0.000 0.443 0.000 0.000 0.001* 0.000 0.000 .001* 
Covera
ge gap 
month 
-0.010 0.006 0.098 -0.012 0.005 0.021* 0.001 0.005 0.795 
DiD 
(Plan 
type* 
time 
interact
ion) 
-0.028 0.036 0.425 0.047 0.064 0.463 0.052 0.035 0.136 
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Diuretics 
Diuretics: Difference-in-Difference analysis - Full versus no coverage plans 
Table 55 compares pre- and post-medication adherence to diuretics for beneficiaries 
enrolled in full coverage versus no coverage plans. No significant differences were found 
in medication adherence of beneficiaries in the full coverage plans compared to 
beneficiaries in the no coverage plan irrespective of whether adherence was measured 
using the PDC, updated MPR or MPR traditional methods.  
 
Diuretics: Difference-in-Difference analysis - Generic versus no coverage plans 
Table 56 compares pre- and post-medication adherence to diuretics for beneficiaries 
enrolled in generic coverage versus no coverage plans. No significant differences were 
found in medication adherence of beneficiaries in the generic coverage plans compared to 
beneficiaries in the no coverage plan irrespective of whether adherence was measured 
using the PDC, updated MPR or MPR traditional methods.  
 
Diuretics: Difference-in-Difference analysis - Full versus generic coverage plans 
Table 57 compares pre- and post-medication adherence to diuretics for beneficiaries 
enrolled in full coverage versus generic coverage plans. No significant differences were 
found in medication adherence of beneficiaries in the generic coverage plans compared to 
beneficiaries in the full coverage plan irrespective of whether adherence was measured 
using the PDC, updated MPR or MPR traditional methods.  
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Table 55: Diuretics: Difference-in-difference analysis: Full versus no coverage plan 
 
 
 
 
 
Param
eter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
n 170   97   97   
Gende
r 
0.104 0.044 0.019 0.016 0.024 0.505 0.023 0.018 0.201 
MTM -0.043 0.087 0.622 0.037 0.042 0.371 0.056 0.032 0.083 
HMO 0.039 0.048 0.413 -0.018 0.026 0.506 0.004 0.020 0.834 
Plan 
type  
-0.025 0.067 0.711 0.054 0.195 0.782 0.030 0.026 0.257 
Time 0.144 0.030 .001* -0.238 0.122 0.055 -0.006 0.023 0.801 
Age 0.003 0.003 0.246 0.001 0.002 0.590 0.002 0.001 0.275 
Risk -0.004 0.004 0.307 -0.005 0.003 0.150 -0.004 0.003 0.128 
Incom
e 
0.000 0.000 0.806 0.000 0.000 0.609 0.000 0.000 .001* 
Cover
age 
gap 
month 
0.004 0.011 0.694 0.003 0.006 0.646 0.010 0.005 0.039 
DiD 
(Plan 
type* 
time 
intera
ction) 
0.008 0.048 0.870 -0.023 0.193 0.905 -0.009 0.036 0.799 
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Table 56: Diuretics: Difference-in-difference analysis: Generic versus No Coverage 
plan 
 
 
 
  
Param
eter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
n 329   167   167   
Gende
r 
0.002 0.033 0.536 -0.005 0.020 0.806 0.017 0.002 0.450 
MTM 0.012 0.053 0.817 -0.015 0.030 0.613 0.012 0.033 0.708 
HMO 0.051 0.042 0.231 0.008 0.026 0.761 0.039 0.029 0.190 
Plan 
type  
-0.015 0.049 0.754 -0.070 0.114 0.538 0.021 0.028 0.434 
Time 0.143 0.032 0.001 -0.238 0.091 0.011 -0.005 0.027 0.832 
Age 0.002 0.002 0.211 0.001 0.001 0.627 0.002 0.001 0.061 
Risk -0.005 0.002 0.062 -0.005 0.002 0.785 0.001 0.002 0.611 
Incom
e 
-0.001 0.001 0.837 -0.001 0.001 0.600 -0.001 0.001 0.115 
Cover
age 
gap 
month 
0.003 0.008 0.709 0.003 0.005 0.498 0.004 0.006 0.453 
DiD 
(Plan 
type* 
time 
intera
ction) 
0.024 0.039 0.548 0.071 0.113 
 
0.525 -0.007 0.033 0.820 
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Table 57: Diuretics: Difference-in-difference analysis: Full versus Generic Coverage 
plan 
 
 
 
 
Param
eter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value
Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
n 263   157   157   
Gende
r 
0.039 0.035 0.265 -0.010 0.021 0.641 -0.006 0.025 0.811 
MTM 0.040 0.062 0.521 -0.039 0.033 0.237 -0.015 0.039 0.713 
HMO 0.072 0.042 0.089 0.023 0.025 0.346 0.060 0.030 0.045 
Plan 
type 
-0.026 0.060 0.666 0.128 0.106 0.228 0.018 0.038 0.633 
Time 0.167 0.023 0.001
* 
-0.166 0.052 0.002
* 
-0.014 0.021 0.519 
Age 0.005 0.002 0.024 0.002 0.001 0.221 0.003 0.002 .033* 
Risk -0.004 0.003 0.183 0.001 0.002 0.892 0.001 0.003 0.664 
Incom
e 
0.001 0.001 0.618 0.001 0.001 0.698 0.001 0.001 0.254 
Cover
age 
gap 
month 
-0.006 0.009 0.452 0.001 0.005 0.966 0.003 0.006 0.597 
DiD 
(Plan 
type* 
time 
interac
tion) 
-0.016 0.045 0.727 -0.095 0.103 0.360 -0.002 0.041 0.969 
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SSRI: Difference-in-Difference analysis - Full versus no coverage plans 
Table 58 compares pre- and post-medication adherence to SSRI for beneficiaries enrolled 
in full coverage versus no coverage plans. No significant differences were found in 
medication adherence of beneficiaries in the no coverage plan compared to beneficiaries 
in the full prescription drug coverage plan irrespective of whether adherence was 
measured using the PDC, updated MPR or MPR traditional methods.  
 
SSRI: Difference-in-Difference analysis - Generic versus no coverage plans 
Table 59 compares pre- and post-medication adherence to SSRI for beneficiaries enrolled 
in generic coverage versus no coverage plans. No significant differences were found in 
medication adherence of beneficiaries in the generic coverage plans compared to 
beneficiaries in the no coverage plan irrespective of whether adherence was measured 
using the PDC, updated MPR or MPR traditional methods.  
 
SSRI: Difference-in-Difference analysis - Full versus generic coverage plans 
Table 60 compares pre- and post-medication adherence to SSRI for beneficiaries enrolled 
in full coverage versus generic coverage plans. No significant differences were found in 
medication adherence of beneficiaries in the generic coverage plans compared to 
beneficiaries in the full coverage plan irrespective of whether adherence was measured 
using the PDC, updated MPR or MPR traditional methods.  
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Table 58: SSRI: Difference-in-difference analysis: Full versus No Coverage Plan 
 
 
 
 
 
 
 
 
 
 
Parame
ter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estima
te 
SE P-
value 
Estim
ate 
SE P-
value 
n 267   181   181   
Gender 0.041 0.031 0.179 -0.014 0.018 0.441 -0.005 0.020 0.803 
MTM 0.065 0.048 0.172 0.035 0.027 0.210 0.061 0.031 0.047 
HMO 0.038 0.031 0.227 0.019 0.018 0.301 0.025 0.020 0.229 
Plan 
type  
0.105 0.049 0.003 0.162 0.133 0.506 0.017 0.028 0.548 
Time 0.174 0.021 0.001 0.001 0.079 0.044 -0.009 0.019 0.615 
Age 0.002 0.001 0.095 -0.001 0.001 0.241 0.001 0.001 0.679 
Risk -0.008 0.002 0.002 -0.001 0.001 0.398 -0.005 0.001 0.791 
Income 0.001 0.001 0.607 -0.001 0.001 0.001 0.001 0.001 0.001 
Covera
ge gap 
month 
-0.023 0.005 0.001 -0.013 0.003 0.001 -0.009 0.004 0.024 
DiD 
(Plan 
type* 
time 
interact
ion) 
-0.076 
-0.078 
0.036 
0.036 
0.033 
0.032 
-0.084 
-0.104 
0.131 
0.130 
0.523 
0.423 
-0.024 
-0.018 
0.033 
0.031 
0.479 
0.563 
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Table 59: SSRI: Difference-in-difference analysis: Generic versus no coverage plan 
  
 
 
 
 
 
 
 
 
Parame
ter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
n 502   328   328   
Gender 0.025 0.025 0.317 0.003 0.016 0.873 0.006 0.019 0.628 
MTM 0.052 0.035 0.139 0.021 0.020 0.309 0.014 0.160 0.419 
HMO 0.006 0.031 0.835 -0.008 0.018 0.663 0.019 0.014 0.549 
Plan 
type  
0.033 0.037 0.370 -0.016 0.046 0.724 -0.024 0.038 0.614 
Time 0.175 0.021 0.001 -0.162 0.036 0.001 -0.118 0.012 0.008 
Age 0.001 0.001 0.332 0.001 0.001 0.553 0.001 0.001 0.236 
Risk -0.002 0.002 0.200 -0.001 0.001 0.536 -0.001 0.001 0.185 
Income 0.001 0.001 .001 0.001 0.001 0.001 0.001 0.001 0.001 
Covera
ge gap 
month 
-0.027 0.005 0.001 -0.010 0.003 0.004 -0.009 0.004 0.017 
DiD 
(Plan 
type* 
time 
interact
ion) 
-0.030 0.027 0.256 0.024 0.045 0.584 0.014 0.061 0.716 
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Table 60: SSRI: Difference-in-difference analysis: Full versus generic coverage plan 
  
 
 
 
 
 
 
 
 
Parame
ter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
n 408   219   219   
Gender 0.019 0.026 0.453 -0.009 0.015 0.565 -0.011 0.016 0.495 
MTM 0.063 0.037 0.089 0.015 0.022 0.494 -0.011 0.022 0.615 
HMO 0.011 0.030 0.707 -0.008 0.017 0.653 0.008 0.018 0.639 
Plan 
type  
0.074 0.046 0.110 0.116 0.106 0.275 0.022 0.023 0.341 
Time 0.144 0.016 0.001 -0.138 0.053 0.009 -0.025 0.014 0.064 
Age 0.001 0.001 0.742 -0.001 0.001 0.289 0.001 0.001 0.606 
Risk -0.001 0.002 0.528 0.001 0.001 0.984 0.001 0.001 0.803 
Income 0.000 0.000 0.001 0.000 0.000 0.001 0.001 0.000 0.001 
Covera
ge gap 
month 
-0.024 0.005 0.001 -0.009 0.003 0.005 -0.001 0.003 0.717 
DiD 
(Plan 
type* 
time 
interact
ion) 
-0.046 0.034 0.170 -0.109 0.105 0.301 -0.008 0.027 0.771 
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Thyroid Hormones 
Thyroid Hormones: Difference-in-Difference analysis - Full versus no coverage 
plans 
Table 61 compares pre- and post-medication adherence to thyroid hormones for 
beneficiaries enrolled in full coverage versus no coverage plans. No significant 
differences were found in medication adherence of beneficiaries in the full coverage 
plans compared to beneficiaries in the no coverage plan irrespective of whether 
adherence was measured using the PDC, updated MPR or MPR traditional methods.  
 
Thyroid Hormones: Difference-in-Difference analysis - Generic versus no coverage 
plans 
Table 62 compares pre- and post-medication adherence to thyroid hormone for 
beneficiaries enrolled in generic coverage versus no coverage plans. No significant 
differences were found in medication adherence of beneficiaries in the generic coverage 
plans compared to beneficiaries in the no coverage plan irrespective of whether 
adherence was measured using the PDC, updated MPR or MPR traditional methods.  
 
Thyroid Hormones: Difference-in-Difference analysis - Full versus generic coverage 
Table 63 compares pre- and post-medication adherence to thyroid hormones for 
beneficiaries enrolled in full coverage versus generic coverage plans. No significant 
differences were found in medication adherence of beneficiaries in the generic coverage 
plans compared to beneficiaries in the full coverage plan irrespective of whether 
adherence was measured using the PDC, updated MPR or MPR traditional methods. 
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Table 61: Thyroid Hormones: Difference-in-difference analysis: Full versus No 
Coverage 
 
 
Para
meter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
N 299   237   237   
Gend
er 
-0.044 0.018 0.019 -0.013 0.014 0.325 0.008 0.021 0.710 
MT
M 
0.001 0.032 0.973 -0.009 0.022 0.696 0.043 0.034 0.216 
HMO 0.012 0.018 0.501 0.001 0.013 0.953 0.053 0.021 0.011 
Plan 
type  
0.040 0.031 0.194 0.010 0.165 0.954 0.046 0.024 0.055 
Time 0.061 0.016 0.001 -0.312 0.105 0.003 0.011 0.018 0.526 
Age 0.003 0.001 0.004 0.002 0.001 0.017 0.002 0.001 0.078 
Risk -0.002 0.002 0.241 -0.002 0.001 0.097 -0.002 0.002 0.326 
Inco
me 
0.001 0.001 .001 0.001 0.001 .001 0.001 0.001 .001 
Cove
rage 
gap 
mont
h 
-0.004 0.003 0.235 -0.003 0.003 0.234 -0.008 0.004 0.055 
DiD 
(Plan 
type* 
time 
inter
actio
n) 
-0.014 0.026 0.580 0.018 0.164 0.912 -0.025 0.028 0.377 
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Table 62: Thyroid: Difference-in-difference analysis: Generic versus no coverage 
plan 
 
 
 
 
 
 
  
 
Parame
ter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
N 550   397   397   
Gender 0.003 0.017 0.839 -0.003 0.014 0.812 0.015 0.021 0.479 
MTM -0.012 0.023 0.595 -0.012 0.016 0.475 0.010 0.025 0.671 
HMO 0.010 0.020 0.621 0.001 0.016 0.929 0.041 0.023 0.083 
Plan 
type  
-0.040 0.026 0.120 0.071 0.153 0.642 0.044 0.021 0.032 
Time 0.061 0.018 0.001 -0.312 0.122 0.011 0.011 0.018 0.529 
Age 0.001 0.001 0.200 0.001 0.001 0.247 -0.001 0.001 0.455 
Risk 0.001 0.001 0.814 0.001 0.001 0.675 0.001 0.001 0.730 
Income 0.001 0.001 0.001 0.000 0.001 .001 0.001 0.001 .001 
Covera
ge gap 
month 
-0.003 0.003 0.317 -0.003 0.003 0.339 0.005 0.004 0.207 
DiD 
(Plan 
type* 
time 
interact
ion) 
0.019 0.022 0.388 -0.082 0.151 0.586 -0.043 0.022 0.058 
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Table 63: Thyroid: Difference-in-difference analysis: Full versus generic coverage 
plan 
  
 
 
 
 
 
 
Parame
ter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
N 477   356   356   
Gender -0.003 0.018 0.849 0.001 0.013 0.997 -0.005 0.021 0.815 
MTM 0.001 0.024 0.979 0.008 0.016 0.630 0.044 0.025 0.076 
HMO 0.008 0.020 0.693 -0.003 0.014 0.827 0.013 0.022 0.569 
Plan 
type  
0.072 0.032 0.027 -0.068 0.168 0.686 0.008 0.025 0.743 
Time 0.080 0.013 0.001 -0.394 0.087 0.001 -0.031 0.014 0.024 
Age 0.001 0.001 0.660 0.001 0.001 0.918 -0.002 0.001 0.050 
Risk 0.001 0.001 0.946 0.001 0.001 0.612 0.001 0.001 0.992 
Income 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 .001 
Covera
ge gap 
month 
-0.006 0.003 0.060 -0.004 0.003 0.110 -0.005 0.004 0.185 
DiD 
(Plan 
type* 
time 
interact
ion) 
-0.033 0.026 0.197 0.100 0.167 0.547 0.891 0.034 0.364 
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PPI 
PPI: Difference-in-Difference analysis - Full versus no coverage plans 
Table 64 compares pre- and post-medication adherence to PPI for beneficiaries enrolled 
in full coverage versus no coverage plans. The impact of the coverage gap on medication 
adherence varied depending on the method used to measure medication adherence. When 
medication adherence was measured using the PDC method, medication adherence of 
beneficiaries in the no coverage gap compared to beneficiaries in the full coverage plan 
decreased significantly by 0.181 (18.1%, p≤0.017) after hitting the coverage gap. 
However, when measured using the updated MPR and MPR traditional methods, there 
was no significant difference in pre- and post medication adherence for beneficiaries in 
the no coverage plan compared to beneficiaries in the full coverage plan. 
 
PPI: Difference-in-Difference analysis - Generic versus no coverage plans 
Table 65 compares pre- and post-medication adherence to PPI for beneficiaries enrolled 
in generic coverage versus no coverage plans. No significant differences were found in 
medication adherence of beneficiaries in the generic coverage plans compared to 
beneficiaries in the no coverage plan irrespective of whether adherence was measured 
using the PDC, updated MPR or MPR traditional methods.  
 
PPI: Difference-in-Difference analysis - Full versus generic coverage plans 
Table 66 compares pre- and post-medication adherence to PPI for beneficiaries enrolled 
in full coverage versus generic coverage plans. No significant differences were found in 
medication adherence of beneficiaries in the generic coverage plans compared to 
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beneficiaries in the full coverage plan irrespective of whether adherence was measured 
using the PDC, updated MPR or MPR traditional methods.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
208 
 
Table 64: PPI: Difference-in-difference analysis: Full versus no coverage plan 
 
 
 
 
 
 
 
 
 
Parame
ter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
N 273   161   161   
Gender 0.001 0.032 0.998 -0.006 0.022 0.796 -0.013 0.023 0.582 
MTM 0.072 0.067 0.282 0.072 0.038 0.059 0.035 0.041 0.384 
HMO 0.003 0.034 0.926 0.015 0.023 0.525 0.040 0.025 0.101 
Plan 
type  
0.267 0.047   0.001 0.108 0.062 0.083 0.044 0.032 0.164 
Time 0.251 0.026    0.001 -0.089 0.049 0.073 -0.019 0.031 0.544 
Age 0.001 0.002 0.710 -0.002 0.001 0.224 -0.002 0.001 0.272 
Risk -0.008 0.003 0.006 -0.006 0.002 0.008 -0.005 0.002 0.051 
Income 0.000 0.000 0.177 0.000 0.000    0.001 0.000 0.000 0.258 
Covera
ge gap 
month 
-0.026 0.007 0.000 -0.007 0.005 0.141 -0.005 0.005 0.307 
DiD 
(Plan 
type* 
time 
interact
ion) 
-0.181 
 
0.037 
 
0.001* 
 
-0.094 
 
0.062 
 
0.131 
 
0.008 
 
0.039
 
0.831 
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Table 65: PPI: Difference-in-difference analysis: Generic versus no coverage plan 
 
 
 
 
 
 
 
Param
eter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estima
te 
SE P-
value 
Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
n 403   185   185   
Gende
r 
0.008 0.030 0.786 0.001 0.023 0.949 0.010 0.022 0.645 
MTM -0.046 0.048 0.335 -0.033 0.031 0.281 -0.040 0.030 0.177 
HMO -0.029 0.037 0.443 0.040 0.029 0.174 0.031 0.028 0.274 
Plan 
type  
0.011 0.045 0.798 0.015 0.050 0.757 0.011 0.029 0.711 
Time 0.251 0.030 0.001* -0.089 0.042 0.036 -0.019 0.034 0.578 
Age 0.001 0.001 0.844 0.000 0.001 0.937 0.001 0.001 0.256 
Risk -0.004 0.002 0.103 -0.004 0.002 0.056 -0.002 0.002 0.366 
Incom
e 
0.001 0.001 0.192 0.001 0.001 0.001 0.001 0.001 .001* 
Cover
age 
gap 
month 
-0.022 0.007 0.001* -0.005 0.006 0.412 0.010 0.005 0.072 
DiD 
(Plan 
type* 
time 
intera
ction) 
-0.017 0.038 0.642 -0.019 0.051 0.705 0.009 0.042 0.826 
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Table 66: PPI: Difference-in-difference analysis: Full versus generic coverage plan 
  
 
 
 
Param
eter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
n 392   228   228   
Gende
r 
0.027 0.028 0.333 0.032 0.018 0.075 0.034 0.021 0.097 
MTM -0.019 0.045 0.673 -0.010 0.026 0.695 -0.029 0.031 0.345 
HMO -0.003 0.032 0.936 0.011 0.019 0.567 0.025 0.023 0.278 
Plan 
type  
0.263 0.044    
0.001 
0.095 0.050 0.058 0.042 0.027 0.122 
Time 0.233 0.020    
0.001 
-0.109 0.033 0.001 -0.010 0.023 0.661 
Age 0.001 0.001 0.898 0.000 0.001 0.797 0.001 0.001 0.303 
Risk -0.004 0.002 0.121 -0.006 0.002 0.001 -0.004 0.002 0.045 
Incom
e 
0.000 0.000 0.497 0.000 0.000    
0.001 
0.000 0.000 0.001 
Cover
age 
gap 
month 
-0.018 0.006 0.001 -0.010 0.004 0.010 -0.002 0.004 0.599 
DiD 
(Plan 
type* 
time 
intera
ction) 
-0.074 0.035 0.189 
 
 
 
-0.075 0.049 0.126 0.000 0.034 0.990 
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CCI 
CCI: Difference-in-Difference analysis - Full versus no coverage plans 
Table 67 compares pre- and post-medication adherence to CCI for beneficiaries enrolled 
in full coverage versus no coverage plans. No significant differences were found in 
medication adherence of beneficiaries in the generic coverage plans compared to 
beneficiaries in the no coverage plan irrespective of whether adherence was measured 
using the PDC, updated MPR or MPR traditional methods.  
 
CCI: Difference-in-Difference analysis - Generic versus no coverage plans 
Table 687 compares pre- and post-medication adherence to CCI for beneficiaries enrolled 
in generic coverage versus no coverage plans. No significant differences were found in 
medication adherence of beneficiaries in the generic coverage plans compared to 
beneficiaries in the no coverage plan irrespective of whether adherence was measured 
using the PDC, updated MPR or MPR traditional methods.  
 
CCI: Difference-in-Difference analysis - Full versus generic coverage 
Table 69 compares pre- and post-medication adherence to CCI for beneficiaries enrolled 
in full coverage versus generic coverage plans. No significant differences were found in 
medication adherence of beneficiaries in the generic coverage plans compared to 
beneficiaries in the no coverage plan irrespective of whether adherence was measured 
using the PDC, updated MPR or MPR traditional methods.  
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Table 67: CCI: Difference-in-difference analysis: Full versus no coverage plan 
 
 
 
 
 
 
 
 
 
Parame
ter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
n 295   211   211   
Gender 0.011 0.022 0.612 -0.004 0.013 0.785 0.013 0.017 0.449 
MTM -0.063 0.043 0.149 -0.022 0.022 0.320 0.026 0.029 0.366 
HMO 0.009 0.024 0.722 0.006 0.014 0.670 0.009 0.018 0.629 
Plan 
type  
0.082 0.041 0.044* -0.017 0.051 0.742 -0.016 0.020 0.433 
Time 0.106 0.018 0.001* -0.153 0.030 0.001* -0.027 0.014 0.064 
Age 0.001 0.001 0.641 0.000 0.001 0.644 0.000 0.001 0.971 
Risk 0.001 0.002 0.489 -0.001 0.001 0.333 0.000 0.002 0.885 
Income 0.000 0.000 .001* 0.001 0.001 0.001* 0.000 0.000 .001* 
Covera
ge gap 
month 
-0.009 0.005 0.057 -0.002 0.003 0.578 -0.002 0.004 0.688 
DiD 
(Plan 
type* 
time 
interact
ion) 
-0.048 0.030 0.108 0.031 0.049 0.536 0.001 0.024 0.988 
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Table 68: CCI: Difference-in-difference analysis: Generic versus no coverage plan 
 
 
 
 
 
 
 
 
Parame
ter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estim
ate 
SE P-value
n 553   406   406   
Gender 0.027 0.020 0.177 -0.004 0.011 0.684 -0.004 0.013 0.785 
MTM -0.001 0.028 0.973 0.006 0.014 0.680 -0.022 0.022 0.320 
HMO -0.012 0.025 0.628 -0.006 0.013 0.665 0.006 0.014 0.670 
Plan 
type  
0.000 0.031 0.997 -0.012 0.039 0.757 -0.017 0.051 0.742 
Time 0.106 0.018 0.001 -0.153 0.031 0.001 -0.153 0.030 0.001* 
Age 0.000 0.001 0.775 0.001 0.001 0.984 0.000 0.001 0.644 
Risk -0.005 0.001 0.000 -0.003 0.001 0.001 -0.001 0.001 0.333 
Income 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001* 
Covera
ge gap 
month 
-0.021 0.004 0.001 -0.006 0.002 0.020 -0.002 0.003 0.578 
DiD 
(Plan 
type* 
time 
interact
ion) 
-0.023 0.023 0.308 0.016 0.038 0.676 0.010 0.001 0.894 
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Table 69: CCI: Difference-in-difference analysis: Full versus generic coverage plan 
  
 
 
 
 
 
Parame
ter 
PDC 
 
MPR Updated MPR Traditional 
 
 Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
Estim
ate 
SE P-
value 
n 474   346   346   
Gender 0.012 0.021 0.582 -0.015 0.011 0.190 -0.006 0.015 0.681 
MTM 0.002 0.032 0.943 0.009 0.016 0.580 0.023 0.022 0.286 
HMO -0.008 0.025 0.764 0.006 0.014 0.668 -0.004 0.018 0.819 
Plan 
type  
0.060 0.038 0.109 -0.009 0.047 0.850 -0.001 0.022 0.973 
Time 0.083 0.013 0.001 -0.137 0.021 0.001 -0.014 0.012 0.256 
Age 0.000 0.001 0.921 0.000 0.001 0.874 -0.001 0.001 0.484 
Risk -0.006 0.001 0.001 -0.002 0.001 0.019 0.001 0.001 0.903 
Income 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 .001 
Covera
ge gap 
month 
-0.017 0.004 0.001 -0.005 0.003 0.045 -0.001 0.003 0.828 
DiD 
(Plan 
type* 
time 
interact
ion) 
-0.025 0.027 0.360 0.015 0.046 0.743 -0.013 0.026 0.612 
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Medical Costs incurred by beneficiaries who hit the coverage gap 
XYZ health care services provided data on medical costs associated with Medicare Part 
A and B services for beneficiaries who hit the coverage gap. Medical costs refer to the 
costs that were associated with medical claims (all claims except for pharmacy claims) 
and paid by XYZ healthcare services for the beneficiary.  
Figure 7 compares differences in medical costs between beneficiaries enrolled in 
a Medicare Part D plan but did not reach the coverage gap with beneficiaries who 
reached the coverage gap. As is evident in the graph, medical costs incurred by 
beneficiaries who hit the coverage gap were nearly double the costs incurred by 
beneficiaries who did not hit the coverage gap. This trend was observed across all 12 
months. 
Figure 6 Comparison of per member per month medical costs for beneficiaries who 
did not hit the coverage gap with beneficiaries who hit the coverage gap by month 
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Figure 8 compares the difference in per member per month (PMPM) medical 
costs incurred pre- and post-coverage gap for beneficiaries who hit the coverage gap in 
2007.  The graph indicates that the after hitting the coverage gap there was considerable 
increase in the per member per month total medical costs compared to their costs before 
hitting the coverage gap. The costs difference pre- and post-coverage gap was observed 
to be higher during the first 6 months of the year relative to the last 6 months of the year. 
Figure 7 Comparison of per member per month medical costs Pre- and Post-
Coverage gap for each month 
 
 
 
XYZ healthcare services reported that of all the beneficiaries who hit the coverage 
gap, for nearly quarter of beneficiaries (633 beneficiaries), higher costs were incurred 
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during the post- coverage gap compared to costs spent on these beneficiaries before they 
hit the coverage gap. The PMPMs for 633 beneficiaries in specific utilization categories 
(emergency room visits, inpatient hospitalizations, outpatient hospitalizations, and other 
(all costs not included in the previous 3 categories) is reported in figure 9. The largest 
difference in costs pre- and post- coverage gap was observed for inpatient costs and the 
least difference was observed for emergency room visits.  
 
Figure 8 Comparison of per member per month medical costs Pre- and Post-
Coverage gap by specific categories 
 
 
SUMMARY 
 
Nearly seventeen percent or 2,494 beneficiaries remained in the coverage gap and less 
than 1% or 117 beneficiaries reached the catastrophic coverage limit in the year 2007. 
Beneficiaries in the no coverage gap plan filled significantly less number of prescriptions 
than beneficiaries in the full or generic coverage plans after hitting the coverage gap. A 
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comparison of medication adherence of beneficiaries in the full coverage versus no 
coverage plans, indicated a decrease in post-coverage gap medication adherence for 
beneficiaries taking statins, ARB’s and PPI’s when measured using the PDC as a measure 
of adherence.  A comparison of medication adherence of beneficiaries in the generic 
coverage versus no coverage plans indicated a decrease in post-coverage gap medication 
adherence for beneficiaries taking statins and ARB’s, when measured using the PDC as a 
measure of adherence. No significant post-coverage gap differences were observed 
between beneficiaries enrolled in the full coverage plan and generic coverage plan for 
any of the drug classes. 
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CHAPTER 5 
DISCUSSION 
 
This chapter presents a discussion of the study results and recommendations for future 
research. The chapter begins with a discussion of results with respect to each of the 
research objectives and other important findings in the study. Following the discussion of 
the results, the limitations of the research design and recommendations for future 
research are presented. Finally, strengths of this study, significant findings and 
implications from this study are presented. 
 
Discussion of study results 
Medicare Part D coverage gap 
Nearly eighteen percent of beneficiaries, enrolled in an MA-PD plan offered by 
XYZ services who met the study inclusion and exclusion criteria, hit the coverage gap in 
the year 2007. Nearly seventeen percent or 2,494 beneficiaries remained in the coverage 
gap and less than 1% or 117 beneficiaries reached the catastrophic coverage limit in the 
year 2007. A study conducted by the Kaiser Family Foundation reported similar results.  
The study estimates indicated that 14% of Part D enrollees (3.4 million Medicare 
beneficiaries) reached the coverage gap in 2007. (Hoadley J, et al., 2007). Results from a 
study conducted by Zhang and colleagues (2009) indicated that 5 percent of Medicare 
beneficiaries in the study reached the catastrophic coverage level.(Zhang, et al., 2009) 
Nearly 90% of beneficiaries hit the coverage gap in the last 6 months of the year 
with about one fifth (21.22%) of the beneficiaries hitting the coverage gap in the months 
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of June and July, 2007. With less than one percent of all beneficiaries who hit the 
coverage gap being covered under catastrophic coverage limit, this translates to nearly 
ninety percent of Medicare beneficiaries who hit the coverage gap, having no prescription 
drug coverage for about 5 or 6 months. The 2010 health care reform legislation, includes 
a clause on reduction of the out-of-pocket amount that qualifies for Part D catastrophic 
coverage beginning 2014 through 2019.(Kaiser Family Foundation, 2010b)  With only 
1% beneficiaries in this study and 5% from the study conducted by Zang and colleagues 
(2009) hitting the catastrophic coverage results, these results bring to light the 
significance of reduction in catastrophic coverage limits.(Zhang, et al., 2009) However, 
in lieu of a phased reduction in the catastrophic coverage limits beginning only in 2014 
and spread out over a period of 5 years proposed under the current health care reform 
legislation, a more immediate reduction in the catastrophic coverage limit may be more 
advantageous to Medicare beneficiaries. 
Of the beneficiaries who hit the coverage gap, nearly one third (31.72%) were 
enrolled in a plan which offered no prescription drug coverage during the coverage gap, 
nearly half were enrolled in a plan which covered generic drugs during the coverage gap 
and the remaining 17% were enrolled in a plan which covered both brand name and 
generic drugs during the coverage gap. Similar results were reported by Zhang et al 
(2009), with about 25 percent of beneficiaries enrolled in a plan without prescription drug 
coverage during the coverage gap hit the coverage gap.(Zhang, et al., 2009) The results 
from this study indicate that nearly a third of Medicare beneficiaries who hit the coverage 
gap did not have any prescription drug coverage during 2007. 
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 The 2010 health care reform does address increased coverage during the 
Medicare Part D coverage gap. Under the proposed Medicare reform legislation, the 
coverage gap will be phased from 100% coverage gap in 2010 to 25% coverage gap by 
2020. Specifically, the legislation indicates that in 2010, Part D enrollees with any 
spending in the coverage gap will receive a $250 rebate. (Kaiser Family Foundation, 
2010b)  Medicare coverage discount programs will be initiated in 2011, with 
pharmaceutical manufacturers providing a 50 percent discount on brand-name drugs to 
Part D enrollees with spending in the coverage gap. A reduction in coinsurance for 
generic drugs in the coverage gap is slated beginning in 2011, and a reduction in 
coinsurance for brand-name drugs in the gap is slated beginning in 2013. The  beneficiary 
coinsurance rate for both brands and generics are slated to reduce from 100 percent in 
2010 to 25 percent in 2020, until enrollees qualify for catastrophic coverage.(Kaiser 
Family Foundation, 2010b) This translates into Medicare beneficiaries being responsible 
for 25% of their prescription drug costs in 2020 with higher percentages in the preceding 
decade. Therefore, even with the health care reform, Medicare beneficiaries are exposed 
to considerable amounts of cost-sharing over the next decade and beyond.  
As has been described at length in chapter 2, cost-sharing and lack of prescription 
drug coverage are associated with decreased prescription drug utilization. Decreased 
prescription drug utilization in Medicare beneficiaries has been associated with decreased 
adherence, increased hospitalizations, increased emergency department visits and higher 
out-of-pocket costs.(Chandra, et al., 2007; Chernew, et al., 2008; Hsu, et al., 2006; Joyce, 
et al., 2007; S. Soumerai, et al., 2006; Steinman, et al., 2001; Stuart & Grana, 1998; 
Tamblyn, et al., 2001a; Tseng, et al., 2004) 
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Demographics of beneficiaries who hit the coverage gap 
Medicare beneficiaries who hit the coverage gap were on average 73 years old, 
female, had high number of co-morbid conditions, and an annual income of 
approximately $40,000. It is important to note that for a group of individuals with about 
$40,000 in annual income, average true out-of-pocket (OOP) expenses of $1,075 for 
prescription drugs alone might place considerable financial burden and may potentially 
lead to decreased utilization of prescription drugs. In essence, beneficiaries who hit the 
coverage gap in this study had poorer health, low income, and high out-of-pocket costs.  
In addition to OOP expenses associated with prescription drugs, Medicare beneficiaries 
may also bear expenses for other health care needs such as hospitalizations, Medicare 
Part A and B premiums, etc. Medicare beneficiaries with high out-of-pocket expenses are 
less likely to fill prescription drugs.(S. Soumerai, et al., 2006; Steinman, et al., 2001) As 
indicated above, decreased prescription drug utilization is associated with adverse clinical 
and economic outcomes and as health care reform is underway in the United States, it is 
important to consider these characteristics. (Chandra, et al., 2007; Chernew, et al., 2008; 
Hsu, et al., 2006; Joyce, et al., 2007; S. Soumerai, et al., 2006; Steinman, et al., 2001; 
Stuart & Grana, 1998; Tamblyn, et al., 2001a; Tseng, et al., 2004)  
 
Pre- and Post-coverage gap prescription drug utilization in a sample of New Mexico 
Medicare beneficiaries 
The first objective of the study was to compare prescription drug utilization of a 
sample of New Mexico Medicare beneficiaries enrolled in a Medicare Part D plan with 
full prescription drug coverage during the coverage gap with prescription drug utilization 
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of Medicare beneficiaries enrolled in a plan providing no gap coverage. The results of 
this study indicate that beneficiaries enrolled in a health plan which does not cover 
prescription drugs during the coverage gap, fill significantly fewer prescriptions (15 
prescriptions) than beneficiaries who have prescription drug coverage during the 
coverage gap.  A decrease in prescription drug utilization, (15.85% decrease in average 
days of therapy) after beneficiaries hit the coverage gap, was reported by Sun and 
Lee.(Sun & Lee, 2007)  Zhang, et al, also reported that prescription drug utilization of 
beneficiaries with no prescription drug coverage during the coverage gap was 14% lower 
compared to utilization of beneficiaries with full prescription drug coverage during the 
gap. (Zhang, et al., 2009) 
Decreased prescription drug utilization has been associated with adverse clinical 
and economic events. With the limitation that only one year of data was available and 
data on the exact date a beneficiary hit the coverage gap was not available, the results 
from this study describe a very clear trend of increased medical costs borne by XYZ 
health care services for beneficiaries who hit the coverage gap. The results of this study 
found that medical costs incurred by beneficiaries who hit the coverage gap were nearly 
double the costs incurred by beneficiaries who did not hit the coverage gap. This trend 
was observed across all 12 months. Further, higher costs were incurred in the post- 
coverage gap period compared to costs spent on these beneficiaries before they hit the 
coverage gap. Additionally, the largest difference in costs pre- and post- coverage gap 
was observed for inpatient costs and the smallest difference was observed for emergency 
room visits.  From an economic stand point, the costs associated with increased 
hospitalizations and emergency room visits, as a result of lower utilization of prescription 
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drugs are also paid by Medicare and at higher amount than it would typically cost to 
include coverage of prescription drugs. This basic principle is important to highlight 
when arguments against provision of prescription drugs during the coverage gap are 
made.  
The second objective of the study was to compare prescription drug utilization of 
a sample of New Mexico Medicare beneficiaries enrolled in a Medicare Part D plan 
covering generic drugs during the coverage gap with prescription drug utilization of 
Medicare beneficiaries enrolled in a plan providing no gap coverage. The results of this 
study indicate that beneficiaries enrolled in a health plan which does not cover 
prescription drugs during the coverage gap, fill significantly fewer prescriptions (13 
prescriptions) than beneficiaries who have generic drug coverage during the coverage 
gap. A review of the literature indicated that studies comparing prescription drug 
utilization between plans covering generic drugs during the coverage gap and plans 
providing no prescription drug coverage during the coverage gap have not been reported. 
However, one study reported that a prescription drug benefit with no caps on utilization 
of generic drugs was associated with a reduction in prescription costs and no increases in 
nonprescription-related healthcare service utilization. (R Balkrishnan, et al., 2001) 
The third objective of the study was to compare prescription drug utilization of a 
sample of New Mexico Medicare beneficiaries enrolled in a Medicare Part D plan with 
full prescription drug coverage during the coverage gap with prescription drug utilization 
of Medicare beneficiaries enrolled in a plan covering generic drugs during the coverage 
gap. No difference in prescription drug utilization, after hitting the coverage gap, was 
found when beneficiaries in the full coverage plan were compared with beneficiaries in 
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the generic coverage plan. These results bring forth a very important consideration from a 
health policy perspective. The results of this study indicate that prescription drug 
utilization of beneficiaries enrolled in a plan covering generic prescription drugs during 
the coverage gap are comparable to the prescription drug utilization of beneficiaries 
enrolled in a plan covering all prescription drugs. Given that generic drugs are 
considerably cheaper compared to brand name prescription drugs, inclusion of generic 
drugs in the coverage gap may prevent the adverse clinical and economic outcomes due 
to lack of prescription drug coverage without placing considerable economic burden on 
Medicare.  
The 2010 health care reform legislation includes a reduction in coinsurance for 
generic drugs in the coverage gap beginning in 2011and a reduction in coinsurance for 
brand-name drugs in the gap is slated beginning in 2013. The beneficiary coinsurance 
rate for both brands and generics are slated to reduce from 100 percent in 2010 to 25 
percent in 2020. The results of this study indicate that prescription drug utilization of 
beneficiaries enrolled in a plan covering generic prescription drugs during the coverage 
gap are comparable to that of beneficiaries enrolled in a plan covering all prescription 
drugs. Therefore, in lieu of brand name coverage during the coverage gap, a more 
pragmatic option from an economic standpoint might be 100% inclusion of generic drugs 
during the coverage gap beginning immediately instead of a phased decrease in co-
insurance of brand name prescription drugs. Research could be conducted to compare 
cost-savings introduced by providing no coverage of brand name prescription drugs and 
the cost borne by the provision of 100% generic drug coverage during the coverage gap.  
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Pre- and Post-coverage gap medication adherence in a sample of New Mexico 
Medicare beneficiaries 
 The fourth objective of the study was to compare medication adherence to ten 
select drug classes, of a sample of New Mexico Medicare beneficiaries, enrolled in a 
Medicare Part D plan with full prescription drug coverage during the coverage gap with 
medication adherence of Medicare beneficiaries enrolled in a plan providing no gap 
coverage.  A comparison of medication adherence of beneficiaries in the full coverage 
versus no coverage plans, indicated a decrease in post-coverage gap medication 
adherence for beneficiaries on statins, ARB’s and PPI’s when measured using the PDC as 
a measure of adherence. Post-coverage gap, for beneficiaries in the no coverage plan, 
adherence to statins decreased significantly by 5.8%, adherence to ARB’s decreased 
significantly by 16%, and adherence to PPI’s decreased significantly by 18.1%. Although 
not significant, decreased medication adherence was observed for ACEI, SSRI’s, beta-
blockers, biguanides, diuretics, thyroid hormones and CCI.  
A study conducted by Raebel, et. al (2008) also reported significant reduction in 
adherence to anti-hyperlipidemics, anti-hypertensives, anti-depressants and diuretics. 
(Raebel, et al., 2008) Another study conducted by the Kaiser Family Foundation (2008) 
reported that  20% beneficiaries on PPIs, 15% on anti-depressants, 18% on osteoporosis 
medications, 16% on ACEI, 14% on ARB’s, 13% on statins, 8% on Alzheimer’s 
medications and 10% on oral anti-diabetics stopped taking medications after hitting the 
coverage gap. (Hoadley J, et al., 2007) However, it is important to note that both these 
studies are descriptive in nature and methodologically limited due to lack of control of 
confounding factors. The results reported based on this study, however, are based on a 
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quasi-experimental, cross-sectional, retrospective, pre-post with control group study 
design.  
Improvements in clinical outcomes have been reported for various disease states 
with improved medication adherence. Reports indicate a significant decrease in 
depression severity (for patients with major depression) with a 20-25% improvement in 
adherence to antidepressants (W. Katon et al., 1996; Wayne Katon et al., 2001; W. Katon 
et al., 1995; Peveler, George, Kinmonth, Campbell, & Thompson, 1999); significant 
improvements in HbA1c levels have been observed with a 10% increase in adherence to 
anti-diabetic medications (Pladevall et al., 2004); significant improvements in LDL 
cholesterol levels have been observed with a 10-30% increase in adherence to cholesterol 
lowering medications (Lee, Grace, & Taylor, 2006; Pladevall, et al., 2004); and 
significant improvements in blood pressure control have been observed with a 8-30% 
increase in adherence to antihypertensives. (Lee, et al., 2006; Schroeder, Fahey, & 
Ebrahim, 2004) Based on this literature review, the decreased adherence even at the low 
values observed in this study, may result in adverse clinical outcomes such as increased 
hospitalizations, emergency visits and increased costs. (Chandra, et al., 2007; Chernew, 
et al., 2008; Hsu, et al., 2006; Joyce, et al., 2007; S. Soumerai, et al., 2006; Steinman, et 
al., 2001; Stuart & Grana, 1998; Tamblyn, et al., 2001a; Tseng, et al., 2004)  
In 2007, a study conducted by Dana Goldman and colleagues examined the 
relationship between copayments for cholesterol-lowering drugs and compliance in the 
year after initiation of therapy and the association between compliance and subsequent 
hospital and emergency department (ED) use for up to four years after initiation, using 
claims data from eighty-eight health plans during 1997-2001.(Goldman, et al., 2007) 
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Results of the study indicated significant adverse impact of copayments on compliance in 
all risk groups with each $10 rise in copayments associated with a decrease of five 
percentage points in average compliance in a plan-year. The authors estimated that for 
high- and medium-risk patients', reducing copayments on cholesterol-lowering 
medications from $10 to $0, pharmacy payments would have increased by $486 million, 
but inpatient hospital spending would have declined by $839 million. Further, spending 
on ED visits would also have declined. 
The results of this study indicated significant decrease in adherence for statins, 
ARB’s and PPI’s for beneficiaries enrolled in the no coverage plans. It is important to 
consider the potential clinical and economic adverse impacts with decreased adherence, 
particularly of essential medications such as statins, ARB’s, and PPI’s. Further, decreased 
medication adherence to essential medications is of considerable concern in the Medicare 
population as the Medicare population typically includes older patients with high number 
of co-morbid conditions, low income and high OOP expenses.  It is thus important to 
weigh the cost of inclusion of prescription drugs during the coverage gap with the 
potential costs and impacts on health due to clinical adverse events associated with 
reduced medication adherence of essential medications.  
The fifth objective of the study was to compare medication adherence to select 
drug classes, of a sample of New Mexico Medicare beneficiaries, enrolled in a Medicare 
Part D plan covering generic drugs during the coverage gap with medication adherence of 
Medicare beneficiaries enrolled in a plan providing no gap coverage. A comparison of 
medication adherence of beneficiaries in the generic coverage versus no coverage plans 
indicated a decrease in post-coverage gap medication adherence for beneficiaries taking 
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statins and ARB’s, when measured using the PDC as a measure of adherence. Post-
coverage gap, for beneficiaries in the no coverage plan, adherence to statins decreased 
significantly by 1.1% and adherence to ARB’s decreased by 12.1%. A review of the 
literature indicated that studies comparing adherence to medications between plans 
covering generic drugs during the coverage gap and plans providing no prescription drug 
during the coverage gap have not been reported. Given that inclusion of generic drugs 
during the coverage gap results in greater medication adherence compared to no 
prescription drug coverage during the coverage gap, and generic drugs are cheaper than 
brand name drugs, as stated earlier, it is important to consider provision of generic drugs 
during the coverage gap.  
The sixth objective of the study was to compare medication adherence to ten 
select drug classes, of a sample of New Mexico Medicare beneficiaries enrolled in a 
Medicare Part D plan with full prescription drug coverage during the coverage gap with 
medication adherence of Medicare beneficiaries enrolled in a plan covering generic drugs 
during the coverage gap. No significant post-coverage gap differences were observed 
between beneficiaries enrolled in the full coverage plan and generic coverage plan for 
any of the drug classes. A review of the literature indicated that studies comparing 
adherence to medications between plans covering generic drugs during the coverage gap 
and plans providing full prescription drug coverage during the coverage gap have not 
been reported, thus precluding comparisons to other studies.  Based on these results, with 
no differences between adherence with generic or full prescription drug coverage during 
the coverage gap, as was described earlier, inclusion of generic drugs during the coverage 
gap may alleviate not only the clinical adverse outcomes but also the economic adverse 
230 
 
outcomes. 
In addition to assessing the impact of the Medicare Part D coverage gap on 
prescription drug utilization and medication adherence, this research brought forth 
important findings. Based on the difference-in-difference analyses, it was observed that  
when comparing beneficiaries enrolled in the generic coverage plan with beneficiaries 
enrolled in the no coverage plan and full coverage plans, beneficiaries who did not 
receive MTM services had lower prescription drug utilization than beneficiaries who 
received MTM services.  XYZ health care services provides MTM eligible members an 
invitation to schedule an appointment with a clinical pharmacist. The clinical pharmacist 
identifies opportunities for the member to lower average monthly pharmacy costs by 
suggesting strategies such as switching to generic, tablet splitting, more cost effective 
formulary alternatives, eliminating duplicate or unnecessary prescriptions, prescription to 
over-the-counter switches, etc. The clinical pharmacist also identifies medication related 
problems such as overdosage, underdosage, adverse drug reaction, untreated medical 
condition, failure to receive medication, drug interaction, drug use without an indication, 
etc. Based on the results of this study, the MTM services provided by a clinical 
pharmacist translate into improved prescription drug utilization. This represents an 
important finding and highlights the importance of MTM services provided by clinical 
pharmacists improving prescription drug utilization and thus clinical outcomes. 
Further, the results of the study also indicated that, irrespective of the health plan 
that beneficiaries were enrolled in, a beneficiary’s income and risk score were significant 
predictors of prescription drug utilization and medication adherence for a majority of the 
drug classes. The exclusion criteria of this study were set such that beneficiaries who 
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received low income subsidies were excluded from the analyses. Therefore, this study 
represents beneficiaries who did not qualify for any financial help and their low income 
resulted in decreased prescription drug utilization and medication adherence. Similarly, 
beneficiaries with high risk scores, that is, beneficiaries with high co-morbidities had 
reduced prescription drug utilization and medication adherence for a majority of the drug 
classes irrespective of the health plan they were enrolled in. As health care reform is 
underway, it is important to provide additional financial support and added prescription 
drug coverage to low income beneficiaries and beneficiaries with a higher number of co-
morbidities. 
Measures of medication adherence 
The results of this study bring forth an important methodological consideration. 
Significant differences in medication adherence were observed only when adherence was 
measured using the PDC and not when measured using the updated MPR and MPR 
traditional methods. The updated MPR and MPR traditional methods resulted in an over-
inflated adherence value. The algorithms used in this study were checked multiple times 
for accuracy. Further, as a validity check of the algorithms, the results on medication 
adherence calculations obtained by using the algorithms were cross checked with manual 
calculations for a few beneficiaries and consistent results provided evidence that 
calculation errors were unlikely. One explanation for inflated adherence value when 
measured using the MPR might be due to the fact that the MPR does not accurately 
account for oversupply of medications which result in higher values. Even when 
oversupply from one period is accounted for by transferring it to the next period, the 
results are inflated depending on the amount of oversupply that is carried forward from 
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one period to another. For the purposes of difference-in-difference analyses, outlying 
MPR values (>1.2, a cut-off commonly employed in the literature) were deleted from 
analyses. Despite this, the 20% excess MPR, potentially impacted the results.  One 
consideration, if an MPR is to be used for analyses, depending on the objective of the 
study, more accurate results might be obtained with truncating the MPR to value of 1. 
The PDC, on the other hand, does not need any adjustments as it measures adherence 
based on availability of medications on a per day basis and is a more robust measure of 
adherence. Similar concerns of over-inflated projection of adherence values when using 
MPR instead of the PDC as a measure of adherence have been reported in the literature. 
(Martin, et al., 2009)  
The results of this study bring to light the criticality and the importance of 
choosing an appropriate measure of adherence. An MPR has its advantage in its 
simplicity of calculation and widespread use. It is an appropriate measure of adherence 
when the objective of determining adherence is a very quick measure of a patient’s 
medication consumption behavior in clinical settings or for the purposes of patient 
counseling, etc. It is important to note however, that the traditional MPR formula does 
not allow for accounting of drug switches and over-supplies without modifications to the 
formula reported in the literature. As the formula used for traditional MPR calculations 
does not permit for carrying over medication from one period to another, it is not a 
suitable measure of adherence when comparing adherence in two periods of time. Drug 
switches, over-supply and carryover of medications from one time period to another can 
be accomplished by adjusting the formula as was done in this study. Adjustment of the 
formula does involve a fair amount of complexity to ensure accurate calculations, 
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especially when using large databases. Further, this adjustment brings forth the issue of 
very high MPR values at the end of the period which leads to statistical issues when using 
the MPR as a unit of analyses. It is important that researchers appropriately truncate the 
MPR when using it in additional analyses.  
Although significant complexity is associated with calculating the PDC, it 
provides an accurate measure of adherence as it assesses if a patient has medication for 
each day in the period being assessed and also carries forward excess medications from 
one period to another. Based on the results of this study, it is recommended that when the 
objective of measurement of adherence is assessing a policy impact as was done in this 
study it is important to use the more robust measure of adherence- the PDC.  Similar 
recommendations and concerns of over-inflated projection of adherence values when 
using MPR instead of the PDC as a measure of adherence have been reported in the 
literature. (Martin, et al., 2009) 
Limitations 
 The results of this study should be interpreted in the light of some limitations. 
This study uses a retrospective database, which limits inference of a cause-effect 
relationship. However, the use of a quasi-experimental research design comparing the 
study group with a control group and use of robust analytical techniques such as the 
difference-in-difference analysis which aid in assessing the impact of the effects of time 
and within subject variations while controlling for confounding factors provide 
confidence in interpretation of results. 
 Medication adherence in this study is calculated from a pharmacy claims 
database. Data from pharmacy claims only implies that prescriptions were filled but does 
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not confirm that medications were ingested by the patient. However, medication 
possession is the first and necessary step for consumption of medication and MPR has 
been widely used and validated as a measure of adherence. 
  Medication adherence is impacted by a number of factors such as patient 
characteristics, health care provider related characteristics, environmental barriers, 
education, socio-economic status, etc. The data available for this study did not provide 
for some of these variables which might impact adherence calculations and the results of 
the study should be interpreted in the light of this limitation. However, where possible, 
proxy measures have been used. For example, although information about health status 
was not available, co-morbidity scores were assessed and used as an indicator of a 
beneficiary’s health status. While income at an individual level was not available, zip 
code based income was used as an indicator of socio-economic status. Further 
demographic and health plan related factors were controlled for in this study. 
 There is a potential for selection bias in this study. It is possible that beneficiaries 
choose one health plan over another based on their anticipation of health care needs. For 
example, a sicker beneficiary might choose a plan which offers gap coverage compared 
to a healthier beneficiary.  Every effort was made to control for selection bias in this 
study by using statistical controls for confounding factors such as control for health plan 
type and co-morbidities.  
 As per the MMA, pharmacies are required to submit all claims for prescription 
drugs purchased by Medicare beneficiaries, as they contribute toward TrOOP costs, 
which determines their eligibility for catastrophic coverage. However, it is possible that 
some pharmacies may not submit claims for cash payments. It is also possible that some 
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beneficiaries may receive free samples from their physicians, receive financial assistance 
from pharmaceutical manufacturers or purchase prescription drugs on the Internet. It was 
not possible to account for medications which Medicare beneficiaries receive from these 
sources and should be considered when interpreting results of this study. 
 The results of this study are based on enrollees from one health plan in New 
Mexico. This limits the generalizability of the findings to other populations. However, 
the health plan data used for this study is one of the largest health plans in New Mexico 
and has broad coverage which might provide a representative sample for Medicare 
beneficiaries in New Mexico. Further, the population characteristics of Medicare 
beneficiaries in New Mexico are very similar to the characteristics of US Medicare 
beneficiaries. The results of this study may thus be generalizable to Medicare 
beneficiaries in other health plans in New Mexico and other parts of the country. 
Future research 
Upon data availability from the CMS, it is important to assess the impact of the coverage 
gap on prescription drug utilization and medication adherence on a national sample of 
Medicare beneficiaries.  Also upon data availability from the CMS, it would be 
interesting to compare the impact of the Part D coverage gap on beneficiaries enrolled in 
PDP plans with beneficiaries enrolled in MA-PD plans. Another important area of 
research is the assessment of the impact of the coverage gap on different ethnic groups. 
With three years of Medicare Part D data available, it would be interesting to observe the 
patterns of utilization and medication adherence of beneficiaries who hit the coverage gap 
from one calendar year to another.    
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Strengths of this study 
Few studies have assessed the impact of the Medicare Part D coverage gap. Further, the 
studies conducted to date lack adequate methodological robustness. The results of this 
study however, are based on a quasi-experimental, cross-sectional, retrospective, pre-post 
with control group study design. This study design controls for demographic and health 
plan characteristics, and more importantly controls for the effect of time and within 
person variations while comparing with a control group by using robust statistical 
methods. To the best of our knowledge this study is the first methodologically robust 
study to assess the impact of the coverage gap on prescription drug utilization and 
medication adherence.  
This study, upon publication in scientific journals, may also add to the literature 
on the importance of choosing the right method of measurement of medication 
adherence.  Based on a review of the literature conducted for this study, it was observed 
that the literature around measures of medication adherence is very inconsistent and no 
clear guidelines are available even from task forces.  Different studies have used different 
measures of adherence. The terminology and the definitions used to describe a measure 
of adherence are also highly inconsistent. Even measures of adherence have been 
described very inconsistently in the literature. For example, one study describes the PDC 
as equivalent to the MPR when it is truncated to 1. (Hess, et al., 2006) These 
inconsistencies resulted in the use of three different methods of medication adherence 
measurement for the purposes of this study. This study highlights the robustness and 
importance of using the PDC as a measure of medication adherence, particularly for 
health policy research issues. Based on the results of this study it is our recommendation 
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that the PDC which calculates availability of medication per day be used as a measure of 
adherence as against using measures such as the MPR which might result in over inflated 
adherence values.  
Significance and Implications from this study 
  Despite introduction of Medicare Part D, nearly 17% of Medicare beneficiaries 
in this study did not have any prescription drug coverage for a period of time during the 
year. The results of this study further confirm reports in the literature that lack of 
prescription drug coverage, as is experienced by beneficiaries who hit the coverage gap, 
leads to decreased prescription drug utilization and decreased medication adherence of 
essential medications such as anti-hypertensives, anti-hyperlipidemics, and proton pump 
inhibitors. With the caveat of limitations of the data used, this study provides some 
evidence on the adverse clinical and economic impacts of decreased utilization and 
medication adherence of essential prescription drugs. From a purely economic 
perspective, it is important to note that short-term savings from decreased prescription 
drug coverage of essential drugs might be offset by increased costs due to increased 
hospitalizations and emergency department visits over a long term. Thus based on the 
results of this study it is our recommendation that the coverage gap be eliminated from 
the Medicare Part D benefit structure.  
The coverage gap amount has increased every year since the inception of 
Medicare Part D. In 2009, for plans offering the standard Medicare Part D benefit, the 
coverage gap amounted to $3,454 and it has been projected that the coverage gap will 
exceed $6,000 by 2016. (Hoadley J, Thompsoni J, Hargrave E, Cubanski J, & Neuman T, 
2008)  This is concerning as the literature provides ample evidence that Medicare 
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beneficiaries have a disproportionate need of prescription drugs, incur high OOP 
expenses (relative to their income) and have limited financial resources. (J Cubanski, et 
al., 2005) The House and Senate healthcare reform bills have proposed phasing out the 
coinsurance rate in the coverage gap from 100% to the standard 25% amount by 2020. 
(Kaiser Family Foundation, 2010a) While this is a step in the right direction, it is critical 
to understand the adverse clinical and economic outcomes associated with the lack of 
adequate prescription drug coverage for another decade.  
In conclusion, the results from this study, in addition to providing further 
evidence that lack of prescription drug coverage leads to decreased utilization of essential 
prescription drugs, also highlight that no significant post-coverage gap differences were 
observed between beneficiaries enrolled in the full coverage plan and generic coverage 
plan for any of the drug classes. Based on these results, in the interim, as the coverage 
gap is being proposed to be phased out, provision of generic drugs during the coverage 
gap would be beneficial to Medicare beneficiaries. 
 
 
 
 
 
 
 
 
  
239 
 
REFERENCES 
 
Andersen, R. M. (1995). Revisiting the Behavioral Model and Access to Medical Care: 
Does it Matter? Journal of Health and Social Behavior, 36(1), 1-10. 
Baker, D. W., Feinglass, J., Durazo-Arvizu, R., Witt, W. P., Sudano, J. J., & Thompson, 
J. A. (2006). Changes in health for the uninsured after reaching age-eligibility for 
Medicare. J Gen Intern Med, 21(11), 1144-1149. 
Balkrishnan, R. (1998). Predictors of medication adherence in the elderly. Clinical 
Therapeutics, 20(4), 764-771. 
Balkrishnan, R., Byerly, W., Camacho, F., Shrestha, A., & Anderson, R. ( 2001). Effect 
of prescription benefit changes on medical care utilization in a Medicare HMO 
population. American Journal of  Managed Care, 7, 1093-1100. 
Blais, L., Boucher, J., Couture, J., Rahme, E., & LeLorier, J. (2001). Impact of a cost-
sharing drug insuranceplan on drug utilization among older people. Journal of the 
American Geriatrics Society, 49(4), 410-414. 
Blustein, J. (2000). Drug coverage and drug purchases by Medicare beneficiaries with 
hypertension. Health Aff, 19(2), 219-230. 
Brenson, R., & Horvath, J. (2002). The Clinical Characteristics of Medicare Beneficiaries 
and Implications for Medicare Reform Retrieved June 28, 2008, from 
http://www.medicareadvocacy.org/chronic_PartnerPaper_ClinChars.htm#_edn2) 
Card, D., Dobkin, C., & Maestas, N. (2004). The Impact of nearly universal insurance 
coverage on health care utilization and health: evidence from Medicare.   
Retrieved October 8, 2008, from http://www.nber.org/papers/w10365 
Medicare Prescription Drug, Improvement, and Modernization Act of 2003 § 101 (2004). 
Centers for Medicare and Medicaid Services. (2006). 2006 Standard Medicare 
Prescription Drug Coverage: Understanding Costs to Beneficiaries- The Twelfth 
in the MLN Matters Series on Drug Plans.   Retrieved August 24, 2007, from 
http://www.cms.hhs.gov/MLNMattersArticles/downloads/SE0618.pdf 
Centers for Medicare and Medicaid Services. (2007). Medicare and you, 2007.   
Retrieved February 10, 2008, from 
http://www.dads.state.tx.us/medicare/MedicareandYou%202007_eng.pdf 
Centers for Medicare and Medicaid Services. (2008a). Medicare and you, 2008.   
Retrieved February 10, 2008, from 
http://www.medicare.gov/Publications/Pubs/pdf/10050.pdf 
Centers for Medicare and Medicaid Services. (2008b). Medicare eligibility tool.   
Retrieved September 12, 2008, from 
http://www.medicare.gov/MedicareEligibility/Home.asp?dest=NAV|Home|Gener
alEnrollment#TabTop 
Chandra, A., Gruber, J., & McKnight, R. (2007). Patient cost-sharing, hospitalization 
offsets, and the design of optimal health insurance for the elderly: National 
Bureau of Economic Research, working paper 12972. 
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987). A new method of 
classifying prognostic comorbidity in longitudinal studies: development and 
validation. Journal of Chronic Diseases, 40(5), 373. 
Chawla AJ, Hatzmann MR, & Long SR. (2001). Developing performance measures for 
prescription drug management. Health Care Financing Review, 22(3), 71-84. 
240 
 
Chen, H., Nwangwu, A., Aparasu, R., Essien, E., Sun, S., & Lee, K. (2008). The Impact 
of Medicare Part D on Psychotropic Utilization and Financial Burden for 
Community-Based Seniors. Psychiatr Serv, 59(10), 1191-1197. 
Chernew, M. E., Shah, M. R., Wegh, A., Rosenberg, S. N., Juster, I. A., Rosen, A. B., et 
al. (2008). Impact Of Decreasing Copayments On Medication Adherence Within 
A Disease Management Environment. Health Aff, 27(1), 103-112. 
Cole, J. A., Norman, H., Weatherby, L. B., & Walker, A. M. (2006). Drug copayment 
and adherence in chronic heart failure: effect on cost and outcomes. 
Pharmacotherapy, 26(8), 1157-1164. 
Compton, L. (2009). ZIP Code Census data. In R. Naik (Ed.) (E-mail communication 
ed.). Albuquerque: Bureau of Business and Economic Research. 
Cox, E. R., & Henderson, R. R. (2002). Prescription use behavior among medicare 
beneficiaries with capped prescription benefits. J Manag Care Pharm, 8(5), 360-
364. 
Cox, E. R., Jernigan, C., Coons, S. J., & Draugalis, J. L. (2001). Medicare beneficiaries' 
management of capped prescription benefits. Med Care, 39(3), 296-301. 
Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. (2008). 
Medication Compliance and Persistence: Terminology and Definitions. Value in 
Health, 11(1), 44-47. 
Cronk, A., Humphries, T. L., Delate, T., Clark, D., & Morris, B. (2008). Medication 
strategies used by Medicare beneficiaries who reach the Part D standard drug-
benefit threshold. Am J Health Syst Pharm, 65(11), 1062-1070. 
Cubanski, J., & Neuman, P. (2007). Status report on Medicare Part D enrollment in 2006: 
Analysis of plan-specific market share and coverage. Health Aff, 26(1), w1-12. 
Retrieved from http://content.healthaffairs.org/cgi/content/abstract/26/1/w1 
doi:10.1377/hlthaff.26.1.w1 
Cubanski, J., Voris, M., Kitchman, M., Neuman, T., & Potetz, L. (2005). Medicare chart 
book.   Retrieved November 30, 2008, from 
http://www.kff.org/medicare/upload/Medicare-Chart-Book-3rd-Edition-Summer-
2005-Report.pdf 
Cutler, D. M., Zeckhauser, R. J., & Anthony, J. C. a. J. P. N. (2000). Chapter 11 The 
anatomy of health insurance Handbook of Health Economics (Vol. Volume 1, 
Part 1, pp. 563-643): Elsevier. 
Dalen, J. E., & Hartz, D. J. (2005). Medicare prescription drug coverage: A very long 
wait for a very modest benefit. The American Journal of Medicine, 118(4), 325-
329. 
Davis, M., Poisal, J., Chulis, G., Zarabozo, C., & Cooper, B. (1999). Prescription drug 
coverage, utilization, and spending among Medicare beneficiaries. Health Aff, 
18(1), 231-243. 
de Groot, V., Beckerman, H., Lankhorst, G. J., & Bouter, L. M. (2003). How to measure 
comorbidity a critical review of available methods. Journal of clinical 
epidemiology, 56(3), 221-229. 
Department of Health and Human Services. (2007). Tracking  beneficiaries' true out-of-
pocket costs for the Part D prescription drug benefit 
 Retrieved August 24, 2008, from http://oig.hhs.gov/oei/reports/oei-03-06-
00360.pdf 
241 
 
Department of Health and Human Services. (2008). Medicare Prescription Drug Plans.   
Retrieved August 1, 2008 
DiMatteo MR, Giordani PJ, Lepper HS, & Croghan TW. (2002). Patient adherence and 
medical treatment outcomes: a meta-analysis. Medical Care, 40(9), 794-811. 
Doescher, M. P., Franks, P., Banthin, J. S., & Clancy, C. M. (2000). Supplemental 
insurance and mortality in elderly Americans: Findings from a national cohort. 
Arch Fam Med, 9(3), 251-257. 
Fairman, K. (2008). The Future of Prescription Drug Cost-Sharing: Real Progress or 
Dropped Opportunity? Journal of Managed Care Pharmacy, 14 (1), 70-82. 
Federman, A. D., Adams, A. S., Ross-Degnan, D., Soumerai, S. B., & Ayanian, J. Z. 
(2001). Supplemental insurance and use of effective cardiovascular drugs among 
elderly Medicare beneficiaries with coronary heart disease. JAMA, 286(14), 1732-
1739. 
Geronimus, A., Bound, J., & Neidert, L. (1995). On the Validity of Using Census 
Geocode Characteristics to Proxy Individual Socioeconomic Characteristics. 
National Bureau of Economic Research, NBER Working Paper 189. Retrieved 
from http://ideas.repec.org/p/nbr/nberte/0189.html 
Gianfrancesco, F. D., Baines, A. P., & Richards, D. (1994). Utilization effects of 
prescription drug benefits in an aging population. Health Care Financ Rev, 15(3), 
113. 
Gilman, B. H., & Kautter, J. (2008). Impact of Multitiered Copayments on the Use and 
Cost of Prescription Drugs among Medicare Beneficiaries. Health Services 
Research, 43(2), 478-495. 
Goldman, D. P., Joyce, G. F., & Zheng, Y. (2007). Prescription drug cost sharing: 
Associations with medication and medicalutilization and spending and health. 
JAMA, 298(1), 61-69. 
Gornick, M. E., Eggers, P. W., Reilly, T. W., Mentnech, R. M., Fitterman, L. K., Kucken, 
L. E., et al. (1996). Effects of Race and Income on Mortality and Use of Services 
among Medicare Beneficiaries. N Engl J Med, 335(11), 791-799. 
Gowrisankaran, G., & Town, R. J. (2004). Managed Care, Drug Benefits and Mortality: 
An Analysis of the Elderly. National Bureau of Economic Research Working 
Paper Series, No. 10204. 
Hess, L. M., Raebel, M. A., Conner, D. A., & Malone, D. C. (2006). Measurement of 
Adherence in Pharmacy Administrative Databases: A Proposal for Standard 
Definitions and Preferred Measures. Ann Pharmacother, 40(7), 1280-1288. 
Hoadley J, Thompsoni J, Hargrave E, Cubanski J, & Neuman T. (2008). Medicare Part D 
2009 data spotlight : the coverage gap.   Retrieved December 28, 2009, from 
http://www.kff.org/medicare/upload/7834.pdf 
Hoadley J, Thompsoni J, Hargrave E, Merrellii K, Cubanski J, & Neuman T. (2007). 
Medicare Part D 2008 data spotlight : the coverage gap.   Retrieved August 3, 
2008, from http://www.kff.org/medicare/upload/7707.pdf 
Hoadley, J., Hargrave, E., Cubanski, J., & Neuman, T. (2008). Medicare Part D coverage 
gap: Costs and Consequences in 2007.   Retrieved December 20, 2008, from 
http://www.kff.org/medicare/upload/7811.pdf 
Hsu, J., Fung, V., Price, M., Huang, J., Brand, R., Hui, R., et al. (2008). Medicare 
Beneficiaries' Knowledge of Part D Prescription Drug Program Benefits and 
242 
 
Responses to Drug Costs. JAMA, 299(16), 1929-1936. 
Hsu, J., Price, M., Huang, J., Brand, R., Fung, V., Hui, R., et al. (2006). Unintended 
Consequences of Caps on Medicare Drug Benefits. N Engl J Med, 354(22), 2349-
2359. 
Ingenix. (2009). A Clinical Episode-Based Approach to Predictive Modeling: Impact 
Pro™. 2009, from http://www.ingenix.com/content/attachments/100-
2167%20Impact%20Pro%20whitepaper.pdf 
Johnson, R. E., Goodman, M. J., Hornbrook, M. C., & Eldredge, M. B. (1997). The effect 
of increased prescription drug cost-sharing on medical care utilization and 
expenses of elderly health maintenance organization members. Medical Care, 
35(11), 1119-1131. 
Joyce, G. F., Goldman, D. P., Karaca-Mandic, P., & Zheng, Y. (2007). Pharmacy benefit 
caps and the chronically ill. Health Aff (Millwood), 26(5), 1333-1344. 
Kaiser Family Foundation. (2007a). Medicare Advantage:The role of private health plans 
in Medicare Retrieved September 16, 2008, from 
http://www.kaiseredu.org/tutorials/medicareadvantage/player.html 
Kaiser Family Foundation. (2007b). Medicare at a glance.   Retrieved February 18, 2008, 
from http://www.kff.org/medicare/upload/1066-10.pdf 
Kaiser Family Foundation. (2007c). The Medicare prescription drug benefit.   Retrieved 
February 12, 2008, from http://www.kff.org/medicare/upload/7044-06.pdf 
Kaiser Family Foundation. (2007d). Medicare:A primer.   Retrieved March 28, 2008, 
from http://www.kff.org/medicare/upload/7615.pdf 
Kaiser Family Foundation. (2007e). New Mexico: Distribution of Medicare Enrollees by 
Age, states (2006-2007), U.S. (2007).   Retrieved March 23, 2009, from 
http://www.statehealthfacts.org/profileind.jsp?ind=294&cat=6&rgn=33 
Kaiser Family Foundation. (2007f). New Mexico: Distribution of Medicare Enrollees by 
Federal Poverty Level, states (2006-2007), U.S. (2007).   Retrieved March 23, 
2009, from 
http://www.statehealthfacts.org/profileind.jsp?ind=295&cat=6&rgn=33 
Kaiser Family Foundation. (2007g). New Mexico: Distribution of Medicare Enrollees by 
Gender, states (2006-2007), U.S. (2007)   Retrieved March 23, 2009, from 
http://www.statehealthfacts.org/profileind.jsp?ind=296&cat=6&rgn=33 
Kaiser Family Foundation. (2007h). New Mexico: Distribution of Medicare Enrollees by 
Race/Ethnicity, states (2006-2007), U.S. (2007)   Retrieved March 23, 2009, from 
http://www.statehealthfacts.org/profileind.jsp?ind=297&cat=6&rgn=33 
Kaiser Family Foundation. (2008). Medicare enrollment as a percent of total population, 
2008.   Retrieved March 28, 2008, from 
http://www.statehealthfacts.org/comparemaptable.jsp?ind=291&cat=6 
Kaiser Family Foundation. (2009). New Mexico: Medicare Beneficiaries with Creditable 
Prescription Drug Coverage by Type, as of February 2009.   Retrieved March 23, 
2009, from 
http://www.statehealthfacts.org/profileind.jsp?ind=307&cat=6&rgn=33 
Kaiser Family Foundation. (2010a). Focus on health reform: Summary of key Medicare 
provisions in White House proposal and House and Senate Health Reform Bills 
Retrieved February, 2010, from 
http://www.kff.org/healthreform/upload/7948_HR3962_HR3590_Summary.pdf 
243 
 
Kaiser Family Foundation. (2010b). Summary of key changes to Medicare in 2010 health 
reform law.   Retrieved July 10th 2010, from 
http://www.kff.org/healthreform/upload/7948-02.pdf 
Katon, W., Robinson, P., Von Korff, M., Lin, E., Bush, T., Ludman, E., et al. (1996). A 
multifaceted intervention to improve treatment of depression in primary care. 
Arch Gen Psychiatry, 53(10), 924-932. 
Katon, W., Rutter, C., Ludman, E. J., Von Korff, M., Lin, E., Simon, G., et al. (2001). A 
Randomized Trial of Relapse Prevention of Depression in Primary Care. Arch 
Gen Psychiatry, 58(3), 241-247. 
Katon, W., Von Korff, M., Lin, E., Walker, E., Simon, G. E., Bush, T., et al. (1995). 
Collaborative management to achieve treatment guidelines. Impact on depression 
in primary care. JAMA, 273(13), 1026-1031. 
Ketcham, J. D., & Simon, K. (2008). Medicare Part D's Effects on Elderly Drug Costs 
and Utilization. National Bureau of Economic Research Working Paper Series, 
No. 14326. 
Khan, N., Kaestner, R., & Lin, S.-J. (2008). Effect of Prescription Drug Coverage on 
Health of the Elderly. Health Services Research, 43(5p1), 1576-1597. 
Khan, N., Kaestner, R., & Lin, S. J. (2007). Prescription Drug Insurance and Its Effect on 
Utilization and Health of the Elderly. National Bureau of Economic Research 
Working Paper Series, No. 12848. 
Kim, S. L., Touchette, D. R., Stubbings, J. A., Schullo-Feulner, A. M., & Pater, K. S. 
(2008). Pilot assessment of patient satisfaction and clinical impact of Medicare 
Part D in diabetic geriatric patients. Pharmacy Practice (18863655), 6(3), 128-
135. 
Klepser, D. G., Huether, J. R., Handke, L. J., & Williams, C. E. (2007). Effect on drug 
utilization and expenditures of a cost-share change from copayment to 
coinsurance. Journal of managed care pharmacy: JMCP, 13(9), 765-777. 
Krieger, N. (1992). Overcoming the absence of socioeconomic data in medical records: 
validation and application of a census-based methodology. Am J Public Health, 
82(5), 703-710. 
Krueger, K., Berger, B., & Felkey, B. (2005). Medication adherence and persistence: A 
comprehensive review. Advances in Therapy, 22(4), 313-356. 
Landon, B. E., Zaslavsky, A. M., Bernard, S. L., Cioffi, M. J., & Cleary, P. D. (2004). 
Comparison of Performance of Traditional Medicare vs Medicare Managed Care. 
JAMA, 291(14), 1744-1752. 
Lee, J. K., Grace, K. A., & Taylor, A. J. (2006). Effect of a Pharmacy Care Program on 
Medication Adherence and Persistence, Blood Pressure, and Low-Density 
Lipoprotein Cholesterol: A Randomized Controlled Trial. JAMA, 296(21), 2563-
2571. 
Lichtenberg, F. (2002). The effects of Medicare on health care utilization and outcomes. 
Forum for Health Economics & Policy (Frontiers in Health Policy Research), 5, 
Article 3. Retrieved from http://www.bepress.com/fhep/5/3 
Lichtenberg , F. (2002). The effects of Medicare on health care utilization and outcomes. 
Forum for Health Economics & Policy (Frontiers in Health Policy Research), 5, 
Article 3. Retrieved from http://www.bepress.com/fhep/5/3 
Lichtenberg, F. R., & Sun, S. X. (2007). The impact of Medicare Part D on prescription 
244 
 
drug use by the elderly. Health Aff (Millwood), 26(6), 1735-1744. 
Lillard, L. A., Rogowski, J., & Kington, R. (1999). Insurance coverage for prescription 
drugs: effects on use and expenditures in the Medicare population. Medical Care, 
37(9), 926-936. 
Madden, J. M., Graves, A. J., Zhang, F., Adams, A. S., Briesacher, B. A., Ross-Degnan, 
D., et al. (2008). Cost-Related Medication Nonadherence and Spending on Basic 
Needs Following Implementation of Medicare Part D. JAMA, 299(16), 1922-
1928. 
Magid, D. J., Koepsell, T. D., Every, N. R., Martin, J. S., Siscovick, D. S., Wagner, E. H., 
et al. (1997). Absence of Association between Insurance Copayments and Delays 
in Seeking Emergency Care among Patients with Myocardial Infarction. N Engl J 
Med, 336(24), 1722-1729. 
Martin, B. C., Wiley-Exley, E. K., Richards, S., Domino, M. E., Carey, T. S., & Sleath, 
B. L. (2009). Contrasting Measures of Adherence with Simple Drug Use, 
Medication Switching, and Therapeutic Duplication. Ann Pharmacother, 43(1), 
36-44. 
McWilliams, J. M., Meara, E., Zaslavsky, A. M., & Ayanian, J. Z. (2007). Health of 
previously uninsured adults after acquiring Medicare coverage. JAMA, 298(24), 
2886-2894. 
Moxey ED, O'Connor JP, Novielli KD, Teutsch S, & Nash DB. (2003). Prescription drug 
use in the elderly: a descriptive analysis. Health Care Financing Review, 24(4), 
127-141. 
National Council on Patient Information and Education. (2007). Enhancing Prescription 
Medicine Adherence:A National Action Plan.   Retrieved March 30, 2008 
NCSS/PASS. (2008). Power Analysis and Sample Size (Version PASS 2005). Kaysville, 
Utah: NCSS Statistical Software. 
Newhouse, J. P. (1996). Free for All?: Lessons from the RAND Health Insurance 
Experiment. (1 ed.): Harvard University Press. 
Osterberg, L., & Blaschke, T. (2005). Adherence to Medication. N Engl J Med, 353(5), 
487-497. 
Pauly, M. V. (2004). Medicare Drug Coverage And Moral Hazard. Health Aff, 23(1), 
113-122. 
Peterson AM, Nau DP, CramerJA , Benner J , Gwadry-Sridhar F , & Nichol M. (2007). A 
checklist for medication compliance and persistence studies using retrospective 
databases. Value in Health, 10(1), 3-12. 
Peveler, R., George, C., Kinmonth, A.-L., Campbell, M., & Thompson, C. (1999). Effect 
of antidepressant drug counselling and information leaflets on adherence to drug 
treatment in primary care: randomised controlled trial. BMJ, 319(7210), 612-615. 
Pilote, L., Beck, C., Richard, H., & Eisenberg, M. J. (2002). The effects of cost-sharing 
on essential drug prescriptions, utilization of medical care and outcomes after 
acute myocardial infarction in elderly patients. CMAJ, 167(3), 246-252. 
Pladevall, M., Williams, L. K., Potts, L. A., Divine, G., Xi, H., & Elston Lafata, J. 
(2004). Clinical Outcomes and Adherence to Medications Measured by Claims 
Data in Patients With Diabetes. Diabetes Care, 27(12), 2800-2805. 
Pope, G. C., Ellis, R. P., Ash, A. S., Bates, D. W., Burstin, H., Iezzoni, L. I., et al. (2000). 
Diagnostic cost group hierarchical condition category models for Medicare risk 
245 
 
adjustment. Final Report to Health Care Financing Administration, December. 
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J., et al. (2005). 
Coding algorithms for defining comorbidities in ICD-9-CM 
and ICD-10 administrative data. Medical Care, 43(11), 1130-1139. 
Raebel, M. A., Delate, T., Ellis, J. L., & Bayliss, E. A. (2008). Effects of reaching the 
drug benefit threshold on Medicare members' healthcare utilization during the 
first year of Medicare Part D. Med Care, 46(10), 1116-1122. 
Rasell, M. E. (1995). Cost Sharing in Health Insurance -- A Reexamination. N Engl J 
Med, 332(17), 1164-1168. 
Rector, T. S., & Venus, P. J. (2004). Do Drug Benefits Help Medicare Beneficiaries 
Afford Prescribed Drugs? Health Aff, 23(4), 213-222. 
Remler, D., & Greene, J. (2009). Cost-Sharing: A Blunt Instrument. Annual Review of 
Public Health, 30(1). 
Rice, T., & Matsuoka, K. Y. (2004). The impact of cost-sharing on appropriate utilization 
and health status: A review of the literature on seniors. Med Care Res Rev, 61(4), 
415-452. 
Rogers, P., & Bullman, R. (1995). Prescription Medicine Compliance:A Review of the 
Baseline of Knowledge-A Report of the National Council on Patient Information 
and Education.   Retrieved March 28, 2008 
Rogers, P. G., & Bullman, W. R. (1996). Prescription Medicine Compliance: A Review 
of the Baseline of Knowledge- A Report of the National Council on Patient 
Information and Education. Journal of Pharmacoepidemiology, 3(2), 3 - 36. 
Safran, D. G., Neuman, P., Schoen, C., Kitchman, M. S., Wilson, I. B., Cooper, B., et al. 
(2005). Prescription Drug Coverage And Seniors: Findings From A 2003 National 
Survey. Health Aff, hlthaff.w5.152. 
Safran, D. G., Neuman, P., Schoen, C., Montgomery, J. E., Li, W., Wilson, I. B., et al. 
(2002). Prescription Drug Coverage And Seniors: How Well Are States Closing 
The Gap? Health Aff, hlthaff.w2.253. 
Schneeweiss, S., Patrick, A. R., Pedan, A., Varasteh, L., Levin, R., Liu, N., et al. (2009). 
The Effect Of Medicare Part D Coverage On Drug Use And Cost Sharing Among 
Seniors Without Prior Drug Benefits. Health Aff, 28(2), w305-316. 
Schroeder, K., Fahey, T., & Ebrahim, S. (2004). Interventions for improving adherence to 
treatment in patients with high blood pressure in ambulatory settings. Cochrane 
Database of Systematic Reviews, (3), Article:CD004804 
Shea, D., Terza, J., Stuart, B., & Briesacher, B. (2007). Estimating the Effects of 
Prescription Drug Coverage for Medicare Beneficiaries. Health Services 
Research, 42(3p1), 933-949. 
Smith, G. D., Ben-Shlomo, Y., & Hart, C. (1999). RE: "USE OF CENSUS-BASED 
AGGREGATE VARIABLES TO PROXY FOR SOCIOECONOMIC GROUP: 
EVIDENCE FROM NATIONAL SAMPLES". Am. J. Epidemiol., 150(9), 996-
997. 
Social Security Administration. (2008). Medicare.   Retrieved September 12, 2008, from 
http://www.socialsecurity.gov/pubs/10043.pdf 
Soumerai, S., Avorn, J., Ross-Degnan, D., & Gortmaker, S. (1987). Payment restrictions 
for prescription drugs under Medicaid. Effects on therapy, cost, and equity. N 
Engl J Med, 317(9), 550-556. 
246 
 
Soumerai, S., McLaughlin, T. J., Ross-Degnan, D., Casteris, C. S., & Bollini, P. (1994). 
Effects of Limiting Medicaid Drug-Reimbursement Benefits on the Use of 
Psychotropic Agents and Acute Mental Health Services by Patients with 
Schizophrenia. N Engl J Med, 331(10), 650-655. 
Soumerai, S., Pierre-Jacques, M., Zhang, F., Ross-Degnan, D., Adams, A. S., Gurwitz, J., 
et al. (2006). Cost-Related Medication Nonadherence Among Elderly and 
Disabled Medicare Beneficiaries: A National Survey 1 Year Before the Medicare 
Drug Benefit. Arch Intern Med, 166(17), 1829-1835. 
Soumerai, S., Ross-Degnan, D., Avorn, J., McLaughlin, T., & Choodnovskiy, I. (1991). 
Effects of Medicaid drug-payment limits on admission to hospitals and nursing 
homes. N Engl J Med, 325(15), 1072-1077. 
Soumerai, S. B., & Ross-Degnan, D. (1999). Inadequate Prescription-Drug Coverage for 
Medicare Enrollees -- A Call to Action. N Engl J Med, 340(9), 722-728. 
Steiner, J. F., & Prochazka, A. V. (1997). The assessment of refill compliance using 
pharmacy records: Methods, validity, and applications. Journal of Clinical 
Epidemiology, 50(1), 105-116. 
Steinman, M., Sands, L., & Covinsky, K. (2001). Self-restriction of medications due to 
cost in seniors without prescription coverage. Journal of General Internal 
Medicine, 16(12), 793-799. 
Stevens, J. (2002). Applied multivariate statistics for the social sciences (4th ed.). 
Mahwah, New Jersey: Lawrence Erlbaum Associates  
Stuart, B., Doshi, J. A., Briesacher, B., Wrobel, M. V., & Baysac, F. (2004). Impact of 
prescription coverage on hospital and physician costs: a case study of medicare 
beneficiaries with chronic obstructive pulmonary disease. Clinical Therapeutics, 
26(10), 1688-1699. 
Stuart, B., & Grana, J. (1998). Ability to Pay and the Decision to Medicate. Medical 
Care, 36(2), 202-211. 
Stuart, B., Simoni-Wastila, L., & Chauncey, D. (2005). Assessing the impact of coverage 
gaps in the Medicare Part D drug benefit. Health Aff, hlthaff.w5.167. 
Stuart, B., & Zacker, C. (1999). Who bears the burden of Medicaid drug copayment 
policies? Health Aff, 18(2), 201-212. 
Sun, S. X., & Lee, K. Y. (2007). The Medicare Part D doughnut hole: effect on pharmacy 
utilization. Manag Care Interface, 20(9), 51-55, 59. 
Tamblyn, R., Laprise, R., Hanley, J. A., Abrahamowicz, M., Scott, S., Mayo, N., et al. 
(2001a). Adverse events associated with prescription drug cost-sharing 
amongpoor and elderly persons. JAMA, 285(4), 421-429. 
Tamblyn, R., Laprise, R., Hanley, J. A., Abrahamowicz, M., Scott, S., Mayo, N., et al. 
(2001b). Adverse eventsassociated with prescription drug cost-sharing amongpoor 
and elderly persons. JAMA, 285(4), 421-429. 
Tseng, C.-W., Brook, R. H., Keeler, E., & Mangione, C. M. (2003). Impact of an Annual 
Dollar Limit or "Cap" on Prescription Drug Benefits for Medicare Patients. 
JAMA, 290(2), 222-227. 
Tseng, C.-W., Brook, R. H., Keeler, E., Steers, W. N., & Mangione, C. M. (2004). Cost-
Lowering Strategies Used by Medicare Beneficiaries Who Exceed Drug Benefit 
Caps and Have a Gap in Drug Coverage. JAMA, 292(8), 952-960. 
US Census Bureau. (2009). American Community Survey (ACS): How to use the data.   
247 
 
Retrieved May 7, 2009, from http://www.census.gov/acs/www/UseData/geo.htm 
Vik, S. A., Maxwell, C. J., & Hogan, D. B. (2004). Measurement, Correlates, and Health 
Outcomes of Medication Adherence Among Seniors. Ann Pharmacother, 38(2), 
303-312. 
Yang, Z., Gilleskie, D. B., & Norton, E. C. (2004). Prescription Drugs, Medical Care, and 
Health Outcomes: A Model of Elderly Health Dynamics. National Bureau of 
Economic Research Working Paper Series, No. 10964. 
Yin, W., Basu, A., Zhang, J. X., Rabbani, A., Meltzer, D. O., & Alexander, G. C. (2008). 
The effect of the Medicare Part D prescription benefit on drug utilization and 
expenditures. Ann Intern Med, 148(3), 169-177. 
Zhang, Y., Donohue, J. M., Newhouse, J. P., & Lave, J. R. (2009). The Effects Of The 
Coverage Gap On Drug Spending: A Closer Look At Medicare Part D. Health 
Aff, 28(2), w317-325. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
248 
 
 
 
 
 
 
 
 
 
 
 
APPENDICES 
 
 
 
 
 
 
 
 
 
 
 
 
249 
 
 
Appendix A: UNM HRRC Approval 
 
250 
 
Appendix B: List of Medicare Part B Drugs Excluded with their GPI numbers 
GPI PRODUCT 
3090361010****  AGALSIDASE BETA                              
8540001000****  ALBUMIN, HUMAN                                                
75100010002020 BACLOFEN INTRATHECAL INJ 0.05 MG/ML (50 MCG/M)         
75100010006440 BACLOFEN INTRATHECAL KIT 2000 MCG/ML                          
75100010006420 BACLOFEN INTRATHECAL KIT 500 MCG/ML             
8680701200****  BOTULINUM TOXIN TYPE A                                            
444000150018** BUDESONIDE (INHALATION) SUSP                    
213000050003** CAPECITABINE TABS                                               
994020200020** CYCLOSPORINE SOLN                              
453040200020** DORNASE ALFA SOLN                                                 
4017004010**** EPOPROSTENOL SODIUM                           
215000100001** ETOPOSIDE CAPS                                               
1910001000****  HEPATITIS B IMMUNE GLOBULIN (HUMAN)                            
221000254021**  HYDROCORTISONE SOD SUCCINATE SOLR 
758000400022** HYLAN INJ                                      
8270005000****  IMIGLUCERASE                                   
1910002010**** IMMUNE GLOBULIN (HUMAN) IV                     
5250504000**** INFLIXIMAB                                   
21405010156420 LEUPROLIDE ACETATE (3 MONTH) FOR INJ KIT 11.2   
21405010106405 LEUPROLIDE ACETATE FOR INJ KIT 3.75 MG         
21405010156430 LEUPROLIDE ACETATE (3 MONTH) FOR INJ KIT 22.5        
21405010206430  LEUPROLIDE ACETATE (4 MONTH) FOR INJ KIT 30 M  
21405010106410  LEUPROLIDE ACETATE FOR INJ KIT 7.5 MG                        
442010451025**  LEVALBUTEROL HCL NEBU                         
 140401010**** MEDROXYPROGESTERONE ACETATE (ANTINEOPLASTIC) 
221000301018** METHYLPREDNISOLONE ACETATE SUSP 
3017007010****  OCTREOTIDE ACETATE                                           
8665505030****  PEGAPTANIB SODIUM                              
160000450025**  PENTAMIDINE ISETHIONATE NEBU                  
4510001010**** PROTEINASE INHIBITOR (HUMAN)                 
1910004500****  RABIES IMMUNE GLOBULIN (HUMAN)               
5907007010****  RISPERIDONE MICROSPHERES                                       
75800070102020  SODIUM HYALURONATE INTRA-ARTICULAR INJ 10 MG       
994040800020** TACROLIMUS SOLN 
 70000700025** TOBRAMYCIN NEBU                                              
3004209000****  ZOLEDRONIC ACID                                 
3090361010**** AGALSIDASE BETA                                                 
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 540001000****  ALBUMIN, HUMAN                                                  
 110000500**** ALTRETAMINE                                    
4530402000**** DORNASE ALFA                                                    
4017004010****  EPOPROSTENOL SODIUM                                              
1910001000**** HEPATITIS B IMMUNE GLOBULIN (HUMAN)                            
 270005000****  IMIGLUCERASE                                                    
1910002010****  IMMUNE GLOBULIN (HUMAN) IV                                   
5250504000****  INFLIXIMAB                                                       
2140501010**** LEUPROLIDE ACETATE                              
3017007010**** OCTREOTIDE ACETATE                                            
4510001010****  PROTEINASE INHIBITOR (HUMAN)                                    
1910004500**** RABIES IMMUNE GLOBULIN (HUMAN)                                   
5907007010****  RISPERIDONE MICROSPHERES                        
44201010102100 ALBUTEROL SULFATE FOR NEBU SOLN                
44201010102515  ALBUTEROL SULFATE SOLN NEBU 0.083%                              
44209902012015  ALBUTEROL-IPRATROPIUM NEBU SOLN 2.5(3)-0.5 MG          
994060100003** AZATHIOPRINE TABS 
211000100003** BUSULFAN TABS                                                    
213000050003**  CAPECITABINE TABS                                               
211010200003** CYCLOPHOSPHAMIDE TABS                          
994020200001** CYCLOSPORINE CAPS                            
9940202030****   CYCLOSPORINE MODIFIED (FOR MICROEMULSION)      
21500010000120 ETOPOSIDE CAP 50 MG 
 15000100001** ETOPOSIDE CAPS                                                   
44100030102020 IPRATROPIUM BROMIDE INHAL SOLN 0.02%           
 11010400003**  MELPHALAN TABS                                
213000400003**  MERCAPTOPURINE TABS                                          
214022500003**  MITOTANE TABS                                  
 94030301001**  MYCOPHENOLATE MOFETIL CAPS                    
994030301003**  MYCOPHENOLATE MOFETIL TABS                                     
9940407000****  SIROLIMUS                                     
994040800001**  TACROLIMUS CAPS                                                
3004209000****  ZOLEDRONIC ACID                                
94100030006100 DIABETIC SUPPLIES 
97202025006300 DIABETIC SUPPLIES 
 
